

---

# ***CLINICAL INVESTIGATION PROGRAM REPORT***

---



***DWIGHT DAVID EISENHOWER  
ARMY MEDICAL CENTER  
FT GORDON, GA 30905***

---

***FY 93***

---

REPORT DOCUMENTATION PAGE			Form Approved OMB No. 0704-0188	
<small>Public reporting burden for this collection of information is estimated to average 1 hour per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing the collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden, to Washington Headquarters Services, Directorate for Information Operations and Reports, 1215 Jefferson Davis Highway, Suite 1204 Arlington, VA 22202-4302 and to the Office of Management and Budget, Paperwork Reduction Project (0704-0188), Washington, DC 20503</small>				
1. AGENCY USE ONLY (Leave blank)	2. REPORT DATE 1 October 1993	3. REPORT TYPE AND DATES COVERED ANNUAL FY 93 - 1 Oct 92 to 30 Sep 93		
4. TITLE AND SUBTITLE Clinical Investigation Program Report RCS MED-300 (R1)			5. FUNDING NUMBERS	
6. AUTHOR(S) Kent M. Plowman, M.D., PhD Colonel, Medical Corps Chief, Department of Clinical Investigation				
7. PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES) Department of Clinical Investigation Dwight David Eisenhower Army Medical Center Fort Gordon, Georgia 30905-5650			8. PERFORMING ORGANIZATION REPORT NUMBER  RCS MED-300 (R1)	
9. SPONSORING / MONITORING AGENCY NAME(S) AND ADDRESS(ES) Commander US Army Health Care Studies and Clinical Investigation Activity Fort Sam Houston, Texas 78234-6060			10. SPONSORING / MONITORING AGENCY REPORT NUMBER	
11. SUPPLEMENTARY NOTES THE FINDINGS IN THIS REPORT ARE NOT TO BE CONSTRUED AS AN OFFICIAL DEPARTMENT OF THE ARMY POSITION UNLESS SO DESIGNATED BY OTHER AUTHORIZED DOCUMENTS.				
12a DISTRIBUTION AVAILABILITY STATEMENT APPROVED FOR PUBLIC RELEASE: DISTRIBUTION UNLIMITED			12b DISTRIBUTION CODE	
13. ABSTRACT (Maximum 200 words) Subject report identifies the research activities conducted by Dwight David Eisenhower Army Medical Center investigators through protocols approved by the Institutional Review Committee for registration with the Department of Clinical Investigation during Fiscal Year 1993, and other known publications and presentations by the Dwight David Eisenhower Army Medical Center professional staff. A detail sheet of each protocol giving the objective, technical approach, and progress is presented.				
14. SUBJECT TERMS			15. NUMBER OF PAGES 204	
			16. PRICE CODE	
17. SECURITY CLASSIFICATION OF REPORT UNCLASSIFIED	18. SECURITY CLASSIFICATION OF THIS PAGE UNCLASSIFIED	19. SECURITY CLASSIFICATION OF ABSTRACT UNCLASSIFIED	20. LIMITATION OF ABSTRACT UL	

## GENERAL INSTRUCTIONS FOR COMPLETING SF 298

The Report Documentation Page (RDP) is used in announcing and cataloging reports. It is important that this information be consistent with the rest of the report, particularly the cover and title page. Instructions for filling in each block of the form follow. It is important to *stay within the lines* to meet *optical scanning requirements*.

### Block 1. Agency Use Only (Leave blank)

**Block 2. Report Date.** Full publication date including day, month, and year, if available (e.g. 1 Jan 88). Must cite at least the year.

**Block 3. Type of Report and Dates Covered**  
State whether report is interim, final, etc. If applicable, enter inclusive report dates (e.g. 10 Jun 87 - 30 Jun 88).

**Block 4. Title and Subtitle** A title is taken from the part of the report that provides the most meaningful and complete information. When a report is prepared in more than one volume, repeat the primary title, add volume number, and include subtitle for the specific volume. On classified documents enter the title classification in parentheses.

**Block 5. Funding Numbers** To include contract and grant numbers, may include program element number(s), project number(s), task number(s), and work unit number(s). Use the following labels:

C - Contract	PR - Project
G - Grant	TA - Task
PE - Program Element	WU - Work Unit Accession No.

**Block 6. Author(s)** Name(s) of person(s) responsible for writing the report, performing the research, or credited with the content of the report. If editor or compiler, this should follow the name(s).

**Block 7. Performing Organization Name(s) and Address(es)** Self-explanatory.

**Block 8. Performing Organization Report Number** Enter the unique alphanumeric report number(s) assigned by the organization performing the report.

**Block 9. Sponsoring/Monitoring Agency Name(s) and Address(es)** Self-explanatory.

**Block 10. Sponsoring/Monitoring Agency Report Number (If known)**

**Block 11. Supplementary Notes** Enter information not included elsewhere such as Prepared in cooperation with; Trans of; To be published in. When a report is revised, include a statement whether the new report supersedes or supplements the older report.

**Block 12a. Distribution/Availability Statement.** Denotes public availability or limitations. Cite any availability to the public. Enter additional limitations or special markings in all capitals (e.g. NOFORN, REL, ITAR).

**DOD** - See DoDD 5230.24, "Distribution Statements on Technical Documents."

**DOE** - See authorities.

**NASA** - See Handbook NHB 2200.2

**NTIS** - Leave blank.

### Block 12b. Distribution Code

**DOD** - Leave blank.

**DOE** - Enter DOE distribution categories from the Standard Distribution for Unclassified Scientific and Technical Reports.

**NASA** - Leave blank.

**NTIS** - Leave blank.

**Block 13. Abstract** Include a brief (Maximum 200 words) factual summary of the most significant information contained in the report.

**Block 14. Subject Terms** Keywords or phrases identifying major subjects in the report.

**Block 15. Number of Pages** Enter the total number of pages.

**Block 16. Price Code** Enter appropriate price code (NTIS only).

**Blocks 17 - 19. Security Classifications** Self-explanatory. Enter U.S. Security Classification in accordance with U.S. Security Regulations (i.e., UNCLASSIFIED). If form contains classified information, stamp classification on the top and bottom of the page.

**Block 20. Limitation of Abstract** This block must be completed to assign a limitation to the abstract. Enter either UL (unlimited) or SAR (same as report). An entry in this block is necessary if the abstract is to be limited. If blank, the abstract is assumed to be unlimited.

**CLINICAL INVESTIGATION**

**PROGRAM REPORT**

**1 October 1993**

**CONTROL SYMBOL: RCS MED-300 (R1)**

**Department of Clinical Investigation  
Dwight David Eisenhower Army Medical Center  
Fort Gordon, Georgia 30905-5650**

**DESTROY THIS REPORT WHEN NO LONGER NEEDED. DO NOT RETURN IT TO THE ORIGINATOR**

**The findings in this report are not to be construed as an official Department of the Army position unless so designated by other authorized documents.**

**Approved for Public Release: Distribution Unlimited**

## FOREWORD

The illustration gracing this year's cover has suffered significant ravages in its survival. It depicts the author, Pedanios Dioskurides, as the scholar on the right recording his observations into his codex. Featured in the center is the allegorical figure of Epinoia (Rationality) holding the mandrake plant which is being faithfully drawn by the artist on the left. The far better known drawing depicting the author with Heuresis in accepting the mandrake plant, was featured on our FY 84 cover. The role of "discovery" and its practical implications are relatively obvious. Dioskurides certainly used his time as a surgeon travelling with the Roman army to good advantage. He gathered the information for his *Materia Medica* by using his military travels well. This document has survived into the modern age by taking his discoveries and combining them with reasoning to formulate a rational basis for therapeutics.

As noted before, military physicians in training should take heed to use their experiences and opportunities for discovery to advantage in advancing knowledge. To this exhortation might be added the implications of the current illustration. Rationality and reasoning are the virtues of the mature scholar who takes the fruits of earlier discovery, reflects on them, records them accurately, and then develops a practice of healing. This higher level of integration of thought is more than theoretical knowledge (*theoria*); it represents a *praxis* involving the whole person.


The style and positioning of the figures suggests some similarities to religious iconography of the general period. The original of this painting probably dated to the fourth century, a time prior to most surviving religious examples. Typically, the icon of Christ would be flanked by the *Theotokos* (his mother, Mary) and the Forerunner (John the Baptizer) or by Moses and Elias, representing the Law and the Prophets in the Transfiguration. Interestingly in this image, only Epinoia is shown in full face and the artist and scholar are shown in profile. This latter depiction tended to represent a non-person. Perhaps this meant to portray the essential anonymity of the persons who do the labor of reasoning in following up on discovery. In any event, that is the practical result of most scholars throughout the ages. A few achieve recognition and even fame. Certainly Dioskurides did with the lasting success of his *Materia Medica*. Of course, most true scholars recognize the vagaries of fame and tend to ignore it as best they can. To do so well requires a visit from *Sophia* (Wisdom).

The progression from *Heuresis* to *Epinoia* to *Sophia* is a difficult one which requires a life dedicated to the truth and a willingness to struggle to find it at all costs. Our experience in the Clinical Investigation Program can help the young physician meet the first lady and perhaps later arrange an introduction to *Epinoia*. We can go no further. Unfortunately, all too many do not show the initial interest. We at EAMC have been fortunate to see a growing number of residents and staff

take a serious interest in scholarly endeavors with a steady growth in protocol based reasearch.

The most serious threat to Clinical Investigation at EAMC has been the continued hold on completing the design and construction of the new research building. It was put on hold a year ago pending the outcome of the GME future. It remains in that state as of this publication.

We in CI lost our most venerable member, Mrs. Rosina Martinez, to early retirement this year. She had been with the program from its founding in 1977. She knew where everything was and what needed to be done. The past six months have been difficult for me without her. I would like to dedicate this Annual Report to her. The only unfitting aspect is that this is the first time the report was not ready for the reproduction process by the end of October. We are not even the first MEDCEN to publish it this year. Our best regards to Rosie in her retirement.



Kent M. Plowman  
COL, MC  
C, Dept. Clin. Invest.

UNIT SUMMARY - FISCAL YEAR 1993

A. Objective.

The Department of Clinical Investigation is responsible to the Deputy Commander for Clinical Services for providing the facilities and atmosphere of inquiry necessary to support and stimulate both basic and clinical medical investigation within DDEAMC.

B. Technical Approach.

All research, investigational, and training activities within the Department of Clinical Investigation are conducted under the guidance of AR 40-38, AR 40-7, AR 70-25, AR 70-18, and HSC Reg 40-23. Careful monitoring of all approved protocols is conducted in order to assure strict compliance with these applicable regulations.

C. Staffing.

Name	Rank	MOS	Title
Plowman, Kent M.	COL	61F00	Chief
Tobias, Steven	MAJ	64A00	Veterinarian
Craft, David	MAJ	68A9B	Immunologist/Microbiologist
Williams, Linda E.	SSG	92B30	NCOIC, Med Lab NCO
Rodriguez-Morales, Janet	SSG	92B30R	Med Lab Sp
Quilici, Kristine	SGT	92B20	Med Lab Sp
Collins, Demetrius	PFC	91T10	Veterinarian Technician
Horner, Jack A.	GM13	01301	Asst C, Res Histologist
McPherson, James C. III, PhD	GS13	01320	Biochemist
Runner, Royce R., MT, ASCP	GS11	00644	Medical Technologist
Best, Norma	GS9	00644	Medical Technologists
Chuang, Augustine H., Ph	GS9	00644	Medical Technologist (MRDC Grant)
Ferguson, Phyllis	GS5	00303	Protocol Coordinator
Searles, Rosa	GS6	00404	Biological Lab Technician
Reisenger, Rebecca	GS4	00312	Clerk-Steno

Officer: 4 authorized; 5 required; 3 assigned  
 Enlisted: 5 authorized; 9 required; 4 assigned  
 Civilian: 7 authorized; 13 required; 8 assigned

One third-party FACT physician assistant employee in Pulmonary Service.

D. Funding.

<u>Type</u>	<u>Fiscal Year 92</u>	<u>Fiscal Year 93</u>
Civilian personnel to include benefits	310,959.00	305,873.97
Consumable supplies	118,789.00	197,964.03
Civilian contracts to include consultants	2,400.00	6,829.00
TDY	2,000.00	4,856.40
Publications	2,243.00	619.40
CEEP	2,499.00	86,590.31
MEDCASE	316,215.00	218,820.71
Military	497,794.00	496,870.00
Total	1,252,899.00	1,318,424.82

Grant Funding:

MRDC - "Non-ionic Surfactants in the Treatment of Third Degree Burns in  
rats."  
FY 93: \$17,624.00

E. Progress.

Protocol Disposition FY 93

	<u>Completed</u>	<u>Terminated</u>	<u>Ongoing to FY 94</u>
FY 78	3		1
FY 84	1		
FY 85			1
FY 87	1		2
FY 88		1	2
FY 89	2	2	2
FY 90	3	4	5
FY 91	29	1	38
FY 92	11	6	60
FY 93	9	10	124
	<hr/> 59	<hr/> 24	<hr/> 235

Number of resident and fellowship programs: 1-Fellowship and 7-Residents  
Number of programs using Clinical Investigation: 13  
Number of residents and fellows on approved protocols: 36  
Number of approved protocols held by this group: 37

Other training programs that use Clinical Investigation: Graduate Students,  
Transitional Interns, Psychology Interns, Nurse Anesthetist: 1 Transitional  
Intern Program - 6 Interns and 1 Psychology Intern Program - 4 Interns.

Number of approved protocols held by this group: 11

Number of hospital staff members on approved protocols: 14  
Number of approved protocols held by this group: 93

Drug evaluation/comparison studies: 20  
Treatment evaluation/comparison studies: 41

**RESEARCH AWARDS**

**Recipients of  
The Eleventh Annual DDEAMC Resident Research Award  
was**

**Captain Brad Waddell, MC  
for his paper**

**"The Effect of Octreotide on Wound Healing in Rats"**

**The paper was based on Protocol 92-26 and was presented at the Eisenhower Army  
Medical Center Annual Resident Research Presentation Day, May 1993.**

**Recipient of  
The Seventh Annual Dental Activity Resident Research Award  
was**

**Major Gregory W. Austin, CPDS, Periodontics Resident  
for his paper**

**"Effect of nicotine on fibroblast integrin expression and distribution in vitro,"  
based on Protocol 91-73.**

INSTITUTIONAL REVIEW COMMITTEE

Clinical Investigation and Human Use Members

Chief, Department of Clinical Investigation, Chairman  
Chief, Department of Medicine  
Chief, Department of Surgery  
Chief, Pharmacy Service  
Research Director, Dental Activity  
Chief, Department of Ministry & Pastoral Care  
Chief, Nursing Education & Staff Development  
Chief, Department of Pathology  
Signal Center Representative, Ft Gordon, Georgia  
Research Director, Department of Family Practice  
Research Director, Department of Psychiatry & Neurology  
Veterinarian, Department of Clinical Investigation  
Medical Center Judge Advocate  
Chief, Nuclear Medicine Service  
Radiation Safety Officer  
Chief, Medical Records Administration Section

Animal Care and Use Members

Chief, Department of Clinical Investigation, Chairman  
Chief, Department of Medicine  
Chief, Department of Surgery  
Veterinarian, Department of Clinical Investigation  
Signal Center Representative, Ft Gordon, Georgia

## TABLE OF CONTENTS

**Foreword**

**Unit Summary - Fiscal Year 1993**

**Publications**

**Presentations**

**Year Initiated  
and Protocol  
Number**

**Page**

### DEPARTMENT OF CLINICAL INVESTIGATION

1987 87-16	Utility of the 60-Kilodalton Oncofetal Tumor Marker in the Effectiveness of Surgical Intervention in the Treatment of Cancer Patients. (O)	18
1987 87-40	Pathology Applications of X-ray Spectrometric Microanalysis. (O)	19
1989 89-38	Non-Ionic Surfactants in the Treatment of Third Degree Burns in Rats. (O) (PR)	20
1990 91-18	Effects of Different Methods of Hair Removal on the Measurement of Skin Blood Flow in the Rat Using a Doppler Laser Blood Perfusion Monitor and the Effect of Elevated Body Core Temperature on Skin Blood Flow. (O)	22
1990 91-19	Development of a Heatstroke Model in the Rat and Treatment with Pluronic Polyols. (O)	24
1990 91-24	Derivation and Characterisation of Human Periodontal Ligament Fibroblasts. (O)	25
1990 91-37	The Effect of Pluronic Polyols on Experimental Edema Produced by Various Means: Arachidonic Acid, Carrageenin Histamine and Thermal Injury. A Study in Rats and Mice. (O)	26
1991 91-74	The Effect of Etidronate in the Treatment of Acute/Chronic Osteomyelitis in the Rat Tibial Model. (O)	27
1992 92-15	Cell Membranes and the Gastric Mucosa from Sodium Fluoride in the rat. (O)	28
1992 92-53	A Study of p53 in the Plasma of Patients in Stages II - VI of Human Immunodeficiency Virus (HIV-1) Infection. (O)	29

## DENTAL ACTIVITY

1990 91-9	Wear and Cutting Efficiency of Sonic Files. (O)	30
1991 91-62	An Evaluation of a Selective Die Spacer Placement Technique. (O)	31
1991 91-72	Evaluation of Heat Generated When Exposed to Titanium Implant Fixture Threads are Removed Using Rotary Instruments. (C)	32
1991 91-73	Effect of Nicotine on Fibroblast Integrin Expression and Distribution in vitro. (O)	33
1991 91-75	Parenteral Application of F-68 and F-127 Surfactants to Belly Wounds in Rats After an Initial Healing Period of 48 and 96 Hours. (C)	34
1991 91-76	The Effects of Parenterally Administered Pluronic F-68 and F-127 on Skin Grafts in the Rat. (C)	35
1991 91-77	Comparison of Effect of Citric Acid Conditioning versus Tetracycline Treatment on Human Gingival Fibroblast Attachment in vitro. (C)	36
1991 91-78	In vitro Effect of 30% Hydrogen Peroxide and Sodium Perborate on Endodontic Sealers in Roots Obturated with Gutta-Percha. (O)	37
1991 91-80	A Comparison of the Effects of Bisphosphonate, Gallium Nitrate, and Calcium Hydroxide on Osteoclast-Like in vitro and in vivo. (O)	38
1992 92-31	A Clinical Study of the Relationship Between Computed Tomography and Bone Sounding. (O)	39
1992 92-44	Influence of the Posterior Horizontal Plate Angle on Pantographic Recording of Immediate Side Shift. (T)	40
1992 92-45	The Effect of Loading on the Porcelain Labial Margin of a Ceramo-Metal Restoration. (C)	41
1992 92-46	A Comparison of Impression Techniques for the CeraOne Abutment. (C)	42
1992 92-56	A Clinical Evaluation of Autogenous Iliac Bone Grafts in Periodontal Osseous Defects. (O)	43
1992 92-57	Evaluation of the Benefits of Screening Tests Done Prior to Periodontal Therapy. (O)	44
1992 92-58	A Comparison of the Clinical Success of the 5mm Nobelpharma Implant Fixture to the Standard 3.75mm Fixture. (O)	45
1992 92-74	Wear and Cutting Efficiency of the Rispi-Sonic File. (O)	46

1992 92-75	The Effects of Intracanal Medicaments, Cements (sealer), and Fillers on Fibroblast Growth and Attachment to a Tooth Which has Received Root Canal Therapy. (O)	47
1992 92-76	Endogenous Prostaglandin Induced by IL-1B and TNFs Regulates Il-6 Production by Human Gingival Fibroblasts. (O)	48
1992 92-77	The Effect of Transforming Growth Factor Beta (TGF-β) in Conjunction with Polyols on Wound Healing Rats. (O)	49
1993 93-39	The Efficacy of Procera Laser Welded Hybrid Restorations (O)	54
1993 93-2	Sealing Ability of Bases and Cements Following Exposure to 30% Hydrogen Peroxide and Sodium Perborate. (O)	50
1993 93-48	An Average Mandibular Anterior Implant Angle (O)	55
1993 93-49	A Comparison of Luting Cements for the CeraOne Abutment System (O)	56
1993 93-11	The Effect of Bone Marrow Stage on Interleukin-6 Production using the HLA(PCR) BR (O)	52
1993 93-12	The Effects of Transforming Growth Factor Beta and platelet Derived Growth Factor on Human Gingival Fibroblasts and Human Periodontal Fibroblasts Grown in Serum and Serum Free Media (O)	53
1993 93-3	Steremicroscopic Evaluation of Apical Retropreparation Shapes Utilising an Ultra-sonic versus a Micro-head Handpiece (O)	51

#### DEPARTMENT OF FAMILY PRACTICE

1992 92-14	Safety and Efficacy of Clarithromycin and Erythromycin Ethylsuccinate Suspensions in the Treatment of Children with Community-Acquired Pneumonia. (O)	60
1992 92-16	Comparison of Family Appgar Scores of Outpatients with Principal Diagnoses and Medication Use. (T)	61
1992 92-24	The Positive and Negative Predictive Value of a Routine Fifty Gram Glucose Screening Test at the Initial Prenatal Visit. (C)	62
1992 92-41	The Effectiveness of Interventions to Increase Compliance with Breast Cancer Screening Guidelines of the US Task Force for Clinical Preventive Services. (T)	63
1992 92-54	Determination of the Prevalence of Genital Chlamydia Infection in Males Using Enzyme Immunoassay of Urinary Sediment. (O)	64
1993 93-14	Smoking Cessation in Active Duty Army Trainees: The Effects of Direct Health Care Provider Advice and Follow-up. (T)	65
1993 93-32	Infant Feeding Practices in the Military Community: The Incidence and Duration of Breast Feeding in the Military Community and the Factors Affecting this Decision (O)	68

1993 93-23	The Effect of Self-Care Booklet on the Self-Efficacy of Parents (O)	66
1993 93-25	HELLP Syndrome: The Incidence - A Prospective Study	67
1993 93-41	Comparison of Oral, Tympanic Skin Thermometry in an Emergency Department	69
1993 93-62	A Survey of Resident Perceptions of Effective Teaching Behaviors in Different Residencies (O)	70

#### DEPARTMENT OF MEDICINE

1989 89-46	Effects of Non-Ionic surfactants in sunburns using a rat model (C)	71
1990 90-16	Study of Vespa Fire Ant Venom in the Diagnosis of Fire Ant Allergy. (O)	72
1990 91-14	Comparison of Intravenous H-2 Antagonists and Their Influence on Gastric Emptying on Insulin Dependent Diabetics. (O)	73
1991 92-1	Serologic Survey of Active Duty Dependent and Retired Military Population for Evidence of <i>Helicobacter pylori</i> ( <i>Campylobacter pylori</i> ) Infection at a US Army Medical Treatment Facility. (T)	74
1991 92-10	A Comparison of the Efficacy, Safety, and Tolerance of Ceftibuten (SCH 39720) 300 mg Given BID and Augmentin 500 mg Given TID in the Treatment of Community Acquired Penumonia. (O)	75
1991 92-9	A Comparison of the Efficacy, Safety, and Tolerance of Ceftibuten (SCH 39720) 400 mg (1 x 400 mg capsule ) in the Fed and Fasted State and Augmentin Amoxicillin/Clavulanate 1.5 gm (1 x 500 mg tablet TIC) in the Fed State in the Treatment of Acute Exacerbations of Chronic Bronchitis. (O)	76
1992 92-18	Prediction of Endogenous Erythropoietin Levels from the Hematocrit and Serum Creatinine. (T)	77
1992 92-30	Techniques of Use of Metered Dose Inhalers. (O)	78
1992 92-47	A Double-Blind, Placebo Controlled, Parallel Group, Multicenter Study of the Use of Weekly Azithromycin as Prophylaxis Against the Development of <i>Mycobacterium avium</i> complex Disease in HIV Infected People. (O)	79
1992 92-60	A Double-Blind Randomized Parallel Study of the Antiemetic Effectiveness of IV Dolasetron Mesylate VS IV Sofran in Patients Receiving Cisplatin Chemotherapy. (O)	80

1992 92-61	A Five Arm Double-Blind Randomized Dose-Response Study of the Antiemetic Effectiveness of IV Dolasetron Mesylate in Patients Receiving Cisplatin Chemotherapy. (O)	81
1992 92-67	Evaluation of the Use of <sup>99m</sup> Tc-Technetium Paratechnetate with Potassium Perchlorate Wash-Out and <sup>99m</sup> Tc-Technetium MIBI in Parathyroid Imaging in Patients with Suspected Parathyroid Neoplasia or Hyperplasia. (T)	82
1992 92-78	A Multicenter, Open Label, Pilot Study of Azithromycin in the Outpatient Treatment of Lower Respiratory Tract Infection Due to Atypical Respiratory Pathogens. (O)	84
1993 93-30	A Multicenter, Open Label, Pilot Study of Azithromycin the Outpatient Treatment of Lower Respiratory Tract Infection Due to Atypical Respiratory Pathogens. (O)	88
1993 93-31	A Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of Three Doses of CP-0127 and Placebo in Patients with Presumed Sepsis and The Systemic Inflammatory Response Syndrome (SIRS) (O)	89
1993 93-24	The Detection of Antibodies to Helicobacter pylori in Samples obtained with the Principal OraSure Oral Specimen Collection Device (O)	86
1993 93-51	A Study to Investigate the Efficacy and Safety of Oral Valacyclovir (1000mg or 500mg, twice daily) Compared with Placebo in the Treatment of Recurrent Genital Herpes in Immunocompetent Patients (O)	91
1993 93-34	A Comparison of Arm and Calf Blood Pressure Values Obtained by the Dinamap Device (C)	90
1993 93-6	Phase I, Trial of VP-16 + Immunex r-GM-CSF in Patients with Advanced Malignancies (O)	85
1992 92-73	Comparative Study of Liver Biopsies and Quantitative Hepatobiliary Scanning in Patients with Hepatitis (C)	83
1993 93-26	A Comparative Trial of 256U87 and Acyclovir for the Treatment of First-Episode Genital Herpes Infection (O)	87
1993 93-64	A Randomized, Double-Blind, Multicenter Trial Comparing 10 Days of Oral Therapy with CP-99,219 (100mg or 300mg Daily) or Ofloxacin (800mg Daily) for the Treatment of Acute Exacerbation of Chronic Bronchitis. (O)	92

#### DEPARTMENT OF NURSING

1992 92-72	Experiences of Couples Participating in a Counseling Program to Abate Spouse Abuse: A Descriptive Clinical Report. (C)	93
1993 93-15	Satisfaction with Patient Controlled Analgesia (O)	94

## OB/GYN

- 1993  
93-5 The Effect of Uncomplicated Labor and Delivery on Serum Levels of Creatine Kinase (C) 95

## PATHOLOGY

- 1993  
93-50 Application of Ophthalmoscopic Examination Fluorescein Angiography in Early Diagnosis of Candida Endophthalmitis in Rabbits (O) 96

## DEPARTMENT OF PSYCHIATRY AND NEUROLOGY

- 1992  
92-23 Determinants in the Development of Insight for Substance Dependence in Rehabilitation Facility Inpatients. (C) 97
- 1992  
92-43 The First Break Psychosis Study. (C) 98
- 1992  
92-59 Monitoring of Mood States in Substance Dependent Subjects in Inpatient Rehabilitation Facility. (O) 100
- 1993  
93-13 Dexamethasone Augmentation in the Treatment of Major Depression (O) 101
- 1993  
93-27 Evaluation of Smoking Rates After Cessation of Alcohol or Illicit Drug Use (O) 103
- 1993  
93-37 The Relationship of Menstrual Phase to Presentation of Acute Psychiatric Treatment (O) 104
- 1993  
93-47 A Double-Blind, Placebo Controlled Exploratory Study of Sertraline in Adolescent Outpatients with Non-Delusional Major Depressive Disorder (O) 105
- 1993  
93-18 Determination of Effects of Birth Order (First born vs Second Born) on Death Anxiety in a Military Outpatient and Non-Psychiatric Population 102

## DEPARTMENT OF RADIOLOGY

- 1990  
90-1 Technetium 99m Antimony Trisulfide Colloid for Investigation of Lymphatic Drainage. (O) 106
- 1990  
90-36 Treatment of Internal Contamination by Plutonium and Other Transuranic Elements With Two Investigational New Drugs (Ca-DTPA and Zn-DTPA). (O) 107
- 1990  
91-13 Scintigraphy of Tumors of Neuroectodermal Origin with 131-Iodine-Meta-Iodobenzylguanidine Sulfate (131-I-MIBG). (O) 108
- 1991  
91-39 Adrenal Imaging with 131Iodine-6-Beta-IodoMethyl-Nor-cholesterol (NP-59). (O) 109

DEPARTMENT OF SURGERY

1985 85-5	Advanced Trauma Life Support Course. (O)	110
1988 88-5	Investigation of Cryotreatment on the Epiphysis of Growing Rabbit Bones. (O)	111
1988 88-6	Distal thigh pain and stress transfer in uncemented total hip arthroplasties. A scientigraphic analysis	112
1990 90-25	A Prospective Randomized Study of the Prophylaxis of Thromboembolism: Dihydroergotamine/Heparin versus Sodium Warfarin in Total Joint Patients. (T)	113
1990 90-32	Training General Surgery Residents Utilizing Goat and Pig Models. (O)	114
1991 91-59	Use of the Rat Model for Teaching and Practicing Microvascular Surgical Technique. (O)	115
1991 91-81	Evaluation of the Current Routine Post Op Feeding Regimens. (O)	116
1991 91-82	The Effect of Non-Ionic Surfactants on GI Mucosal Integrity and Bacterial Translocation from the Gut. (C)	117
1992 92-3	Free Dermal Fat Grafts in Expanded Tissue Recipient Pockets in the Pig. (T)	118
1992 92-4	The Effect of Pentoxifyline vs Allopurinol on Sigmoid Mucosal Ischemia During Abdominal Aortic Surgery. (O)	119
1992 92-12	Implications of Urinary Phosphate Level After Thyroid or Parathyroid Surgery. (T)	120
1992 92-13	The Effect of IV Pentoxifylline on Endotoxin Mediated Small Bowel Mucosal Ischemia Using the Pig Model. (O)	121
1992 92-21	A Comparison of Rigidity of Combat External Fixators. (T)	122
1992 92-26	The Effects of Somatostatin Analog (Octreotide Acetate) on Wound Healing in the Mouse Model. (O)	123
1992 92-27	Natural History of Free Gallstones Within the Peritoneum in a Rabbit Model and Mouse Model. (O)	124
1992 92-52	Laparoscopic Appendectomy vs Standard Appendectomy. (O)	125
1993 93-35	Effects of Somatostatin Analog (Octreotide Acetate) on Wound Healing in Bowel and Gastric Anastomosis in the Rat Model. (O)	130

1993 93-36	Efficacy of a New Blunt Tip Trocar (T)	131
1993 93-4	The Effect of Early Enteral Feeding on Patients Undergoing Abdominal Aortic Surgery (O)	127
1993 93-38	Biomechanical Analysis: Multiple Leg Screw vs Plate Fixation of the Distal Fibula (O)	132
1993 93-40	The Predictors of Long-Term Outcome in Elderly Patients with Colles' Fractures (T)	133
1993 93-16	Stomach Valve Redesign Efficacy Study (C)	128
1993 93-17	Gastrostomy Tube Balloon Comparison Study (T)	129
1993 93-42	Mechanical Peritoneal Retraction Laparoscopic Surgery (O)	134
1993 93-61	The Effect of Vitamin A on the Steroid Induced Defect in Wound Healing: A Time Course Study in Mice (O)	135
1993 93-63	The Adverse Effects of Octreotide on Wound Healing in Rats Study in Mice (O)	136
1993 93-65	The Use of 1% Lidocaine With/Without Epinephrine in Breast Biopsy (O)	137
1993 93-1	Early Detection of Hearing Loss Due to Ototoxic Agents by High Frequency Auditory Evaluation (T)	126

SOUTHWEST ONCOLOGY GROUP

1990 91-27	SWOG 8809: A Phase III Study of Alpha-Interferon Consolidation Following Chemotherapy with ProMACE-MOPP (Day 1-8) in Patients with Low Grade Malignant Lymphoma. (O)	138
1990 91-29	SWOG 8854 (ECOG 1189, NCCTG 898051) Prognostic Value of Cytometry Measurements of Breast Cancer DNA from Postmenopausal Patients with Involved Nodes and Receptor Positive Tumors: A Companion Protocol to SWOG 8814. (O)	139
1990 91-30	SWOG 8814 (ECOG-4188, NCCTG-883051) Phase III Comparison of Adjuvant Chemoendocrine Therapy with CAF and Concurrent or Delayed Tamoxifen to Tamoxifen Alone in Postmenopausal Patients with Involved Axillary Lymph Nodes and Positive Receptors. (O)	140
1990 91-31	SWOG 8897 (EST-2188, CALGB-8897, INT 0102) Phase III Comparison of Adjuvant Chemotherapy with or without Endocrine Therapy in High-Risk, Node Negative Breast Cancer Patients, and a Natural History Follow-Up Study in Low-Risk, Node Negative Patients. (O)	141
1990 91-34	SWOG 8931: (EST-3189, INT-0108) Phase III Comparison of CAF and a 16-Week Multi-Drug Regimen as Adjuvant Therapy for Patients with Hormone Receptor Negative, Node Positive Breast Cancer. (O)	142

1990 91-35	SWOG 8947 - Central Lymphoma Serum Repository Protocol. (Comparison Study to SWOG 8516, 8736, 8809 or 8816.) (O)	143
1990 91-36	SWOG 9037 - Prediction of Recurrence and Survival in Node Negative Breast Cancer Patients Using a Panel of Prognostic Factors. (T)	144
1991 91-41	SWOG 8736 - Treatment of Localized Non-Hodgkin's Lymphoma: Comparison of Chemotherapy (CHOP) to Chemotherapy Plus Radiation Therapy. (O)	145
1992 91-42	SWOG 9040 - Intergroup Rectal Adjuvant Protocol, A Phase III study (C)	146
1991 91-50	SWOG 8851 - Phase III Comparison of Combination Chemotherapy (CAF) and Chemohormonal Therapy (CAF + Soladex or CAF + Soladex + Tamoxifen) in Premenopausal Women with Axillary Node Positive, Receptor Positive Breast Cancer -- Intergroup. (O)	147
1991 91-53	SWOG 8952 - Treatment of Advanced Hodgkin's Disease - A Randomized Study Comparing ABVD vs NOPP/ABV Hybrid. (O)	148
1991 91-55	SWOG 9013 - A Prospective Randomized Comparison of Combined Modality Therapy Squamous Carcinoma of the Esophagus: Chemotherapy Plus Surgery versus Surgery Alone for Patients with Local Regional Disease, Phase III Intergroup. (O)	149
1991 91-67	SWOG 9012, Evaluation of Low Dose Alpha-Interferon in patients with Advanced Renal Cell Carcinoma. (C)	150
1991 91-68	SWOG 9028, A Phase III Randomized Trial of Combinatio.. Therapy for Multiple Myeloma Comparison of (1) VAD to VAD/Verapamil/Quinine for Induction with Crossover to VAD/Verapamil/Quinine for VAD Induction Failures; (2) Alpha 2-b Interferon or Alpha 2-b Interferon Plus Prednisone for Remission Maintenance. (O)	151
1991 91-69	SWOG 9111, (EST-1690) Post-Operative Adjuvant Interferon Alpha-2 in Resected High Risk Primary and Regionally Metastatic Melanoma, Intergroup. (O)	153
1991 91-70	SWOG 9125, A Phase II Trial of CVAD/Verapamil/Quinine for Treatment of Non-Hodgkins Lymphoma. (O)	154
1992 92-6	SWOG 9008, Trial of Adjuvant Chemoradiation After Gastric Reaction for Adenocarcinoma, Phase III. (O)	155
1992 92-7	SWOG 9108 (CALGB-9011, NCIC-CTGCL.1), A Phase III Comparison of Fludarabine Phosphate vs Chlorambucil vs (fludarabine) Phosphate Plus Chlorambucil in Previously Untreated B-Cell Lymphocytic Leukemia. (O)	156
1992 92-37	SWOG 9007, Cytogenic Studies in Leukemia Patients, Ancillary. (O)	157
1992 92-38	SWOG 9031, A Double-Blind Placebo Controlled Trial of Daunomycin and Cytosine Arabinoside with or without rhG-CSF in Elderly Patients with Acute Myeloid Leukemia, Phase III. (O)	158

1992 92-39	SWOG 9139, Adjuvant Therapy of Primary Osteogenic Sarcoma Phase II. (O)	159
1992 92-40	SWOG 9151, Evaluation of Topotecan in Hepatoma. (O)	160
1992 92-48	SWOG 9054, Ancillary Bone Mineral Density Study in Premenopausal Women on EST 5188 (Intergroup 0101). (O)	161
1992 92-49	SWOG 9019, A Phase III, Randomized Prospective Comparison Between Chemotherapy Plus Radiotherapy and the Same Chemotherapy Plus Radiotherapy Together with Surgery for Selected Stage IIIA (Positive Mediastinal Nodes) and Selected Stage IIIB (No Malignant Effusion) Non-Small Cell Lung Cancer. (O)	162
1992 92-50	SWOG 9035, Randomized Trial of Adjuvant Immunotherapy with an Allogenic Melanoma Vaccine for Patients with Intermediate Thickness Node Negative Malignant Melanoma (T aNOMO). (O)	163
1992 92-51	SWOG 9116, Evaluation of Piroxantrone in Disseminated Malignant Melanoma, Phase II. (T)	164
1992 92-62	SWOG 9062, Evaluation of 96 Hour Infusion 5-FU + Cisplatin + Alpha Interferon in Patients with Recurrent/Metastatic Squamous Cell Carcinoma of Head and Neck, Phase II. (T)	165
1992 92-63	SWOG 9134, A Phase II, Trial of Taxol and Granulocyte-Colony Stimulating Factor (G-CSF) in Patients with Advanced Soft-Tissue Sarcoma. (T)	166
1992 92-64	SWOG 9135, A Phase II Trial of Taxol and Granulocyte-Colony Stimulating Factor (G-CSF) in Patients with Pancreatic Adenocarcinoma. (T)	167
1992 92-65	SWOG 9147, Evaluation of Tamoxifen in Desmoid Tumors, Phase II. (T)	168
1992 92-68	SWOG 8955, Treatment of Stage D, Hormone Refractory Carcinoma of the Prostate with 5-Fluorouracil and Roferon-A Phase II. (O)	169
1992 92-69	SWOG 9059, Phase III Comparison of Standard Radiotherapy versus Radiotherapy Plus Simultaneous Cisplatin, versus Split-Course Radiotherapy Plus Simultaneous Cisplatin and 5-Fluorouracil, in Patients with Unresectable Squamous Cell Carcinoma of the Head and Neck. (O)	170
1992 92-70	SWOG 9129, Phase III Randomized Study of All-Trans Retinoic Acid versus Cytosine Arabinoside and Daunorubicin as Induction Therapy for Patients with Previously Untreated Acute Promyelocytic Leukemia. (O)	171
1992 92-71	SWOG 9150, Evaluation of Topotecan in Gastric Cancer, Phase II. (O)	172
1993 93-56	SWOG 9248, A Phase II Trial of Paclitaxel (TAXOL) in Patients with Metastatic Refractory Carcinoma of the Breast. (O)	190

1993 93-7	SWOG 9104, Evaluation of Doxorubicin/Vinblastine Combined with 173 Inhibitors (Trifluoperazine/Verapamil) of P-Glycoprotein in Patients with Advanced Renal Cell Carcinoma, Phase II (O)	
1993 93-8	SWOG 9133, Randomization Trial of Subtotal Nodal Irradiation versus Doxorubicin Plus Vinblastine and Subtotal Nodal Irradiation for Stage I-IIA Hodgkin's Disease, Phase III (O)	174
1993 93-9	SWOG 9148, A Phase II Study of Cisplatin Preceded by a 12- Hour 175 Continuous Infusion of Concurrent Hydroxyurea and Cytosine Arabioside (ARA-C) for Patients with Untreated Extensive Stage Small Cell and Non-Small Cell Lung Carcinoma (O)	175
1993 93-10	SWOG 9215, Quality of Life on Breast Cancer Adjuvant Trial (T)	176
1993 93-19	SWOG 9003, Fludarabine for Waldenstrom's Macroglobulinemia (WM): A Phase II Pilot Study for Untreated and Previously Treated Patients.	177
1993 93-20	SWOG 9015, A Randomized Trial of Pre- and Post-Operative Chemotherapy Compared to Surgery Alone for Patients with Operable Non-Small Cell Carcinoma of the Lung, Phase III (O)	178
1993 93-21	SWOG 9201, Phase III, Trial to Preserve the Larynx: Induction Chemotherapy and Radiation Therapy versus Radiation Therapy (O)	179
1993 93-22	SWOG 9205, Central Prostate Cancer Serum Repository Protocol (O)	180
1993 93-28	SWOG 9158, Evaluation of Trans Retinoic Acid and Alpha Interferon in Patients with Squamous Cell Carcinoma of the Larynx (Stage IV) (O)	181
1993 93-29	SWOG 9216, A Randomized Phase III Study of CODE Plus Thoracic Irradiation versus Alternating CAV and EP for Extensive Stage Small Cell Lung Cancer (O)	182
1993 93-43	SWOG 9126, A Controlled Trial of Cyclosporine as a Chemotherapy Resistance Modifier in High Risk Acute Myeloid Leukemia, Phase III (O)	183
1993 93-44	SWOG 9237, Evaluation of Tapotecan in Refractory and Relapsing Multiple Myeloma, Phase II (O)	184
1993 93-45	SWOG 9240, A Phase II Trial of CVAD for Treatment of Non- Hodgkin's Lymphoma (O)	185
1993 93-46	SWOG 9246, A Phase II Evaluation of Taxol in Patients with Relapsed Non-Hodgkin's Lymphoma or Relapsed Hodgkin's Disease. (O)	186
1993 93-53	SWOG 9221, Phase III Double-Blind Randomized Trial of 13-cis Retinoic Acid (13-cRA) to Prevent Second Primary Tumors (SOTs) in Stage I non-Small Cell Lung Cancer. (O)	187
1993 93-54	SWOG 9157, Trial of All Trans-Retinoic Acid in Hepatoma, Phase II (O)	188

1993 93-55	SWOG 9210, A Phase III Randomized Trial of Combination Therapy for Multiple Myeloma Comparison of (1) VAD-P to VAD-P/Quinine for Induction; (2) Randomization of Prednisone Dose Intensity for Remission Maintenance. (O)	189
1993 93-56	SWOG 9248, A Phase II Trial of Paclitaxel (Taxol) in Patients with Metastatic Refractory Carcinoma of the Breast (O)	190

USA MEDDAC, FT CAMPBELL, KY

1981 78-14	Intraocular Lens Study. (O)	192
1990 78-14A	Pediatric Intraocular Lens Study. (C)	193
1992 92-33	Prolotherapy in the Treatment of Chronic Low Back Pain - A Double-Blind Study. (T)	194
1992 92-55	The Effects of Parental Deployment on Childhood Behavior. (O)	195
1993 93-52	Pregnancy Exercise Patterns and Post-partum Fitness (O)	197

USA MEDDAC, FT RUCKER, AL

1993 93-60	Clinical Comparability of Two Once-Daily Forms of Diltiazem: Effect of Substitution on Blood-Pressure Control (O)	198
---------------	---	-----

USA MEDDAC, FT JACKSON, SC

1993 93-33	Vocal Cord Function and Voice Quality Evaluation of Active Duty US Army Drill Instructors (O)	196
---------------	---	-----

Author Index

Subject Index

Distribution List

\*\*\*\*\*

Code:

O - Ongoing  
C - Completed  
T - Terminated  
W - Withdrawn  
P - Published  
PR - Presented

**PUBLICATIONS FY 93**

**DEPARTMENT OF CLINICAL INVESTIGATION**

Pashley DH, Ciucchi B, Hidehiko S, and Horner, JA: Permeability of Dentin to Adhesive Agents. Quintessence International 1993;24:618-631

Simpson MD, Horner JA, Brewer PD, Eichmiller F, Pashley DH: Effects of Aluminum Oxalate/Glycine Pretreatment Solutions of Dentin Pumeability. Am Journal of Dentistry 1992;5(6):324-328

Hamilton JN, Thompson SH, Scheidt MJ, McQuade MJ, VanDyke T, Plowman K: Correlation of Subclinical candidal colonization of the dorsal tongue surface with the Walter Reed Staging Scheme for patients infected with HIV-1. Oral Surg Oral Med Oral Path 1992; 73(1):47-51.

Guy SC, Mcquade MJ, Scheidt MJ, McPherson JC, Rossman JA, VanDyke TE: "Invitro Attachment of Human Gingival Fibroblasts to Endosseous Implant Materials." Journal of Periodontology 1993;64(6): 542-546.

Tewfik HM, Pashley DH, Horner JA, Sharawy MM: "Structural and Functional - Changes in Root Dentin Following Exposure to KTP/532 Laser." Journal of Endodontics, 1993;10(19): 492-497.

Sutherland DE: "Labcalc - A PC-Compatible Spreadsheet Template for Laboratory Calculations." Laboratory Medicine, 1993;8(24) 525-529.

Foster KH, Kulild JC, Weller RN: "Effect of Smear Layer Removal on the Diffusion of Calcium Hydroxide Through Radicular Dentin." Journal of Endodontics, 1993;3(19) 136-140.

Simpson MD, Horner JA, Brewer PD, Eichmiller F, Pashley DH: Effects of aluminum oxalate/glycine pretreatment solutions on dentin permeability. Am J Dent 1992; 5(6):324-328.

McCollum J, O'Neal RB, Brennan WA, Van Dyke TE, Horner JA: The effect of titanium implant abutment surface irregularities on plaque accumulation in vivo. J Periodontol 1992; 63:802-805.

## DENTAL ACTIVITY

Steidley KE, Thompson SH, McQuate MJ, Strong SL, Scheidt MJ, Van Dyke TE: A comparison of T4:T8 lymphocyte ratio in the periodontal lesion of healthy and HIV-positive patients. *J Periodontol* 1992; 63:753-756.

McCollum J, O'Neal RB, Brennan WA, Van Dyke TE, Horner JA: The effect of titanium implant abutment surface irregularities on plaque accumulation in vivo. *J Periodontol* 1992; 63:802-805.

Liewehr FR, Rouse LE and O'Neill LJ: A Preclinisal Model for Exodontia. *J Dent Educ* 1992;56(6):396-398

Liewehr FR, Kulild JC, Primack PD: Improved Density of Gutta-Pucha After Warm Lateral Condensation. *J Endodon.* 1993(10)19: 489-491.

Pashley DH, Ciucchi B, Hidehiko S, and Horner, JA: Permeability of Dentin to Adhesive Agents. *Quintessence International* 1993;24:618-631

Hamilton JN, Thompson SH, Scheidt MJ, McQuade MJ, VanDyke T, Plowman K: Correlation of Subclinical candidal colonization of the dorsal tongue surface with the Walter Reed Staging Scheme for patients infected with HIV-1. *Oral Surg Oral Med Oral Path* 1992; 73(1):47-51.

Steflic DE, Sisk AL, Parr GR, Gardner LK, Hanes PJ, Lake FT, Berkery DJ, Brewer P: "Psteogenesis at the dental implant interface: High-voltage electron microscopic and conventional transmission electron microscopic observations. *J. Biomed Mat Res* 1993; 27:791-800.

Liewehr Fr, Kulild JC and Primack PD: Obturation of a C-Shaped Canal Using an Improved Method of Warm Lateral Condensation. *Journal of Endodontics*, 1993;9(19):474-477.

Schneck DL, Gross PD, Tabor MW: "Odontogenix Myxoma - Report of 2 Cases with Reconstruction Considerations." *Journal of Oral and Maxillofacial Surgery*, 1993;51(8):35-940.

Jurcak JJ, Bellizzi R, Loushine RJ: "Successful Single-Visit Endodontics During Operation Desert Shield." *Journal of Endodontics*, 1993;19(8):412-413.

Peacock ME, Sutherland DE, Schuster GS, Brennan WA, O'Neal RB, Rong SL, VanDyke TE: "The Effect of Nicotine on Reproduction and Attachment of Human Gingival Fibroblasts In-Vitro." *Journal of Periodontology*, 1993;64(7):658 - 665.

## DEPARTMENT OF FAMILY PRACTICE

Blount BW, Krober M, Gloych SS, et al: The nutritional status of rural Bolivian children. *Military Medicine* 1993;6:158:367-370.

Goldman DP, Arsenstein AW, Bolan CD: Human Ehrlichiosis - A Newly Recognized Tick-borne Disease. *Am Fam Phys* 1992;46(1):199-208.

Blount BW, Hart G, Ehreth JL: A Description of the content of Army family practice. *J Am Board Fam Pract* 1993;6:143-152.

## DEPARTMENT OF PATHOLOGY

Steidley KE, Thompson SH, McQuade MJ, Strong SL, Scheidt MJ, Van Dyke TE: A comparison of T4:T8 lymphocyte ratio in the periodontal lesion of healthy and HIV-positive patients. *J Periodontal* 1992; 63:753-756.

Steflik DE, Parr Gr, Sisk AL, Lake FT, Hanes PJ, Berkery DJ, and Brewer PD: Osteoblast activity at the dental bone-implant interface: Transmission electron microscopic and high voltage electron microscopic observations. Accepted for publication, 1994.

Steflik De, Sisk AL, Parr GR, Gardner LK, Hanes PJ, Lake FT, Berkery DJ, Brewer P: Osteogenesis at the dental interface: High-voltage electron microscopic and conventional transmission electron microscopic observations. *J Biomed Mat Res* 1993;27:791-800.

Sisk AL, Steflik De, Parr GR, Lake FT, Hanes PJ, Horner J, Brewer P, McKinney RV. Scanning Electron Microscopic (SEM) Observations From A Comparative Implant Investigation. *J. Dent. Res.* 1992;71:22.

Steflik DE, Sisk AL, Parr GR, Lake FT, Hanes PJ, Brewer P. TEM and HVEM of Osteogenesis At the Implant Interface. *J. Dent. Res.* 1993;72:354.

Gardner LK, Steflik DE, Parr Gr, Sisk AL, Hanes PJ, Brewer P, Horner J. SEM Morphometry of the Bone INTERface to Prosthodontically Loaded Implants. *J. Dent. Res.* 1993;72(Special Issue): 273.

Steflik De, Parr Gr, Sisk AL, Hanes PJ, Lake FT, Berkery DJ, Brewer P, Horner J, Gardner LK, Koth DL. Ultrastructural and Histomorphometric Observations of a Comparative Experimental Dental Implant Investigaiton. *Trans. Doc. Biomat.* 1993;16:108.

Simpson MD, Horner JA, Brewer PD, Eichmiller F, Pashley DH: Effects of Aluminum Oxalate/Glycine Pretreatment Solutions of Dentin Pumeability. *Am Journal of Dentistry* 1992;5(6):324-328

Hamilton JN, Thompson SH, Scheidt MJ, McQuade MJ, VanDyke T, Plowman K: Correlation of Subclinical candidal colonization of the dorsal tongue surface with the Walter Reed Staging Scheme for patients infected with HIV-1. *Oral Surg Oral Med Oral Path* 1992; 73(1):47-51.

Sen JK, Keaton MR: Acute myelogenous, minimally differentiated (Mo) leukemia subsequent to chemotherapy for chronic lymphocytic leukemia. *Am Soc Clin Pathol Check Sample Hematology No. H 92-10 (H-247)*, Chicago: ASCP Press 1993.

Romero N, Ranlett RD: Myxoid malignant fibrous histiocytoma. Chicago (IL), American Society of Clinical Pathologists Check Sample TD 93-4 (TD-120), 1993.

Wilkerson RW, Sen JK: Intravascular large cell lymphomatosis (angiotropic large cell lymphoma). Chicago (IL), American Society of Clinical Pathologists Check Sample TD 93-5 (TD-121), 1993.

Steflik DE, Song MJ, Sisk AL, Parr GR, Hanes PJ, McKinney RV, Singh BB, Brewer P. High Voltage Electron Microscopic Studies of the Calcified Bone Interface with Endosteal Dental Implants. *Proc. Elect. Microsc. Soc. Amer.* 1991;21:36-37.

Steflik DE, Berkery DJ, Parr Gr, Sisk AL, Hanes PJ, Lake FT, Singh BB, Brewer P. The Bone-Dental Implant Interface: HVEM and TEM Observations. *Proc. Electr. Microsc. Soc. of America.* 1992;22(2):918-919.

Steflik DE, Sisk Al, Parr Gr, Gardner LK, Hanes PJ, Lake FT, Berkery DJ, Brewer P. Osteogenesis At the Dental Implant Interface: High Voltage Electron Microscopic and Conventional Transmission Electron Microscopic Observations. J. Biomed. Mat. Res. 1993;27(6): 791-800.

Sisk Al, Steflik DE, Parr Gr, Lake Ft, Hanes PJ, Horner J, Brewer P, McKinney RV. Scanning Electron Microscopic (SEM) Observations Observations From a Comparative Implant Investigaiton. J. Dent. Res. 1992;71:221.

#### DEPARTMENT OF MEDICINE

Sokol MS Kavolius J, Schaaf M, and D'Avis J: Recurrent Hyper-parathyroidism from Benign Neoplastic Seeding. Surgery 1993;113:456-61

Hilburn RB, Bookstaver D, and Warren W: Angiotensin - Converting Enzyme Inhibitor Hepatotoxicity. Annals of Pharmacotherapy 1993;19(9):474-477

Bettis VM, Vaughn RY, Guill MA: Erythematous plaques on the eyelids. Arch Dermatology 1993; 129(4):495-496.

Sokol MS, Kavolius J, Schaaf M, and D'Avis J: Recurrent Hyperparathyroidism from benign neoplastic seeding: A review with recommendations for management. Surgery 1993;113:456-461.

Stafford CT, Wise SL, Robinson DA, Crosby BL and Hoffman DR: Safety and efficacy of fire ant venom in the diagnosis of fire ant allergy. J Allergy Clin Immunol 1992;90:653-661.

Whitlock WL, Dietrich RA, Steimke EH, Tenholder MF. Rodotorula Rubra Contamination in Fiberoptic Bronchoscopy. Chest 102: 1516-9, November 1992.

Hilburn RB, Bookstaver D, Whitlock WL. Angiotensin-converting enzyme inhibitor hepatotoxicity: further insights. The Annals of Pharmacotherapy, 1993;27(9):1142,

Tenholder MF, Whitlock WL. Can the Nebulizer Survive? Arch Intern Med 153:2389, October 1993.

Fink L, Bauer F, Perry: American Journal of Hematology 1993;3(44) 196-200.

Johnson WM, Busnardo MS: "Silicosis Following Employment in the Manufacture of Silica Flour and Industrial Sand." Journal of Occupational Medicine, 1993;35(7):716 - 719.

#### DEPARTMENT OF NURSING

Anderson FD, Maloney JP and Redland AR: Study of Hope in Patients with Critical Burn Injuries from Nursing Forum. J. Burn Care Rehabilitation 1993;14:207-214.

Anderson FD, Cunningham SG and Jaloney JP: Indirect Blood Pressure Measurement - A Need to Reassess. American Journal of Critical Care. 1993;2:272-279.

## PSYCHIATRY & NEUROLOGY

Jensen PS, Shervette RE, Xenakis SN, Ricters J: American Journal of Psychiatry, 1993;8(150) 1203 - 1209.

Garland, FN: "Combat Stress-Control in the Postwar Theater - Mental-Health Consultation During the Redeployment Phase of Operation-Desert-Storm." Military Medicine, 1993;158(5):334-338.

## DEPARTMENT OF SURGERY

### General Surgery Service

Modesto VL, Satava RM, Jones, J: Delayed hemorrhage: A manifestation of occult vascular injury. Military Medicine 1993;158(7):6.

### Orthopaedic Service

Taylor DC, Dalton JD, Seaber AV, Garrett WE: Experimental Muscle Strain Injuries: Early Functional and Structural Deficits, and the Increased Risk for Reinjury. American Journal of Sports Medicine: 1993; 21:190-194.

Litschue P, Dougherty T, Taylor DC, Brooks D, Ryan J: The Effect of Cryopreservation on the Biomechanical Properties of the Muscle-Tendon Unit in a Rabbit Model. Letterman Army Institute of Research Institute Report, April, 1993.

Bernhardt M, Hynes RA, Blume HW, White AA: "Cervical Spondylotic Myelopathy." Journal of Bone and Joint Surgery-American Volume, 1993;75A: 119-128.

Jacob E, Erpelding JM, Murphy KP: A retrospective analysis of open fractures sustained by U.S. military personnel during Operation Just Cause. Mil Med 1992; 157(10):552-556.

PRESENTATIONS FY 93

DEPARTMENT OF CLINICAL INVESTIGATION

Chuang AH, Farnsworth WJ, McPherson JC III, McPherson JC Jr: Pluronic F-68 protects red blood cells from fluoride induced hemolysis at various temperatures. Combined Mtg SE Regional Chap Soc Toxicology and SE Regional Sec Soc Experi Biol Med, Athens, GA, 15-16 Oct 1992.

McPherson JC Jr, Fransworth WJ, Chuang AH, Runner RR, McPherson JC III: Saline wash injury of the red blood cell can be prevented by poloxamer 188. Combined Mtg SE Regional Chap Soc Toxicology and SE Regional Sec Soc Experi Biol Med, Athens, GA, 15-16 Oct 1992.

Farnsworth WJ, Chuang AH, Runner RR, McPherson JC III, McPherson JC Jr: Rheological changes in rat red blood cells following successive washings in saline, an albumin solution, or a pluronic F-68 solution. Southern Biomed Eng Conf, Memphis, TN, 2-4 Oct 1992.

McPherson JC Jr, Runner RR, Farnsworth WJ, Chuang AH, McPherson JC III: Fluoride ion decreases red blood cell deformability. Am Chemical Soc, Div Fluoride Chem Mtg, St Petersburg Beach, FL, 25-30 Jan 1993.

Chuang AH, Farnsworth WJ, McPherson JC III, McPherson JC Jr: Polaxamer 188 protects red blood cells from the hemolytic action of fluoride ion. Am Chemical Soc, Div Fluoride Chem Mtg, St Petersburg Beach, FL, 25-30 Jan 1993.

Farnsworth WJ, Chuang AH, McPherson JC III, McPherson JC Jr: The role of pH and temperature on the hemolytic activity of fluoride ion. Am Chemical Soc, Div Fluoride Chem Mtg, St Petersburg Beach FL, 25-30 Jan 1993.

Jones R, McPherson J III, Brennan W, Dirksen TR, Van Dyke T: Delayed administration of pluronic F-68 increased wound strength in rats. Int Assn Dent Res Mtg, Chicago, IL, 10-14 Mar 1993.

Stone R, Dirksen TR, McPherson J Jr, Brennan W, McPherson J III: Blood coagulation following intravenous administration of pluronic polyols. Int Assn Dent Res, Chicago, IL, 10-14 Mar 1993.

Horner JA, Paustian PW, Chuang AH, Runner RR, McPherson JC III, McPherson JC Jr: Poloxamer 407 increases rouleau formation *in vivo* but not *in vitro*. Federation Mtgs, New Orleans, LA, 28 Mar - 1 Apr 1993.

Paustian PW, Chuang AH, Runner RR, McPherson JC III, McPherson JC Jr: Comparison of poloxamers 188 and 407 on early burn wound contraction. Federation Mtgs, New Orleans, LA, 28 Mar - 1 Apr 1993.

Runner RR, Stone RL, McPherson JC III, McPherson JC Jr: Poloxamer 188 administration alters some events in the blood clotting cascade. Federation Mtgs, New Orleans, LA, 28 Mar - 1 Apr 1993.

Tobias SW, Stone RL, Runner RR, McPherson JC III, McPherson JC Jr: The erythrocyte sedimentation rate of blood in normal rats injected with pluronic F-127. Federation Mtgs, New Orleans, LA, 28 Mar - 1 Apr 1993.

Chuang AH, Farnsworth WJ, McPherson JC III, McPherson JC Jr: Temperature dependent fluoride induced hemolysis is antagonized by poloxamer 188. Federation Mtgs, New Orleans, LA, 28 Mar - 1 Apr 1993.

Farnsworth WJ, Chuang AH, Runner RR, McPherson III, McPherson JC Jr: The "glass effect" on red blood cells can be prevented by pluronic F-68. Federation Mtgs, New Orleans, LA, 28 Mar - 1 Apr 1993.

McPherson JC Jr, Runner RR, Farnsworth WJ, Chuang AH, McPherson JC III: Fluoride ion decreases red blood cell deformability. Nat'l Mtg Am Chem Soc Div Fluoride Chemistry. St. Petersburg Beach, FL, 25-30 Jan 1993.

Chuang AH, Farnsworth WJ, McPherson JC III, McPherson JC Jr: Poloxamer 188 protects red blood cells from the hemolytic action of fluoride ion. Nat'l Mtg Am Chem Soc Div Fluoride Chemistry. St. Petersburg Beach, FL, 25-30 Jan 1993.

Farnsworth WJ, Chuang AH, McPherson JC III, McPherson JC Jr: The role of pH and temperature on the hemolytic activity of fluoride ion. Nat'l Mtg Am Chem Soc Div Fluoride Chemistry. St. Petersburg Beach, FL, 25-30 Jan 1993.

Horner JA, paustian PW, Chuang AH, et al: Polaxamer 407 increases rouleau formation in vivo but not in vitro. FASEBS, New Orleans, LA 28 Mar - 1 Apr 93.

Paustian PW, Chuang AH, Runner Rr, et al: Comparison of poloxamers 188 and 407 on early burn wound contraction. FASEBS, New Orleans, LA, 28 Mar-1 Apr 93.

Runner Rr, Stone RL, McPherson JC III, et al: Poloxamer 188 administration alters some events in the blood clotting cascade. FASEBS, New Orleans, LA, 28 Mar - 1 Apr 93.

Tobias SW, Stone RL, Runner Rr, et al: The erythrocyte sedimentation rate of blood in normal rats injected with pluronic F-127. FASEBS, New Orleans, LA 28 Mar - 1 Apr 93.

Chuang AH, Farnsworth WJ, McPherson JC III, et al: Temperature dependent fluoride induced hemolysis is antagonized by poloxamer 188. FASEBS, New Orleans, LA, 28 Mar-1 Apr 93.

Farnsworth WJ, Chuang AH, Runner Rr, et al: The "glass effect" on red blood cells can be prevented by pluronic F-68. FASEBS, New Orleans, LA, 28 Mar - 1 Apr 93.

Aracuri M, LaVelle W, Tabor M, Fridrich K: Hyperbaric Oxygen Therapy Combined with Transcutaneous and Transmucosal Titanium Implants in Post-Radiotherapy Patients. Fifth International Congress on Preprosthetic Surgery: Vienna, Austria, 1993.

Paustain PW: Poloxamer 188 as a Treatment for Third-Degree Burns. Academic Emergency Medicine; 22:927,1993. Presented at the Annual Meeting of the society for Academic Emergency Medicine, May 17-20, 1993 in San Francisco, CA.

Farnsworth WJ, Chuang AH, Runner RR, McPherson III JC, and McPherson JC Jr. "Proceedings of the Eleventh Southern Biomedical Engineering Conference". 11:22-24, 1993

#### DENTAL ACTIVITY

Jones R, McPherson J III, Brennan W, Dirksen TR, VanDyke T: Delayed Administration of pluronic F-68 increased wound strength in rats. Int Assn Dent Res, Chicago, IL, 10-14 Mar 93.

Stone R, Dirksen TR, McPherson J Jr, Brennan W, McPherson J III: Blood coagulation following intravenous administration of pluronic polyols. Int Assn Dent Res, Chicago, IL, 10-14 Mar 93.

#### FAMILY PRACTICE

Carroll D: The family physician in disaster assistance. Unif Svc Acad Fam Phys, Corpus Christi, TX, 21-25 Mar 1993.

Blount BW: Time management. Unif Svc Acad Fam Phys, Corpus Christi, TX, 21-25 Mar 1993.

Dekoning B: EAMC's response to gateway to care. Unif Svc Acad Fam Phys, Corpus Christi, TX, 21-25 Mar 1993.

Wright G: The use of the computer-prescribing system as an instructional aid. Unif Svc Acad Fam Phys, Corpus Christi, TX, 21-25 Mar 1993.

Leibert B: Postpartum blues. Unif Svc Acad Fam Phys, Corpus Christi, TX, 21-25 Mar 1993.

Phelps K: Central diabetes insipidus presenting as acute renal failure. Unif Svc Acad Fam Phys, Corpus Christi, TX, 21-25 Mar 1993.

Moody R: Physician interface with a computer system. Unif Svc Acad Fam Phys, Corpus Christi, TX, 21-25 Mar 1993.

Robins G: The effect of terbutaline tocolysis on fetal weight and gestational duration. Unif Svc Acad Fam Phys, Corpus Christi, TX, 21-25 Mar 1993.

Beck RA: Retreat of Hemophilus Influenza Type B: Analysis of an immunization Program and Implications for OTO-HNS, Sep 1992.

Beck RA: Tumefactive fibroinflammatory lesion of pterygomaxillary space. Ann Mtg Am Acad OTO-HNS, Sep 1992.

Beck RA: Creation of a knowledge base in facial plastic and reconstructive surgery. Am Acad Facial Plastic Reconstructive Surg, Sep 1992.

Beck RA: Current Concepts in Otology Neurol. St. Thomas, VI, 10 Feb 93.

Blount BW, Hart G, Ehreth JL: A description of the content of army family practice. J Am Board Fam Pract 1993; 6:143-152.

Carroll D: The family physician in disaster assistance. Unif Svc Acad Fam Phys Corpus Christi, TX, 21-25 Mar 1993.

Blount BW: Time Management. Unif Svc Acad Fam Phys, Corpus Christi, Tx, 21-25 Mar 1993.

Blount BW: Caring for the bicultural family. Unif Svc Acad Fam Phys, Corpus Christi, TX, 21-25 Mar 1993.

Dekoning B: EAMC's response to gateway to care. Unif Svc Acad Fam Phys, Corpus Christi, TX, 21-25 Mar 1993.

Wright G: The use of the computer-prescribing system as an instructional aid. Unif Svc Acad Fam Phys, Corpus Christi, TX, 21-25 Mar 1993.

Leibert G: Postpartum blues. Unif Svc Acad Fam Phys, Corpus Christi, TX, 21-25 Mar 1993.

Phelps K: Central diabetes insipidus presenting as acute renal failure. Unif Svc Acad Fam Phys, Corpus Christi, TX, 21-25 Mar 1993.

Robins G: The effect of terbutaline tocolysis on fetal weight and gestational duration. Unif Svc Acad Fam Phys, Corpus Christi, TX, 21-25 Mar 1993.

#### DEPARTMENT OF MEDICINE

O'Connell MA, Sklarew PR, Goodman DL: Vocal cord dysfunction (VCD) in the outpatient setting. Am Coll Allergy Immunol Ann Mtg, Chicago, IL, 14-18 Nov 1992.

O'Connell MA: Effects of Beta adrenergic antagonists (BAA) on intracellular cyclic nucleotide generation in guinea pig airway smooth muscle. Am Acad Allergy Immunol 50th Anniversary Mtg, Chicago, IL, 12-16 Mar 1993.

Sen JK, Keaton MR: Acute myelogenous, minimally differentiated (Mo) leukemia subsequent to chemotherapy for chronic lymphocytic leukemia. Am Soc Clin Pathol Check Sample Hematology No. H 92-10 (H-247), Chicago: ASCP Press 1993.

O'Connell MA: Effects of Beta adrenergic antagonists (BAA) on intracellular cyclic nucleotide generation in guinea pig airway smooth muscle. Am Acad Allergy Immunol 50th Anniversary Mtg, Chicago, IL, 12-16 Mar 93.

Whitlock, WL: "Improved Metered-dose Inhaler Technique", 59th Annual International Scientific Assembly, American College of Chest Physicians, Orlando, FL 24-28 Oct 1993.

Whitlock WL: American College of Physicians, (Annual US Army Sponsored Meeting), "Diaphragmatic Myoclonus." Nov 1993.

#### PHARMACY SERVICE

Bookstaver DA: Evaluation of niacin compliance. Southeast Regional Clin Pharmacy Cholesterol Council, 26 Oct 1992.

**DEPARTMENT OF PATHOLOGY**

Baldwin J, RANLETT RD, BREWER PD: Localized fibrous pleural lesion of the lung (Paper from Podium). Presented 11th Ann Resid Research Day Seminar, DDEAMC, Fort Gordon (GA), 21 May 1993.

Baldwin J, RANLETT RD, BREWER PD: Localized fibrous pleural lesion of the lung (Poster). Presented 11th Ann Res Research Day Seminar, DDEAMC, Fort Gordon (GA), 21 May 1993.

LEWIS, DM: Clinical pathology conference. Presented at Oral Pathology, Oral Diagnosis, and Oral Medicine Short Course, US Army Dental Activity, Walter Reed Army Medical Center, Washington (DC), 26-30 April 1993.

LYLE JD: Decentralized laboratory testing. Invited workshop for presentation at 18th Ann Mtg Soc Armed Forces Med Lab Sci, Reno (NV), 1993.

SEN JK, STINCER LB, BREWER PD: B-cell chronic lymphocytic leukemia with immunologic features of hairy cell leukemia (CD5 negative, CD11C positive) (Poster). Presented 7th Annual Postgraduate Pathology Symposium, Med Coll of Georgia, Augusta (GA), 24-25 April 1993.

SHIKLE JF: Wegener's granulomatosis (Case Report). Presented Quarterly Meeting Augusta Regional Society of Pathologists, Fort Gordon (GA), 28 October 1993.

SHIKLE JF: Lepromatous leprosy (Case Report). Presented Quarterly Meeting Augusta Regional Society of Pathologists, Fort Gordon (GA), 28 October 1993.

Steflik DE, Sisk AL, Parr GR, Hanes PJ, Lake FT, BREWER PD, McKinney RV, Koth DL: Dental implant-bone interface: TEM and HVEM observations. (Paper from Podium). Presented 21st Ann Mtg Amer Assoc Dent Res, Boston (MA), 14 March 1993.

Steflik DE, Sisk AL, Parr GR, Lake FT, Hanes PJ, BREWER PD: TEM and HVEM of osteogenesis at the implant interface (Paper from Podium). Presented 71st Ann Mtg Int Assoc Dent Res, Chicago (IL), 13 March 1993.

Steflik DE, Parr GR, Sisk AL, Hanes PJ, Lake FT, Berkery DJ, BREWER PD, Gardner LK: Ultrastructural and histomorphometric observations of a comparative experimental dental implant investigation (Paper from Podium). Accepted for presentation 25th Int Biomaterials Symposium, and 19th Ann Mtg Soc for Biomaterials, Birmingham (AL), 29 Apr 1993.

WHITE JC: The HPLC method for hemoglobin A1C. Invited lecture to Department of Pathology staff, Augusta Regional Medical Center, Augusta (GA), 14 July 1993.

WHITE JC: Blood lead testing. Invited seminar to Department of Pathology & Area Laboratory Services staff, Madigan Army Medical Center, Fort Lewis (WA), 24-26 August 1993.

WHITE JC: Blood lead testing. Invited seminar to Preventive Medicine staff, Office of The Surgeon General, Alexandria (VA), 13 September 1993.

WHITE JC: Blood lead testing. Invited seminar to Department of Pathology & Area Laboratory Services staff, Walter Reed Army Medical Center, Washington (DC), 14-16 September 1993.

WOZNIAK A, MANSELL KB, BREWER PD, GOODHUE WW: The contaminated blood culture rate at a tertiary care teaching medical center (Poster). Presented 7th Annual Postgraduate Pathology Symposium, Med Coll of Georgia, Augusta (GA),

24-25 April 1993.

WOZNIAK A, BENTON FR, GOODHUE WW, Thomas DE, BREWER PD: Hepatitis B virus infection: seroprevalence in a US Army blood donor population, and hepatitis B surface antigen testing (Poster). Accepted for presentation at Soc Armed Forces Med Lab Sci 18th Annual Meeting, Reno (NV), 1993.

WOZNIAK A, MANSELL KB, BREWER PD, GOODHUE WW: The contaminated blood culture rate at a tertiary care teaching medical center (Poster). Accepted for presentation at the 94th Ann Mtg Amer Soc for Microbiol, Las Vega (NV), 1993.

WOZNIAK A, GOODHUE WW, YARDE-BAKER HE, GREEN J, BREWER PD: The correlation of acid-fast bacteria (AFB) direct smears with AFB cultures, using sputa from undiagnosed patients (Poster). Accepted for presentation at the 94th Ann Mtg Amer Soc for Microbiol, Las Vegas (NV), 1993.

#### DEPARTMENT OF PSYCHIATRY & NEUROLOGY

Sahebarao PM, Mukherjee S, Correnti EE, Hemant S, Kelkar, Chandramohan GW, Costa RM, and Sheffer R.: Plasma Membrane Phospholipid and Cholesterol Distribution of Skin Fibroblasts from Drug-Naive Patients at the Onset of Psychosis submitted at the Society of Biological Psychiatry Annual Meeting - 1993.

Sheffer R, Correnti E, Mukherjee S, Costa: "Neurological Signs at the Onset of Psychosis APA Annual Meeting, San Francisco, CA, 24 May 1993

Sheeley, Warden, Staudenmeier, Salazar: Traumatic Brain injury and Alcohol in a military population, APA Annual Meeting, San Francisco, CA, 24 May 1993

Mukherjee S, Scheffer R, Correnti E, Mahadek et al: Fibroblasts Studies in the First Break Psychosis Study APA Annual Meeting San Francisco, CA, 25 May 1993.

Mahadek, Mukherjee S, Scheffer R, Correnti E, et al: Abnormal Growth of Skin Fibroblasts from Drug Naive Psychotic Patients, Biological Psych Annual Meeting 20 May 1993.

Ryder GC: Fourteenth Annual Operational Aeromedical Problems Course, Aeromedical Psychiatry and Alcoholism, 24 Mar 93.

Williford J: American Society of Psychosomatic Obstetrics and Gynecology, Charleston, SC, March 1993.

Williford J: Georgia Psychiatric Physicians Association Annual Meeting, Atlanta, GA, February 1993.

Schenk, D: American Psychiatric Association Annual Meeting, San Francisco, CA, May 1993.

Perrotta, C: Menninger Military Psychiatry Conference, Topeka, KS, February 1993.

#### DEPARTMENT OF SURGERY

##### General Surgery Service

Beck R. Current concepts in otology neurology. St Thomas, Virgin Islands, 10 Feb 1993.

Workman CR, Modesto VL, Lepage PA, Calton WC, Martindale RG: Laparoscopic Gastrostomy Using Four-Point Fixation, Scientific Exhibit, American College of Surgeons annual Meeting, New Orleans, LA, 12-15 Oct 1992.

Mulligan CR, Calton WC, Craft D, Best N, Martindale Rg: The Influence of "Immune Modulating" Formulas on Endotoxin Stimulated Bacterial Translocation in Mice, Gary P. Wratten Symposium, Breckenridge, CO, 29 Mar - 1 Apr 1993.

Cresci G, Calton WC, Martindale RG: The Influence of Immune Stimulating Formulas on Bacterial Translocation in the Mouse Model, American society for Parenteral and Enteral Nutrition, San Diego, CA, February 1993.

Chapman DC, Martindale Rg, Calton WC: Effect of Corticosteroids and vitamin A On Initial Stages of Wound Healing, Gary P. Wratten Symposium, Breckenridge, CO, 19 Mar - 1 Apr 1993.

Flaherty SF, Ramirez MF, Martindale RG: Assessment of Right Ventricular Ejection Fraction Catheter, Gary P. Wratten Symposium, Breckenridge, CO, 19 Mar - 1 Apr 1993.

Duh OY, Engleharta A, Grant JP, Wolfe B, Gadacz T, Martindale RG, Way LW: Prospective Evaluation of Safety and Efficacy of Laparoscopic Gastrostomy, Society of American Gastrointestinal Endoscopic Surgeons, Phoenix, Arizona, Apr 1993.

Chapman DC, Martindale RG: Influence of Vitamin A On Steriod Induced Defects in Wound Healing, A dose Response, Gary P. Wratten Symposium, Breckenridge, CO, Apr 1993.

Harkins MP, Modesto VL, Lepage PA, St.Jean MR: Utilization of the "Crochet Hook Technique" in the Management of Branch Varicostits of the Lower Extremity. Scientific Exhibit, American College of Surgeons Anual Meeting, New Orleans, LA, 12 - 15 Oct 1992.

Waddell BE: The Effects of Octreotide on Wound Healing in Rats. The 79th Annual Clinical Congress American College of Surgeons Meeting, San Francisco, CA, 10 - 15 Oct 1993.

Jurkovich GH, Alverdy JC, Martindale RAG, Kudsk KA: Discouraging Post-operative Sepsis. Contemporary Surgery, 43:41-68, 1993.

#### Orthopaedic Service

Barja RH: External fixation during Operation Desert Storm: The Howmedica Ultra-x. Inter External Fixation Conf, Granada, Spain, 1-4 Oct 1992.

Barja RH: Pathologic metacarpal fracture secondary to amyloidoma. AAOS, San Francisco, CA, 18 Feb 1993.

Cresci, AB: Arthroscopic Evaluation and the Treatment of Osteochondral Lesions of the First Metatarsophalangeal Joint:, Federal Service Podiatry Conference, Hampton, Virginia, 27 Apr 93.

Erpelding, JM: Proximal Humerus Fractures: Indications and Technique for Arthroplasty, Jan 1993, 2nd SE Fracture Symposium, Charlotte, North Carolina.

Barja, RH: Hand Pathology IQ, American Academy of Orthopaedic Surgeons, Annual Convention San Francisco, California, February 1993.

Barja, RH: Use of External Fixator During Operation Desert Storm, The Persian Gulf War, The annual Meeting of the Virginia Orthopaedic Society,

Williamsburg, Virginia, April 30-May 2, 1993.

Barja, RH: Wound Healing, Upper Extremity and hand Therapy Course, Eisenhower Army Medical Center, Fort Gordon, Georgia, March 1-12, 1993.

Barja, RH: Hand Tumors, Benign and Malignant, Upper Extremity and Hand Therapy Course, Eisenhower Army Medical Center, Fort Gordon, Georgia, March 1-12, 1993.

Barja, RH: Biomechanics of the Shoulder, biomechanics Course for Orthopaedic Residents, Eisenhower Army Medical Center, Fort Gordon, Georgia, May 14-15, 1993.

Taylor DC: A Comparison of Passive Stretching and Muscular Contraction on the Viscoelastic Characteristics of Skeletal Muscle, 39th Annual Meeting of the Orthopaedic research Society, San Francisco, California February 16, 1993.

Taylor DC: Comparison of Stretching With Contraction on Biomechanical Characteristics of Muscle, 60th Annual Meeting of the American Academy of Orthopaedic Surgeons, San Francisco, California, February 23, 1993.

Taylor DC: Groin Pain in Athletes, 3d Congress of the Knee and Sports Medicine Section of the Western Pacific Orthopaedic Association, Sydney, Australia, September 11, 1993.

Geissele, AE: Thoracoplasty for the Treatment of Rib Prominence in Thoracic Scoliosis: Results and Technique. A Controlled Study, 28th Annual Meeting, Scoliosis Research Society, Dublin, Ireland, September 21, 1993.

Taylor DC: A Comparison of Passive Stretching and Muscular Contraction on the Viscoelastic Characteristics of Skeletal Muscle, 39th Annual Meeting of the Orthopaedic Research Society, San Francisco, CA, February 1993.

Taylor DC: Comparison of Stretching With Contractions on Biomechanical Characteristics of Muscle., 60th Annual Meeting of the American Academy of Orthopaedic Surgeons, San Francisco, CA, February 23, 1993.

Taylor DC: Arthroscopic Stabilization for Acute, Traumatic Anterior Shoulder Instability, Philippine Orthopaedic Society for Sports Medicine Symposium, Manila, Philippines, August 18, 1993.

Taylor DC: Groin Injuries in Athletes, Philippine Orthopaedic Society for Sports Medicine Symposium, Cebu City, Philippines, August 19, 1993.

Taylor DC: Arthroscopic Stabilization for Acute, Traumatic Anterior Shoulder Instability, Philippine Orthopaedic Society for Sports Medicine Symposium, Cebu City, Philippines, August 19, 1993.

Taylor DC: Syndesmosis Sprains of the Ankle, American Orthopaedic Society for Sports Medicine - Western Pacific Orthopaedic Association Traveling Fellowship Conference, Jakarta, Indonesia, August 21, 1993.

Taylor DC: Basic Science in Muscle Stretching and Injury, American Orthopaedic Society for Sports Medicine - Western Pacific Orthopaedic Association Traveling Fellowship Conference, Jakarta, Indonesia, August 23, 1993.

Taylor DC: Groin Injuries in Athletes, American Orthopaedic Society for Sports Medicine - Western Pacific Orthopaedic Association Traveling Fellowship Conference, Jakarta, Indonesia, August 23, 1993.

Taylor DC: Arthroscopic Shoulder Stabilization, American Orthopaedic Society

for Sports Medicine - Western Pacific Orthopaedic Association Traveling Fellowship Conference, Jakarta, Indonesia, August 23, 1993.

Taylor DC: Basic Science Studies in Muscle Stretching and Injury, American Orthopaedic Society for Sports Medicine - Western Pacific Orthopaedic Association Traveling Fellows Symposium, Brisbane, Australia, August 28, 1993.

Taylor DC: Arthroscopic Shoulder Stabilization, American Orthopaedic Society for Sports Medicine - Western Pacific Orthopaedic Association Traveling Fellows Meeting, Adelaide, Australia, August 30, 1993.

Taylor DC: Groin Injuries in Athletes, American Orthopaedic Society for Sports Medicine - Western Pacific Orthopaedic Association Traveling Fellows Meeting, Adelaide, Australia, August 30, 1993.

Taylor DC: Basic Science Studies in Muscle Stretching and Injury, American Orthopaedic Society for Sports Medicine - Western Pacific Orthopaedic Association Traveling Fellows Austin Meeting, Melbourne, Australia, September 1, 1993.

Taylor DC: Syndesmosis Sprains of the Ankle, Sports Medicine and Surgery Update, Wellington, New Zealand, September 3, 1993.

Taylor DC: Groin Injuries in Athletes, sports Medicine and Surgery Update, Wellington, New Zealand, September 3, 1993.

Taylor DC: Arthroscopic Shoulder Stabilization, Sports Medicine and Surgery Update, Wellington, New Zealand, September 3, 1993.

Taylor, DC: Basic Science Studies in Muscle Stretching and Injury, Orthopaedic and Sports Medicine Meeting, Queenstown, New Zealand, September 5, 1993.

Taylor DC: Syndesmosis Sprains of the Ankle, American Orthopaedic Society for Sports Medicine - Western Pacific Orthopaedic Association Sports Medicine Fellows Meeting, Sydney, Australia, September 1993.

Taylor DC: Groin Injuries in Athletes, 3d Congress of the Knee and Sports Medicine Section of Western Pacific Orthopaedic Association, Sydney, Australia, September 11, 1993.

Erpelding JM: "Proximal Humerus Fractures: Indications and Technique for Arthroplasty" at Second Annual Southeast Region Orthopaedic Trauma Association Symposium, January 1993, Charlotte, NC.

Erpelding JM: "Orthopaedic Emergencies in the Rural Trauma Setting", at Rural Emergencies Symposium, July 1993, Glasgow, MT.

Erpelding JM: "Cold Weather Injuries: Recognition and Management", Rural Emergencies Symposium, July 1993, Glasgow, MT.

## ABSTRACTS

### CLINICAL INVESTIGATION

Farnsworth WJ, Chuang AH, Runner RR, McPherson JC, McPherson JC: "The Glass Effect on Red-Blood Cells Can Be Prevented By Pluronic F-68(R)." FASEB Journal, 1993;4(7) 682.

Runner RR, Stone RL, McPherson JC, McPherson JC: "Polaxamer - 188 Administration Alters Some Events in the Blood-Clotting Cascade." FASEB Journal, 1993;4(7) 682.

Tobias SW, Stone RL, Runner RR, McPherson JC, McPherson JC: "The Erythrocyte Sedimentation-Rate of Blood in Normal Rats Injected with Pluronic F-127(R)." FASEB Journal, 1993;4(7) 681.

Horner JA, Paustian PW, Chuang AH, Runner RR, McPherson JC, McPherson JC: "Poloxamer 407 Increases Rouleau Formation In vivo But not In vitro." FASEB Journal, 1993, 4(7) 681.

Chuang AH, Farnsworth WJ, McPherson JC, McPherson JC: "Temperature-Dependent Fluoride Induced Hemolysis is antagonized by Polaxamer - 188." FASEB Journal, 1993 4(7) 681.

Paustian PW, Chuang AH, Runner RR, McPherson JC, McPherson JC: "Comparison of Poloxamer - 188 and Poloxamer - 407 on Early Burn Wound Contraction." FASEB Journal, 1993;3(7) 139.

Paustain PW, Chuang AH, McPherson JC III, McPherson JC Jr.: Palaxamer 188 as a Treatment for Third-Degree Burns from Annual Emergency Medicine.

Nang RM, Sutherland DE, Miller P, Haburchak DR: Reported Reduction in Sexual Activity After Discovery of HIV Seropositivity in U.S. Soldiers

Paustain PW, McPherson JC III, Haase RR, Runner RR, Plowman KM, Ward DF, Nguyen THE, and McPherson JC Jr.: Intravenous Pluronic F-127 in Early Burn Wound Treatments in Rats.

Farnsworth WJ, Chuang AH, Runner RR, McPherson JC III and McPherson JC Jr.: Rheological Changes in Rat Blood Cells Following Successive Washings in Saline, An Albumin, or a Pluronic F-68 Solution.

Shahan MH, Chuang AH, Brennan WA, Dirkesen TR, VanDyke TE, and McPherson JC: The Effect of Chlorhexidine Irrigation on Tensile Wound Strength

Paustian DP, Akujama DP, Chuang AH, McPherson JC III, and McPherson JC Jr.: Wound Repair and Regeneration 1993; 1:118

### DENTAL ACTIVITY

Liewehr FR, Kulild JC, Primack PD: Obturation of A C-Shaped Canal Using An Improved Method of Warm Lateral Condensation.

Arcuri M, Tabor M: Hyperbaric Oxygen Therapy Combined with Transcutaneous and Transmucosal Titanium Implants in Post-Radiotherapy Patients (Abstract).

Guy SC, McQuade MJ, Scheidt MJ, McPherson JC III, Rossmann JA, and VanDyke TE:

In-Vitro Attachment of Human Gingival Fibroblasts to Endosseous Implant Materials.

Shahan MH, Chuang AH, Brennan WA, Dirkesen TR, VanDyke TE, and McPherson JC: The Effect of Chlorhexidine Irrigation on Tensile Wound Strength

Paustian DP, Akujama DP, Chuang AH, McPherson JC III, and McPherson JC Jr.: Wound Repair and Regeneration.

#### DEPARTMENT OF MEDICINE

Whitlock WL, Hilburn RB, Thompson J, Doers JT: "Metered-Dose Inhaler Utilization in a Military Outpatient Setting." 1993;4(147) 98.

#### DEPARTMENT OF PATHOLOGY

Paustain PW, McPherson JC III, Haase RR, Runner RR, Plowman KM, Ward DF, Nguyen THE, and McPherson JC Jr: Intravenous Pluronic F-127 in Early Burn Wound Treatments in Rats.

#### DEPARTMENT OF PSYCHIATRY AND NEUROLOGY

Mahadik SP, Wakade CG, Scheffer R, Correnti E, Borison RL, Mukherjee S: "Abnormal Growth of Skin Fibroblasts from Drug-Naive Psychotic-Patients." Biological Psychiatry, 1993;33:69.

#### DEPARTMENT OF SURGERY

Charney PC, Martindale RG: Early Post-op Enteral Nutrition: Feasibility and Recommendations. RD, 1993, 13:1-8.

Charney PC, Martindale RG: Nutritional Therapy in Patients with Enterocutaneous Fistulas. Submitted to Nutrition in Clinical Practice.

Martindale RA, Calton WC: Clinical Significance of Microbial Translocation, Submitted to Nutrition in Clinical Practice, Aug 1993.

**TOTAL PUBLICATIONS: 69**  
**PRESENTATIONS: 124**  
**ABSTRACTS: 23**

**DETAIL**

**SUMMARY**

**SHEETS**

HSHF-PAT

SUBJECT: Annual Publications Report - November 1993

DETAIL SUMMARY SHEET

<b>Date:</b> 28 Oct 93		<b>Protocol #:</b> 87-16	
<b>Status:</b> Ongoing			
<b>Title:</b> The utility of the 60-kilodalton oncofetal tumor marker in the monitoring of treatment of cancer patients			
<b>Start Date:</b>		<b>Est. Compl. Date:</b>	
<b>Principal Investigator(s):</b> Donald E. Sutherland, PhD, MAJ, MS		<b>Facility:</b> Eisenhower Army Medical Center	
<b>Department/Service:</b> Clinical Investigation, Surgery			
<b>Key Words:</b>		<b>Associate Investigators:</b>	
		<b>Periodic Review Results:</b> Oct 92, Jan 93, & Oct 93 Continue	
<b>Accumulative MEDCASE Cost:</b>			

**Study Objective:** To determine if the 60-kilodalton tumor marker is effective in monitoring the tumor status of patients with various types of cancer by determination of its activity post-surgery.

**Technical Approach:** Patients undergoing surgery for colon, breast, and lung cancer, and melanoma will have plasma drawn prior to surgery and 48 and 72 hours after surgery. The 60-kilodalton oncofetal tumor marker will be determined in all specimens and compared with results obtained in healthy volunteers. If possible, cancer patients will have plasma drawn and assays run on followup examinations, three to six months after surgery.

Total number of subjects enrolled to date: 124  
Total number of subjects enrolled for reporting period: 51

**Progress:** The collection of specimens have been received and are in the process of being analyzed.

HSHF-PAT

SUBJECT: Annual Publications Report - November 1993

DETAIL SUMMARY SHEET

<b>Date:</b>	28 Oct 93	<b>Protocol</b>	<b>Status</b> Ongoing
		<b>#: 87-40</b>	
<b>Title:</b>	Pathology applications of x-ray spectrometric microanalysis		
<b>Start Date:</b>		<b>Est. Compl. Date:</b>	
<b>Principal Investigator(s):</b>		<b>Facility:</b>	
Jack A. Horner, BS		Eisenhower Army Medical Center	
<b>Department/Service:</b>		<b>Associate Investigators:</b>	
Clinical Investigation/Pathology		Phyllis Brewer	
<b>Key Words:</b>			
<b>Accumulative MEDCASE Cost:</b>		<b>Periodic Review Results:</b>	

**Study Objective:** To utilize specimens obtained during routine surgical and autopsy pathology examinations to gain expertise in applications of x-ray spectrometric microanalysis.

**Technical Approach:** Tissue specimens without known abnormalities of elemental composition are selected from the daily laboratory workload. These are examined for establishment of baseline spectrometric spectra following the use of various fixatives. These spectra can then be compared against specimens with known or suspected elemental abnormalities.

**Progress:** Sixteen additional samples were added to the data base. The use of these techniques for blood/lead determinations will be investigated in the near future. Suitable reference standards are being planned and prepared.

HSHF-PAT

SUBJECT: Annual Publications Report - November 1993

DETAIL SUMMARY SHEET

<b>Date:</b> 28 Oct 93		<b>Protocol #:</b> 89-38		<b>Status:</b> Ongoing	
<b>Title:</b> Non-ionic surfactants in the treatment of third degree burns in rats					
<b>Start Date:</b> Jul 89			<b>Est. Compl. Date:</b>		
<b>Principal Investigator(s):</b> James C. McPherson III, PhD			<b>Facility:</b> Eisenhower Army Medical Center		
<b>Department/Service:</b> Clinical Investigation					
<b>Key Words:</b> Surfactant Burn treatment			<b>Associate Investigators:</b> James C. McPherson, Jr., MD Kent M. Plowman, MD, COL, MC Paul W. Paustian, MD Royce R. Runner, MT (ASCP) R. R. Haase, MAJ, MC		
<b>Accumulative MEDCASE Cost:</b>			<b>Periodic Review Results:</b> Oct 93 Continue		

**Study Objective:** To study potential protective effects on non-ionic surfactants in the treatment of third degree burns.

**Technical Approach:** Effect of single and multiple doses of non-ionic surfactants given IV thirty minutes following a full thickness burn will be studied to evaluate burn wound healing.

**Progress:** Pluronic polyols are non-ionic surfactants developed in the 1950's. They are block co-polymers of the ABA type where A is made up of ethylene oxide polymers and B is propylene oxide polymers. They differ only in their molecular weights. This protocol evaluates their effect on third degree scald burns in a rat model. Pluronic polyols were administered 30 minutes following a third degree scald burn to the chest of 300-320 gm male rats. Histological evaluation documented this burn. The pluronic polyol was administered IV at a concentration of 12 mg/ml with a dose of 8 ml/kg B.W. Animals were followed for four weeks (complete healing). Pluronic polyol F-127 showed a significant protection of the burn area as evidenced by a significant reduction in the size of the burn as measured by contraction of the burn area at 48 hours tissue edema measurements in the burn wound showed significantly reduced edema formation in the burn area. This was confirmed by histological evaluation. The blood flow (in the microcirculation) was improved in the burn area as evidenced by thermographic evaluation of the animals and later confirmed in elevated isolated skin flaps where a significant increase in blood flow was measured by Doppler Blood Flow Techniques. Histological evaluation of the burn area revealed a lack of acute inflammation and extravasation of red blood cells into the wound. Pluronic polyols provide a membrane stabilization

HSHF-PAT

SUBJECT: Annual Publications Report - November 1993

effect which when combined with their membrane deforming effect on red blood cells promotes burn wound healing. Similar effects have been noted by our group in the healing of surgical wounds. The deformability of red blood cell membranes increases under the effect of pluronic polyols allows them to transverse partially closed capillaries and venules, allowing oxygen delivery to damaged tissue lysis products to be removed.

Pluronic polyols of different molecular weights have different degrees of effect on these processes. Pluronic polyol dose response curves show a burn

HSHF-PAT  
 SUBJECT: Annual Publications Report - November 1993

DETAIL SUMMARY SHEET

<b>Date:</b> 28 Oct 93		<b>Protocol #:</b> 91-18		<b>Status:</b> Ongoing	
<b>Title:</b> Effects of different methods of hair removal on the measurement of skin blood flow in the rat using a Doppler laser blood perfusion monitor and the effect of elevated body core temperature on skin blood flow					
<b>Start Date:</b> Dec 90			<b>Est. Compl. Date:</b>		
<b>Principal Investigator(s):</b> James C. McPherson III, PhD			<b>Facility:</b> Eisenhower Army Medical Center		
<b>Department/Service:</b> Clinical Investigation					
<b>Key Words:</b> Blood flow			<b>Associate Investigators:</b> A. Henry Chuang, PhD Royce R. Runner, ASCP Paul W. Paustian, MD James C. McPherson, Jr, MD		
<b>Accumulative MEDCASE Cost:</b>			<b>Periodic Review Results:</b> Oct 93 Continue		

**Study Objective:** To determine the best method for hair removal from a rat in order to accurately measure blood flow and to determine if skin blood flow is altered by increasing the body core temperature.

**Technical Approach:** Hair will be removed by clipping (current method), surgical clipping, wet shaving or chemical removal. Skin blood flow will be measured using a Doppler laser flow technique. Increased body core temperature effect on skin blood flow will be measured.

**Progress:** Hair removal by clipping leaves exposed hair follicle shafts and stubble which reflect the laser light to the sensor and give an artificial blood flow reading when they move during normal respiration of the animal. Surgical clippers, designed for use on humans, are not effective on rodents. Wet shaving gives an acceptable skin for blood flow measurements but often results in abrasions of the skin which either interfere with blood flow measurements or increase blood flow locally. Two chemical agents were evaluated to remove hair. Surgex, a thick paste, was effective in hair removal but was difficult to use due to its consistency. When diluted 75%:25% (wt/wt) with Surgilube, the consistency became more cream-like and gave satisfactory results. Surgi-prep has a cream-like consistency from the tube and was easy to apply. It likewise gave satisfactory hair removal which resulted in consistent blood flow measurements with the Doppler Laser blood perfusion monitor. A medical depilatory removes rodent hair in a manner in which it does not abrade the skin and thus results in reproduceable blood flow

HSHF-PAT

SUBJECT: Annual Publications Report - November 1993

measurements. The measurement of body core temperature change on skin blood flow has not been completed.

HSHF-PAT

SUBJECT: Annual Publications Report - November 1993

DETAIL SUMMARY SHEET

<b>Date:</b> 28 Oct 93	<b>Protocol#</b> 91-19	<b>Status</b> Ongoing
<b>Title:</b> Development of a heat stroke model in the rat and treatment with pluronic polyols		
<b>Start Date:</b> Jan 91	<b>Est. Compl. Date:</b> Jan 93	
<b>Principal Investigator(s):</b> James C. McPherson III, PhD	<b>Facility:</b> Eisenhower Army Medical Center	
<b>Department/Service:</b> Clinical Investigation	<b>Associate Investigators:</b> A. Henry Chuang, PhD Paul W. Paustian, MD James C. McPherson Jr, MD	
<b>Key Words:</b> Heat stroke, Pluronic polyols		
<b>Accumulative MEDCASE Cost:</b>	<b>Periodic Review Results:</b> Oct 93 Continue	

**Study Objective:** To evaluate a new model for the production of heatstroke in the rat that will be more consistent in pathophysical parameters, will require less time to develop and will control the biological variation in the model. It will also study the effect of treatment of two pluronic polyols versus saline as the resuscitative fluid in heatstroke victims (in this case rats).

**Technical Approach:** Fur will be removed from the rat and the rat allowed to swim in a heated water bath. Pluronic polyol solutions or saline will be administered as resuscitative fluids. The pluronic polyols have been shown by investigators in this laboratory to have membrane protective properties and have been proposed for use as resuscitative agents.

**Progress:** The rat models of heat stroke that have previously been described do not take into consideration that there is some biological variation in animals in their response to any imposed condition or treatment. The proposed animal model overcomes these objections. Heat stroke is a syndrome occurring in response to an elevated environmental temperature combined with physical exertion. This is the first animal model to combine both factors simultaneously. Pluronic polyols have been shown to protect the red blood cell membrane from mechanical stress. We have demonstrated other effects on red blood cell membranes; i.e., deformability. They have been demonstrated to have a membrane protective effect on the capillary cell membrane. These membrane protective effects may make them useful in treating heat stroke. Supplies necessary to support this protocol have been procured and the protocol is ready to begin.

HSHF-PAT  
 SUBJECT: Annual Publications Report - November 1993

DETAIL SUMMARY SHEET

<b>Date:</b>	28 Oct 93	<b>Protocol</b>	91-24	<b>Status</b>	Ongoing
<b>Title:</b>	Derivation and characterization of human periodontal ligament fibroblasts				
<b>Start Date:</b>	Jan 91	<b>Est. Compl. Date:</b>			
<b>Principal Investigator(s):</b>	James C. McPherson III, PhD		<b>Facility:</b>	Eisenhower Army Medical Center	
<b>Department/Service:</b>	Clinical Investigation		<b>Associate Investigators:</b>	Royce R. Runner Thomas E. Van Dyke, DDS	
<b>Key Words:</b>	Periodontal ligament Tissue culture				
<b>Accumulative MEDCASE Cost:</b>			<b>Periodic Review Results:</b>		

**Study Objective:** To establish human periodontal ligament fibroblasts in tissue culture, characterize the cells and investigate differences between human periodontal ligament fibroblasts and human gingival fibroblasts.

**Technical Approach:** Fibroblast-like cells will be removed from freshly extracted teeth containing the periodontal ligament and grown in tissue culture using techniques specifically developed to isolate and grow the periodontal ligament fibroblasts.

**Progress:** The periodontal ligament is a highly specialized connective tissue which functions to attach the tooth to the alveolus. Evidence implicates cells from the periodontal ligaments as having the capacity to regenerate the periodontium. Periodontal ligament cells removed from freshly extracted teeth have been successfully grown in tissue culture, but the cells are viable for only 2-3 passages. This is in contrast to gingival fibroblast which can be maintained long term in tissue culture, but the cells are viable for only 2-3 passages. This is in contrast to gingival fibroblast which can be maintained long term in tissue culture and are customarily used in tissue culture experiments between the 6th and 10th passages. These, although in close proximity to each other in situ each cell type apparently exhibits unique requirements allowing for cell growth, proliferative rates and macro molecular synthesis. Delineation of these requirements will allow long-term tissue culture of the periodontal ligament cells which may result in regeneration of the periodontal ligament during periodontal compromised conditions.

HSHF-PAT

SUBJECT: Annual Publications Report - November 1993

DETAIL SUMMARY SHEET

<b>Date:</b>	29 Oct 93	<b>Protocol</b>	91-37	<b>Status</b>	Ongoing
<b>Title:</b>	The effect of pluronic polyols on experimental edema produced by various means: Arachidonic acid, carrageenin, histamine and thermal injury. A study in rats and mice.				
<b>Start Date:</b>	Jan 91	<b>Est. Compl. Date:</b>	Jan 93		
<b>Principal Investigator(s):</b>	James C. McPherson III, PhD		<b>Facility:</b>	Eisenhower Army Medical Center	
<b>Department/Service:</b>	Clinical Investigation		<b>Associate Investigators:</b>	Royce R. Runner, ASCP A. Henry Chaung, PhD Paul W. Paustian, MD James C. McPherson Jr, MD	
<b>Key Words:</b>	Edema Pluronic polyols		<b>Periodic Review Results:</b>	Oct 93 Continue	
<b>Accumulative MEDCASE Cost:</b>					

**Study Objective:** Previous investigations in this laboratory supported decreased skin edema in third degree burns. In this study we will investigate both pre- and post-injury IV administration of pluronic polyols on ear, skin and paw edema.

**Technical Approach:** Ear edema will be produced by topical application of the edema causing agents. Paw edema will be produced by injection of the edema causing agents into the foot pad or by thermal injury. Intradermal and topical applications of these agents will be used on the skin. Both pre- and post-injury IV administration of pluronic polyols will be utilized. Edema formation will be measured over time using a fluid displacement method for the paw and a micrometer caliper for the ear.

**Progress:** Pluronic polyol F-68 has been shown to blunt or delay the onset of the edema response, depending upon the time of administration in relation to the time of edema producing agent administration. Previous methods of edema measurement using the paw model used a wetting agent to measure the edema formation. This method was less accurate due to the wetting, drying (if possible) of the paw and the cooling effect of the evaporation of the wetting agent on the paw. We are now using a non-wetting agent to measure paw edema. This has increased our accuracy and reproducibility and reduced the variability between samples. In addition, we have just purchased an automated instrument and data logging system for edema measurements. A new resident has expressed interest in supporting this protocol and coupled with an improved methodology should result in significant progress.

HSHF-PAT

SUBJECT: Annual Publications Report - November 1993

DETAIL SUMMARY SHEET

<b>Date:</b>	29 Oct 93	<b>Protocol</b>	91-74	<b>Status</b>	Ongoing
<b>Title:</b>	The effect of etidronate in the treatment of acute/chronic osteomyelitis in the rat tibial model				
<b>Start Date:</b>			<b>Est. Compl. Date:</b>		
<b>Principal Investigator(s):</b>	David W. Craft, MAJ, MS		<b>Facility:</b>	Eisenhower Army Medical Center	
<b>Department/Service:</b>	Clinical Investigation/Pathology		<b>Associate Investigators:</b>	Donald E. Sutherland, PhD, MAJ, MS Tu H. Nguyen, MD, LTC, MC Norma Best T.B. Buxton, PhD Jack Horner	
<b>Key Words:</b>			<b>Periodic Review Results:</b>	Sep 91 continue	
<b>Accumulative MEDCASE Cost:</b>					

**Objective:** To investigate the effect of etidronate in the treatment of staphylococcal acute/chronic osteomyelitis in an experimental model.

**Technical Approach:** Animal model studies are complete. Analysis of bone by radiography and tensile strength is pending.

**Progress:** A pilot experiment has been initiated to analyze radiographs through objective analysis. Radiographs are being scanned by densitometry in order to assess bone damage parameters defined in the protocol. Procurement of new software for the densitometer has been suggested by the commercial vendor. Critical analysis continues with current capabilities. The instron unit for measuring tensile is now available. Pending radiography and histology, this analysis can be performed.

HSHF-PAT

SUBJECT: Annual Publications Report - November 1993

DETAIL SUMMARY SHEET

<b>Date:</b>	29 Oct 93	<b>Protocol</b>	92-15	<b>Status</b>	Ongoing
<b>Title:</b>	Cell membranes and the gastric mucosa from sodium fluoride in the rat				
<b>Start Date:</b>			<b>Est. Compl. Date:</b>		
<b>Principal Investigator(s):</b>	A. Henry Chuang, PhD		<b>Facility:</b>	Eisenhower Army Medical Center	
<b>Department/Service:</b>	Clinical Investigation		<b>Associate Investigators:</b>	James C. McPherson III, PhD Royce R. Runner James C. McPherson, Jr., MD	
<b>Key Words:</b>					
<b>Accumulative MEDCASE Cost:</b>			<b>Periodic Review Results:</b>	Oct 93 Continue	

**Objective:** To investigate the effects of fluoride ion on red blood cells and the gastric mucosa in the rat. Also to evaluate the effects of pluronic polyols when the red blood cells and the rats are treated with sodium fluoride.

**Technical Approach:** Fresh heparinized rat red blood cells will be incubated in buffered isotonic sodium chloride and sodium fluoride solutions with or without the presence of pluronic polyol, F-68. At various time intervals the percent of hemolysis of red blood cells will be determined. Sodium fluoride solutions will be administered orally to the rats. The stomach and small intestine from the rats treated orally or IV with pluronic polyol, F-127 will be compared with those without F-127.

**Progress:** Since our last progress report on the effects of Pluronic F-68 and F-127 on the protection of the gastric membrane from NaF, we had extended our study with another reagent, Omeprazole, using Alcian Blue dye to measure mucus in the stomach. The results indicated some protective effect of Omeprazole on the stomach mucosa under the toxic level of NaF.

HSHF-PAT  
SUBJECT: Annual Publications Report - November 1993

DETAIL SUMMARY SHEET

<b>Date:</b>	29 Oct 93	<b>Protocol</b>	92-53	<b>Status</b>	Ongoing
<b>Title:</b>	A study of p53 in the plasma of patients in stages II - VI of human immunodeficiency virus (HIV-1) infection				
<b>Start Date:</b>			<b>Est. Compl. Date:</b>		
<b>Principal Investigator(s):</b>	Donald E. Sutherland, PhD, MAJ, MS		<b>Facility:</b>	Eisenhower Army Medical Center	
<b>Department/Service:</b>	Clinical Investigation, Medicine		<b>Associate Investigators:</b>	Daniel B Craig, COL, MC	
<b>Key Words:</b>					
<b>Accumulative MEDCASE Cost:</b>			<b>Periodic Review Results:</b>		

**Study Objective:** To determine if p53 appears and/or increases in the plasma of HIV-seropositive patients in stages II through VI of the disease.

**Technical Approach:** Plasma specimens will be drawn from HIV-positive patients in Stages II-VI of the disease and tested for mutant p53 protein by a specific ELISA technique. Patients who progress to a higher level may be asked for additional samples.

**Subjects enrolled to date:** 19

**Progress:** Nineteen subjects have been enrolled. We are now waiting on the arrival of the p53 kits to begin assaying them.

HSHF-PAT  
 SUBJECT: Annual Publications Report - November 1993

**DETAIL SUMMARY SHEET**

<b>Date:</b> 29 Oct 93		<b>Protocol</b> 91-9		<b>Status</b> Ongoing	
<b>Title:</b> Wear and Cutting Efficiency of Sonic Files					
<b>Start Date:</b>			<b>Est. Compl. Date:</b>		
<b>Principal Investigator(s):</b> Leander Lanier Sr, MAJ, DC			<b>Facility:</b> Eisenhower Army Medical Center		
<b>Department/Service:</b> Dental Activity/Endodontics			<b>Associate Investigators:</b> James C. Kulild, COL, DC Patrice D. Primack, LTC, DC		
<b>Key Words:</b>			Jack A. Horner		
<b>Accumulative MEDCASE Cost:</b>			<b>Periodic Review Results:</b>		

Study Objective: To evaluate the wear of Shaper-sonic files after use in vitro in a simulated root canal in bovine bone and relate this wear to its cutting efficiency.

Technical Approach: Simulated root canals will be prepared from a single bovine femur. Forty-five specimens will be prepared 3x2x2 cm using a band saw. Three pilot holes, simulating artificial root canals, will be drilled along the 3 cm side of each block through the cortical plate completely through the 2 cm side. Three 0.6 mm diameter holes will be drilled in the first group of 15 blocks; 0.7 mm holes in the second group of 15 blocks; and 0.8 mm holes in the last group of 15 blocks. Lubricant will be used throughout the drilling procedure to prevent burning of the bone. The specimens will be maintained in a solution of 0.2% sodium azide to prevent bacterial growth.

Progress: Resident graduated, completed groups A & C but not B. He PCS'd to Ft Benning, GA. He is to return on leave to complete project but as of 28 Sep he has not done so.

HSHF-PAT  
SUBJECT: Annual Publications Report - November 1993

DETAIL SUMMARY SHEET

<u>Date:</u> 29 Oct 93	<u>Protocol</u> 91-62	<u>Status</u> Ongoing
<u>Title:</u> Parotid gland biopsy and transbronchial lung biopsy in the diagnosis of sarcoidosis: A comparison study		
<u>Start Date:</u> Jul 91	<u>Est. Compl. Date:</u>	
<u>Principal Investigator(s):</u> R. Terry Ellis, MAJ, DC	<u>Facility:</u> Eisenhower Army Medical Center	
<u>Department/Service:</u> Dentistry, Pulmonary	<u>Associate Investigators:</u> Michael W. Tabor, COL, DC David M. Lewis, COL, DC Warren L. Whitlock, LTC, MC	
<u>Key Words:</u>		
<u>Accumulative MEDCASE Cost:</u>	<u>Periodic Review Results:</u>	

Study Objective: To relate the involvement of the lungs and parotid gland in sarcoidosis.

Technical Approach: Patients with strong suspicion of sarcoidosis undergo open biopsy of parotid and transbronchial lung biopsy under intravenous sedation. OMS Staff or residents perform intravenous sedation and parotid gland biopsy, then transbronchial lung biopsy is performed by Pulmonary Staff physicians. Tissues are then evaluated by COL David Lewis, Staff Oral Pathologist.

Manpower: Existing clinic staff is utilized.

Number of subjects enrolled to date: 7

No adverse reactions.

Progress:

HSHF-PAT

SUBJECT: Annual Publications Report - November 1993

**DETAIL SUMMARY SHEET**

<b>Date:</b> 29 Oct 93 <b>Protocol</b> 91-72 <b>Status</b> Complete	
<b>Title:</b> Evaluation of heat generated when exposed titanium implant fixture threads are removed using rotary instruments	
<b>Start Date:</b> Aug 91	<b>Est. Compl. Date:</b> Jun 93
<b>Principal Investigator(s):</b> Elise F. Adrian, LTC, DC	<b>Facility:</b> Eisenhower Army Medical Center
<b>Department/Service:</b> Dental Activity	<b>Associate Investigators:</b> William A. Brennan, COL, DC Michael A. Billman, LTC, DC Benjamin S. Hanson, LTC, DC Jack A. Horner
<b>Key Words:</b>	
<b>Accumulative MEDCASE Cost:</b>	<b>Periodic Review Results:</b>

Study Objective: To determine if the technique of recontouring fixture threads raises the temperature of the fixture surface above the critical bone temperature of 47°C.

Technical Approach: A model system will be used to monitor temperature changes along a titanium implant during mechanical removal of exposed fixture threads.

Progress: Project is complete and submitted for publication.

HSHF-PAT  
 SUBJECT: Annual Publications Report - November 1993

**DETAIL SUMMARY SHEET**

<u>Date:</u> 29 Oct 93		<u>Protocol</u> 91-73		<u>Status</u> Complete	
<u>Title:</u> Effect of nicotine on fibroblast integrin expression and distribution in vitro					
<u>Start Date:</u> Sep 91			<u>Est. Compl. Date:</u> Jun 93		
<u>Principal Investigator(s):</u> Gregory W. Austin, MAJ, DC			<u>Facility:</u> Eisenhower Army Medical Center		
<u>Department/Service:</u> Dental Activity/Clinical Investigation			<u>Associate Investigators:</u> Benjamin S. Hanson, LTC, DC Michael A. Billman, LTC, DC William A. Brennan, COL, DC Donald E. Sutherland, MAJ, MS Thomas E. Van Dyke, DDS, PhD		
<u>Key Words:</u>					
<u>Accumulative MEDCASE Cost:</u>			<u>Periodic Review Results:</u>		

Study Objective: To determine the effect of various concentrations of nicotine on human fibroblast integrin expression and distribution in vitro.

Technical Approach: The expression of Beta-1 integrin by human gingival fibroblasts incubated in different concentrations of nicotine, 0.025, 0.05, 0.1, 0.2, and 0.4 uM, is being studied utilizing a monoclonal labelled antibody utilizing flow cytometry, cytoflow, and ELISA methods.

Progress: Project is complete and submitted for publication.

HSHF-PAT

SUBJECT: Annual Publications Report - November 1993

**DETAIL SUMMARY SHEET**

<b>Date:</b>	29 Oct 93	<b>Protocol</b>	91-75	<b>Status</b>	Completed
<b>Title:</b>	Parenteral application of F-68 and F-127 surfactants to belly wounds in rats after an initial healing period of 48 and 96 hours				
<b>Start Date:</b>	Oct 91	<b>Est. Compl. Date:</b>	May 92		
<b>Principal Investigator(s):</b>	Ronnie K. Jones, LTC, DC		<b>Facility:</b>	Eisenhower Army Medical Center	
<b>Department/Service:</b>	Dental Activity/Clinical Investigation		<b>Associate Investigators:</b>	Michael A. Billman, LTC, DC William A. Brennan, COL, DC Benjamin S. Hanson, LTC, DC James C. McPherson III, PhD	
<b>Key Words:</b>					
<b>Accumulative MEDCASE Cost:</b>			<b>Periodic Review Results:</b>	Oct 93 Completed	

**Study Objective:** To assess the effects of parenteral application of F-68 and F-127, non-ionic surfactants, on flank wounds in rats after healing of 24 or 48 hours.

**Technical Approach:**

**Progress:** Project has been completed and article is being submitted.

HSHF-PAT  
 SUBJECT: Annual Publications Report - November 1993

**DETAIL SUMMARY SHEET**

<b>Date:</b>	29 Oct 93	<b>Protocol</b>	91-76	<b>Status</b>	Completed
<b>Title:</b>	The effects of parenterally administered pluronic F-68 and F-127 on skin grafts in the rat				
<b>Start Date:</b> Jul 91	<b>Est. Compl. Date:</b>		Jun 93		
<b>Principal Investigator(s):</b> Dennis P. Akiyama, LTC, DC	<b>Facility:</b> Eisenhower Army Medical Center				
<b>Department/Service:</b> Dental Activity/Clinical Investigation	<b>Associate Investigators:</b> William A. Brennan, COL, DC Michael A. Billman, LTC, DC Benjamin S. Hanson, LTC, DC A. Henry Chaung, PhD James C. McPherson III, PhD James C. McPherson, Jr, MD				
<b>Key Words:</b> Rats, Skin flaps, Wound healing Pluronic polyols, Vasculariation,					
<b>Accumulative MEDCASE Cost:</b>	<b>Periodic Review Results:</b> Sep 92 Continue				

**Study Objective:** To investigate the effects of parenterally administered pluronic polyols F-68 and F-127 on the healing ability of full thickness skin flaps in the rat.

**Technical Approach:** Histology, measurement of vascularity of flaps by injection of vital dyes.

**Progress:** Project is complete. Submitted for publication

HSHF-PAT

SUBJECT: Annual Publications Report - November 1993

DETAIL SUMMARY SHEET

<b>Date:</b> 29 Oct 93	<b>Protocol</b> 91-77	<b>Status</b> Completed
<b>Title:</b> Comparison of effect of citric acid conditioning versus tetracycline on human gingival fibroblast attachment <i>in vitro</i>		
<b>Start Date:</b>	<b>Est. Compl. Date:</b>	
<b>Principal Investigator(s):</b> Eric P. Jankowski, LTC, DC	<b>Facility:</b> Eisenhower Army Medical Center	
<b>Department/Service:</b> Dental Activity/Clinical Investigation	<b>Associate Investigators:</b> William A. Brennan, COL, DC Benjamin S. Hanson, LTC, DC Michael Billman, LTC, DC James McPherson III, PhD Royce R. Runner, ASCP	
<b>Key Words:</b>		
<b>Accumulative MEDCASE Cost:</b>	<b>Periodic Review Results:</b>	

**Study Objective:** To examine and compare the effect on attachment rate and strength of attachment of human gingival fibroblasts (HGF) to dentin chips when the dentin has been conditioned using either citric acid or tetracycline.

**Technical Approach:**

**Progress:** Project is complete. Article being submitted for publication.

HSHF-PAT

SUBJECT: Annual Publications Report - November 1993

DETAIL SUMMARY SHEET

<b>Date:</b> 29 Oct 93 <b>Protocol</b> 91-78 <b>Status:</b> Complete	
<b>Title:</b> <i>in vitro</i> effect of 30% hydrogen peroxide and sodium perborate on endodontic sealers in roots obturated with gutta-percha	
<b>Start Date:</b>	<b>Est. Compl. Date:</b> May 93
<b>Principal Investigator(s):</b> Gary R. Karren, LTC, DC	<b>Facility:</b> Eisenhower Army Medical Center
<b>Department/Service:</b> Dental Activity/Clinical Investigation	<b>Associate Investigators:</b> James C. Kulild, COL, DC Patrice D. Primack, LTC, DC
<b>Key Words:</b>	
<b>Accumulative MEDCASE Cost:</b>	<b>Periodic Review Results:</b>

**Study Objective:** To determine the effect of 30% HP and SP on two root canal sealers used with gutta-percha to obturate root canals.

**Technical Approach:**

**Progress:**

HSHF-PAT  
 SUBJECT: Annual Publications Report - November 1993

DETAIL SUMMARY SHEET

<b>Date:</b>	29 Oct 93	<b>Protocol</b>	91-80	<b>Status</b>	Complete
<b>Title:</b>	A comparison of the effects of bisphosphonate, gallium nitrate, and calcium hydroxide on osteoclast-like cells <i>in vitro</i> and <i>in vivo</i>				
<b>Start Date:</b>			<b>Est. Compl. Date:</b>		
<b>Principal Investigator(s):</b>	Frederick R. Liewehr, MAJ, DC		<b>Facility:</b>	Eisenhower Army Medical Center	
<b>Department/Service:</b>	Dental Activity/Clinical Investigation		<b>Associate Investigators:</b>	James C. Kulild, COL, DC David K. Turgeon, MAJ, MS Donald E. Sutherland, MAJ, MS	
<b>Key Words:</b>					
<b>Accumulative MEDCASE Cost:</b>			<b>Periodic Review Results:</b>		

**Study Objective:** To investigate the ability of bisphosphonate and gallium nitrate impregnated dentin slabs to resist dentinoclastic activity *in vivo* in chick embryos and *in vitro* in tissue culture, and to introduce a simple and inexpensive experimental model which can be used for further dental *in vivo* studies of osteoclastic activity.

**Technical Approach:**

**Progress:**

HSHF-PAT  
SUBJECT: Annual Publications Report - November 1993

DETAIL SUMMARY SHEET

<b>Date:</b>	29 Oct 93	<b>Protocol</b>	92-31	<b>Status</b>	Ongoing
<b>Title:</b>	A clinical study of the relationship between computed tomography and bone sounding				
<b>Start Date:</b>			<b>Est. Compl. Date:</b>		
<b>Principal Investigator(s):</b>	Eric Adrian, LTC, DC		<b>Facility:</b>	Eisenhower Army Medical Center	
<b>Department/Service:</b>	Dental Activity		<b>Associate Investigators:</b>	Benjamin Hanson, LTC, DC William A. Brennan, COL, DC Michael A. Billman, LTC, DC Michael W. Tabor, COL, DC Thomas Raltson, LTC, MC	
<b>Key Words:</b>					
<b>Accumulative MEDCASE Cost:</b>			<b>Periodic Review Results:</b>		

**Study Objective:** The anatomic surface topology of planned implant sites as recorded by CAT Scan and the bone mapping technique will be compared for accuracy, time and cost.

**Technical Approach:** Through the use of a location guide stent the bone is measured using the bone map technique and the CAT Scan.

**Number of subjects enrolled to date:** 20

**Progress:** Twelve patients have been mapped and eight have been scanned.

HSHP-PAT  
 SUBJECT: Annual Publications Report - November 1993

**DETAIL SUMMARY SHEET**

<b>Date:</b>	29 Oct 93	<b>Protocol</b>	92-44	<b>Status</b>	Terminated
<b>Title:</b>	Influence of the posterior horizontal plate angle on pantographic recording of immediate side shift				
<b>Start Date:</b>		<b>Est. Compl. Date:</b>			
<b>Principal Investigator(s):</b>	Marcus F. McDonald, MAJ, MC		<b>Facility:</b>	Eisenhower Army Medical Center	
<b>Department/Service:</b>	Dental Activity		<b>Associate Investigators:</b>	Michael F. Gardner, COL, DC Max Gaston, LTC, DC	
<b>Key Words:</b>					
<b>Accumulative MEDCASE Cost:</b>			<b>Periodic Review Results:</b>		

Study Objective:

Technical Approach:

Progress: Study did not produce usable data, study changed to literature review for possible publication.

HSHF-PAT  
SUBJECT: Annual Publications Report - November 1993

**DETAIL SUMMARY SHEET**

<b>Date:</b> 29 Oct 93 <b>Protocol</b> 92-45 <b>Status</b> Completed	
<b>Title:</b> The effect of loading on the porcelain labial margin of a ceramo-metal restoration	
<b>Start Date:</b>	<b>Est. Compl. Date:</b>
<b>Principal Investigator(s):</b> Karen W. Tillman, LTC, DC	<b>Facility:</b> Eisenhower Army Medical Center
<b>Department/Service:</b> Dental Activity	<b>Associate Investigators:</b> Michael F. Gardner, COL, DC Max L. Gaston, LTC, DC
<b>Key Words:</b>	
<b>Accumulative MEDCASE Cost:</b>	<b>Periodic Review Results:</b>

**Study Objective:**

**Progress:**

**Technical Approach:** Data is being analysed and article is being written for possible publication. Abstract of article will be forwarded to Clinical Investigation when Article is completed.

HSHF-PAT

SUBJECT: Annual Publications Report - November 1993

DETAIL SUMMARY SHEET

<b>Date:</b>	29 Oct 93	<b>Protocol</b>	92-46	<b>Status</b>	Completed
<b>Title:</b>	A comparison of impression techniques for the ceraOne abutment				
<b>Start Date:</b>			<b>Est. Compl. Date:</b>		
<b>Principal Investigator(s):</b>	James K. Schmitt, MAJ, DC		<b>Facility:</b>	Eisenhower Army Medical Center	
<b>Department/Service:</b>	Dental Activity		<b>Associate Investigators:</b>	Michael F. Gardner, COL, DC Eric Adrian, LTC, DC	
<b>Key Words:</b>	autopolymerizing acrylic resin, transfer coping, vinyl polysiloxane				
<b>Accumulative MEDCASE Cost:</b>			<b>Periodic Review Results:</b>		

Study Objective:

Technical Approach:

Progress: Nobelpharma has recently introduced a single tooth implant system, the CeraOne abutment. Two impression techniques are recommended for use with the implant. The first involves taking an impression with a custom tray, then securing the impression coping to the tray autopolymerizing acrylic resin. The alternate technique recommends that the impression coping be shortened to a length not interfering with a stock tray. The tray is then loaded with the impression material and put in place. The coping is entirely embedded in the impression. The purpose of this study was to compare the two techniques. Results showed that the use of autopolymerizing acrylic introduced significant distortion into the system.

HSHF-PAT  
 SUBJECT: Annual Publications Report - November 1993

**DETAIL SUMMARY SHEET**

<b>Date:</b>	29 Oct 93	<b>Protocol</b>	92-56	<b>Status</b>	Ongoing
<b>Title:</b>	A Clinical Evaluation of Autogenous Iliac Bone Grafts in Periodontal Osseous Defects				
<b>Start Date:</b> Jun 92	<b>Est. Compl. Date:</b>		Jun 94		
<b>Principal Investigator(s):</b> Benjamin S. Hanson, DC	<b>Facility:</b> Eisenhower Army Medical Center				
<b>Department/Service:</b> Dental Activity	<b>Associate Investigators:</b> William Brennan, COL, DC				
<b>Key Words:</b> Periodontitis, Iliac graft					
<b>Accumulative MEDCASE Cost:</b>	<b>Periodic Review Results:</b>				

**Study Objective:** To investigate the feasibility of the use of autogenous frozen marrow as a treatment modality in periodontal osseous defects.

**Technical Approach:** Twenty patients with hopeless teeth will be asked to participate in this study. Bone will be harvested from the ilium and stored in MEM at -6 C. Seven days after the cores have been taken they will be placed in periodontal defects.

**Number of subjects enrolled to date:** 4

**Progress:** In the four patients we have treated thus far we have had excellent results.

HSHF-PAT  
SUBJECT: Annual Publications Report - November 1993

DETAIL SUMMARY SHEET

<b>Date:</b>	29 Oct 93	<b>Protocol</b>	92-57	<b>Status</b>	Ongoing
<b>Title:</b>	Evaluation of the benefits of screening tests done prior to periodontal therapy				
<b>Start Date:</b> Jun 92	<b>Est. Compl. Date:</b>		Jun 93		
<b>Principal Investigator(s):</b> Benjamin S. Hanson, LTC, DC	<b>Facility:</b> Eisenhower Army Medical Center				
<b>Department/Service:</b> Dental Activity	<b>Associate Investigators:</b> William Brennan, COL, DC				
<b>Key Words:</b> Screening tests					
<b>Accumulative MEDCASE Cost:</b>	<b>Periodic Review Results:</b>				

**Study Objective:** To investigate the value of adjunctive screening lab tests before periodontal therapy.

**Technical Approach:** One hundred patients over the age of 40 will be selected at random and referred for biochemical and hematologic profiles. The tests will include CBC, UA, SMAC-17, PT, PTT, and platelet count.

**Number of subjects enrolled to date:** 40

**Progress:** No conclusions at this time. Data collection is complete. Article is being written.

HSHF-PAT  
 SUBJECT: Annual Publications Report - November 1993

**DETAIL SUMMARY SHEET**

<b>Date:</b>	29 Oct 93	<b>Protocol#</b>	92-58	<b>Status</b>	Ongoing
<b>Title:</b>	A comparison of the clinical success of the 5mm Nobelpharma implant fixture to the standard 3.75mm fixture				
<b>Start Date:</b>		<b>Est. Compl. Date:</b>	Jun 93		
<b>Principal Investigator(s):</b>	Eric Adrian, LTC, DC		<b>Facility:</b>	Eisenhower Army Medical Center	
<b>Department/Service:</b>	Dental Activity		<b>Associate Investigators:</b>		
<b>Key Words:</b>					
<b>Accumulative MEDCASE Cost:</b>			<b>Periodic Review Results:</b>		

**Study Objective:** To study the clinical success of the 5mm fixture at 1, 2 and 3 year intervals.

**Technical Approach:** Clinical and radiological parameters will be used to compare the new fixture to the 3.75mm fixture.

**Number of subjects enrolled to date:** 15

**Progress:** To date two fixtures have been placed with no complications.

HSHF-PAT  
 SUBJECT: Annual Publications Report - November 1993

**DETAIL SUMMARY SHEET**

<b>Date:</b>	29 Oct 93	<b>Protocol</b>	92-74	<b>Status</b>	Ongoing
<b>Title:</b>	Wear and Cutting Efficiency of the Rispi-sonic File				
<b>Start Date:</b> July 1992	<b>Est. Compl. Date:</b>		April 1994		
<b>Principal Investigator(s):</b> Gordon W. Woollard, MAJ, DC	<b>Facility:</b> Tingay Dental Clinic				
<b>Department/Service:</b> Dental Activity	<b>Associate Investigators:</b> COL P. Primack Dr. R. Anderson Dr. F. Rueggeberg Dr. J. McPherson Mr. J. Horner				
<b>Key Words:</b> sonic; rispisonic; file; efficiency					
<b>Accumulative MEDCASE Cost:</b>	<b>Periodic Review Results:</b>				

**Study Objective:** To determine the cutting efficiency of Rispi-sonic files used in a MM 1500 endosonic system.

**Technical Approach:**

**Progress:** We have set up our research design to include the evaluation of 25 respisonic files, each of which will instruct 10 standard canals placed in methyl methacrylate resin. Each fill will be instrumented for a total of 15 minutes (90 seconds/canal). Scanning Electron Microscopy will be used to follow the file wear patterns and changes in flute design as the file wears.

An apparatus has been designed to eliminate all the variables encountered when a researcher files canals by hand, as is frequently seen in projects of this type.

Nineteen files have been instrumented on the apparatus and we find no correlation of time of use with efficiency or cut of the files. The last six files will be instrumented at this time, with the changes being noted by SEM. Hopefully, reason will be found as to why the files show such varied cutting efficiencies.

HSHF-PAT

SUBJECT: Annual Publications Report - November 1993

DETAIL SUMMARY SHEET

<b>Date:</b>	29 Oct 93	<b>Protocol</b>	92-75	<b>Status</b>	Ongoing
<b>Title:</b>	The Effects of Intracanal Medicaments, Cements (sealer), and Fillers on Fibroblast Growth and Attachment to a Tooth Which has Received Root Canal Therapy				
<b>Start Date:</b>			<b>Est. Compl. Date:</b>		
<b>Principal Investigator(s):</b>	Lawrence G. Breault, MAJ, DC		<b>Facility:</b>	Tingay Dental Clinic	
<b>Department/Service:</b>	Dental Activity		<b>Associate Investigators:</b>		
<b>Key Words:</b>					
<b>Accumulative MEDCASE Cost:</b>			<b>Periodic Review Results:</b>		

**Study Objective:** To investigate the effects that the placemnt of intracanal medicaments, fillers, and cements in endodontically treated teeth may have on periodontal regenerative procedures.

**Technical Approach:** Various medications were placed in roots and then cultured with fibroblasts. MTTs assay was done to determine all viability. Presnetly gathering data.

**Progress:** Local approval late FY 92, no progress to report.

HSHF-PAT

SUBJECT: Annual Publications Report - November 1993

DETAIL SUMMARY SHEET

<b>Date:</b>	29 Oct 93	<b>Protocol</b>	92-76	<b>Status</b>	Ongoing
<b>Title:</b>	Endogenous Prostaglandin Induced by IL-1B and TNFa Regulates IL-6 Production by Human Gingival Fibroblasts				
<b>Start Date:</b>			<b>Est. Compl. Date:</b>		
<b>Principal Investigator(s):</b>	Charlene A. Czuszak, MAJ, DC		<b>Facility:</b>	Tingay Dental Clinic	
<b>Department/Service:</b>	Dental Activity		<b>Associate Investigators:</b>		
<b>Key Words:</b>					
<b>Accumulative MEDCASE Cost:</b>			<b>Periodic Review Results:</b>		

**Study Objective:** To elucidate a mechanism by which the interaction of cytokines, such as IL-1B and TNFa, may promote IL-6 production.

**Technical Approach:** Fibroblast were grown with IL-1B or TNFa and the cultures were assayed for PG2 and IL-6. Cultures were done with and without indomethacin. Data collection is complete

**Progress:** Local approval late FY 92, no progress to report.

HSHF-PAT

SUBJECT: Annual Publications Report - November 1993

DETAIL SUMMARY SHEET

<b>Date:</b>	29 Oct 93	<b>Protocol</b>	92-77	<b>Status</b>	Ongoing
<b>Title:</b>	The Effect of Transforming Growth Factor Beta (TGF-B) in Conjunction with Polyols on Wound Healing Rats				
<b>Start Date:</b>			<b>Est. Compl. Date:</b>		
<b>Principal Investigator(s):</b>	George E. Tolson IV, MAJ, DC		<b>Facility:</b>	Animal Support Facility, Clinical Investigation	
<b>Department/Service:</b>	Dental Activity		<b>Associate Investigators:</b>		
<b>Key Words:</b>					
<b>Accumulative MEDCASE Cost:</b>			<b>Periodic Review Results:</b>		

**Study Objective:** To examine the effects of parenterally administered Transforming Growth Factor Beta in combination with topically applied pluronic polyols F-68 and F-127 on the tensile strength and healing of incisional wounds in the rat.

**Technical Approach:** Various concentration of F-68 and F-127 are applied to a standard wound in a rat. The tensile strength of the incision is then determined with the Instron unit at the time of sacrifice.

**Progress:** Data is being collected.

HSHF-PAT  
SUBJECT: Annual Publications Report - November 1993

DETAIL SUMMARY SHEET

<b>Date:</b>	29 Oct 93	<b>Protocol</b>	93-2	<b>Status</b>	Ongoing
<b>Title:</b>	Sealing Ability of Bases and Cements Following Exposure to 30% Hydrogen Peroxide and Sodium Perborate				
<b>Start Date:</b>			<b>Est. Compl. Date:</b>		
<b>Principal Investigator(s):</b>	Jeffery D. Luzader, MAJ, DC		<b>Facility:</b>	Eisenhower Army Medical Center	
<b>Department/Service:</b>	Dental Activity		<b>Associate Investigators:</b>	Patrice D. Primack, LTC, DC Robert J. Loushine, LTC, DC	
<b>Key Words:</b>					
<b>Accumulative MEDCASE Cost:</b>			<b>Periodic Review Results:</b>		

Study Objective:

Technical Approach:

Progress:

HSHF-PAT.

SUBJECT: Annual Publications Report - November 1993

**DETAIL SUMMARY SHEET**

<b>Date:</b> 29 Oct 93 <b>Protocol</b> 93-3 <b>Status</b> Ongoing	
<b>Title:</b> Stereomicroscopic Evaluation of Apical Retropreparation Shapes Utilizing an Ultra-sonic versus a Micro-head Handpiece	
<b>Start Date:</b>	<b>Est. Compl. Date:</b>
<b>Principal Investigator(s):</b> Thomas F. Armstrong, MAJ, DC	<b>Facility:</b> Eisenhower Army Medical Center
<b>Department/Service:</b> Dental Activity	<b>Associate Investigators:</b> Patrice D. Primack, LTC, DC Robert J. Loushine, LTC, DC
<b>Key Words:</b>	
<b>Accumulative MEDCASE Cost:</b>	<b>Periodic Review Results:</b>

Study Objective:

Technical Approach:

Progress

HSHF-PAT

SUBJECT: Annual Publications Report - November 1993

DETAIL SUMMARY SHEET

<b>Date:</b> 29 Oct 93 <b>Protocol</b> 93-11 <b>Status</b> Ongoing	
<b>Title:</b> The Effect of Bone Marrow Storage on Interleukin-6 Production Using the HLA: (FCR)BR	
<b>Start Date:</b>	<b>Est. Compl. Date:</b>
<b>Principal Investigator(s):</b> Frederick C. Bisch, MAJ, DC	<b>Facility:</b> Eisenhower Army Medical Center
<b>Department/Service:</b> Dental Activity	<b>Associate Investigators:</b> Benjamin S. Hanson, LTC, DC William A. Brennan, COL, DC Michael A. Billman, LTC, MC Val L. Kudryck, LTC, DC
<b>Key Words:</b>	
<b>Accumulative MEDCASE Cost:</b>	<b>Periodic Review Results:</b>

**Study Objective:** Determine the effects of storage temperature and time on IL-6 production.

**Technical approach:** Culture osteoblasts and then store for various time frames from 1 day to 14 days at temperatures ranging from 4° C to 70° C and assay for IL-6 production.

**Progress:** Presently gathering data.

HSHF-PAT.  
 SUBJECT: Annual Publications Report - November 1993

**DETAIL SUMMARY SHEET**

<b>Date:</b>	29 Oct 93	<b>Protocol</b>	93-12	<b>Status</b>	Ongoing
<b>Title:</b>	The Effects of Transforming Growth Factor Beta and Platelet Derived Growth Factor on Human Gingival Fibroblasts and Human Periodontal Fibroblasts Grown in Serum and Serum Free Media				
<b>Start Date:</b>			<b>Est. Compl. Date:</b>		
<b>Principal Investigator(s):</b>	Thomas J. Butts, MAJ, DC		<b>Facility:</b>	Eisenhower Army Medical Center	
<b>Department/Service:</b>	Dental Activity		<b>Associate Investigators:</b>	William A. Brennan, COL, DC Benjamin S. Hanson, LTC, DC Michael A. Billman, LTC, DC Val L. Kudryk, LTC, DC Donald E. Sutherland, MAJ, MS	
<b>Key Words:</b>			<b>Periodic Review Results:</b>		
<b>Accumulative MEDCASE Cost:</b>			<b>Periodic Review Results:</b>		

**Study Objective:** Determine if the use of TGF-B & PDGF might enhance second healing.

**Technical Approach:** Fibroblast are grown in vitro and then cultured with TGFβ or PDGF.

**Progress:** Cells are then surveyed for viability and growth. Presently gathering data.

HSHF-PAT

SUBJECT: Annual Publications Report - November 1993

DETAIL SUMMARY SHEET

<b>Date:</b>	29 Oct 93	<b>Protocol</b>	93-39	<b>Status</b>	Ongoing
<b>Title:</b>	The Efficacy of Procera Laser Welded Hybrid Restorations				
<b>Start Date:</b>		<b>Est. Compl. Date:</b>			
<b>Principal Investigator(s):</b>	Eric D. Adrian, LTC, DC		<b>Facility:</b>	Tingay Dental Clinic	
<b>Department/Service:</b>		<b>Associate Investigators:</b>	COL John Agar, DC COL Michael Billman, DC COL Michael Gardner, DC COL James Hughbanks, DC LTC Ben Hanson, DC LTC Max Gaston, DC LTC Elise Adrian, DC LTC Stephen Cameron, DC		
<b>Key Words:</b>					
<b>Accumulative MEDCASE Cost:</b>		<b>Periodic Review Results:</b>			

**Objective:** To compare the clinical performance of Procera laser welded hybrid restorations to the current lost wax cast framework technique in the restoration of human mandibular edentulous patients.

**Technical Approach:** The study includes a randomly assigned control group consisting of implant supported restorations made with a cast nobel alloy framework. All patients will be treated with a minimum of five Branemark system implants per patient and a hybrid cantilevered prostheses.

**Number of subjects enrolled for the reporting period:**

**Progress:** Final approval is suspended pending resolution of funding issues.

HSHF-PAT

SUBJECT: Annual Publications Report - November 1993

**DETAIL SUMMARY SHEET**

<b>Date:</b> 29 Oct 93 <b>Protocol</b> 93-48 <b>Status</b> Ongoing	
<b>Title:</b> An Average Mandibular Anterior Implant Angle	
<b>Start Date:</b>	<b>Est. Compl. Date:</b>
<b>Principal Investigator(s):</b> Walter J. Morris, MAJ, DC	<b>Facility:</b> Tingay Dental Clinic
<b>Department/Service:</b>	<b>Associate Investigators:</b> COL Michael F. Gardner, DC COL Max Gaston, DC LTC Eric Adrian, DC LTC Eladio DeLeon, DC
<b>Key Words:</b>	
<b>Accumulative MEDCASE Cost:</b>	<b>Periodic Review Results:</b>

**Objective:** To evaluate existing radiographs to see if a significant mandibular anterior implant trajectory angle or range of angles can be used to guide the placing of mandibular anterior implants.

**Technical Approach:**

**Number of subjects enrolled for the reporting period:**

**Progress:** Data is still being gathered.

HSHF-PAT

SUBJECT: Annual Publications Report - November 1993

DETAIL SUMMARY SHEET

<b>Date:</b> 29 Oct 93 <b>Protocol</b> 93-49 <b>Status</b> Ongoing	
<b>Title:</b> A Comparison of Luting Cements for the CeraOne Abutment System	
<b>Start Date:</b>	<b>Est. Compl. Date:</b>
<b>Principal Investigator(s):</b> James E. Parker, MAJ, DC	<b>Facility:</b> Tingay Dental Clinic
<b>Department/Service:</b>	<b>Associate Investigators:</b> COL Max Gaston, DC LTC Eric Adrian, DC Michael F. Gardner, DDS
<b>Key Words:</b>	
<b>Accumulative MEDCASE Cost:</b>	<b>Periodic Review Results:</b>

**Objective:** To evaluate the effectiveness of different luting cements on the retention of a ceramic crown and titanium implant abutment using the Instron to measure retention forces.

**Technical Approach:**

**Number of subjects enrolled for the reporting period:**

**Progress:** Data is still being collected.

HSHF-PAT

SUBJECT: Annual Publications Report - November 1993

DETAIL SUMMARY SHEET

<b>Date:</b>	29 Oct 93	<b>Protocol</b>	92-14	<b>Status</b>	Completed
<b>Title:</b>	Safety and efficacy of clarithromycin and erythromycin ethylsuccinate suspensions in the treatment of children with community-acquired pneumonia				
<b>Start Date:</b>			<b>Est. Compl. Date:</b>		
<b>Principal Investigator(s):</b>	George W. Wright, MAJ, MC		<b>Facility:</b>	Eisenhower Army Medical Center	
<b>Department/Service:</b>	Family Practice		<b>Associate Investigators:</b>	Bruce M. LeClair, MAJ, MC	
<b>Key Words:</b>					
<b>Accumulative MEDCASE Cost:</b>			<b>Periodic Review Results:</b>		

**Study Objective:** To compare the efficacy and safety of clarithromycin and erythromycin ethylsuccinate suspensions in the treatment of children with community-acquired pneumonia who are suitable candidates for oral macrolide therapy.

**Technical Approach:** Randomized, investigator blind, multicenter trial.

**Subjects enrolled to date:** 3

**Progress:** Three patients enrolled. Study completed 30 April 1993 with no serious side effects.

HSHF-PAT  
 SUBJECT: Annual Publications Report - November 1993

**DETAIL SUMMARY SHEET**

<b>Date:</b> 29 Oct 93		<b>Protocol</b> 92-16		<b>Status</b> Terminated	
<b>Title:</b> Comparison of family Apgar scores of outpatients with principal diagnoses and medication use					
<b>Start Date:</b>			<b>Est. Compl. Date:</b>		
<b>Principal Investigator(s):</b> H. James Huffnagle, CPT, MC			<b>Facility:</b> Eisenhower Army Medical Center		
<b>Department/Service:</b> Family Practice			<b>Associate Investigators:</b> Roger Bruce, LTC, MC		
<b>Key Words:</b>					
<b>Accumulative MEDCASE Cost:</b>			<b>Periodic Review Results:</b>		

**Study Objective:** To compare the family apgar scores of outpatients with their respective principal (1-3) diagnoses and number of current medications.

**Technical Approach:**

**Progress:** Inconclusive data.

HSHF-PAT

SUBJECT: Annual Publications Report - November 1993

DETAIL SUMMARY SHEET

<b>Date:</b>	29 Oct 93	<b>Protocol</b>	92-24	<b>Status</b>	Terminated
<b>Title:</b>	The positive and negative predictive value of a routine fifty gram glucose screening test at the initial prenatal visit				
<b>Start Date:</b>			<b>Est. Compl. Date:</b>		
<b>Principal Investigator(s):</b>	Karen S. Phelps, CPT, MC		<b>Facility:</b>	Eisenhower Army Medical Center	
<b>Department/Service:</b>	Family Practice		<b>Associate Investigators:</b>	Kim DeStefano, CPT, MC	
<b>Key Words:</b>					
<b>Accumulative MEDCASE Cost:</b>			<b>Periodic Review Results:</b>		

**Study Objective:** To determine usefulness of 1° glucola in all antepartum patients at first prenatal visit.

**Technical Approach:**

**Number of subjects enrolled to date:** 0

**Progress:** Cancelled after pilot study review.

HSHF-PAT

SUBJECT: Annual Publications Report - November 1993

DETAIL SUMMARY SHEET

<b>Date:</b>	29 Oct 93	<b>Protocol</b>	92-41	<b>Status</b>	Terminated
<b>Title:</b>	The effectiveness of interventions to increase compliance with breast cancer screening guidelines of the US task force for clinical preventive services				
<b>Start Date:</b>			<b>Est. Compl. Date:</b>		
<b>Principal Investigator(s):</b>	Dale Carroll, COL, MC		<b>Facility:</b>	Eisenhower Army Medical Center	
<b>Department/Service:</b>			<b>Associate Investigators:</b>		
<b>Key Words:</b>					
<b>Accumulative MEDCASE Cost:</b>			<b>Periodic Review Results:</b>		

**Study Objective:** To develop a multi-component educational program aimed at both providers and patients within the primary care environment which will successfully increase compliance with current breast cancer screening recommendations and to identify and educate young soldiers at high risk for breast cancer regarding the importance of routine breast self-examination, clinical breast examinations, and mammography.

**Technical Approach:**

Subjects enrolled to date: 0

**Progress:** This study was not started pending funding approval from MRDC and the principal investigator has left the service.

HSHF-PAT

SUBJECT: Annual Publications Report - November 1993

DETAIL SUMMARY SHEET

<b>Date:</b> 29 Oct 93 <b>Protocol</b> 92-54 <b>Status</b> Terminated	
<b>Title:</b> Determination of the prevalence of genital chlamydia infection in males using enzyme immunoassay of urinary sediment	
<b>Start Date:</b> May 92	<b>Est. Compl. Date:</b>
<b>Principal Investigator(s):</b> Thomas P. Garigan, CPT, MC	<b>Facility:</b> Eisenhower Army Medical Center
<b>Department/Service:</b> Family Practice	<b>Associate Investigators:</b> Eugenia Walsh, CPT, MC David P. Goldman, CPT, MC
<b>Key Words:</b>	
<b>Accumulative MEDCASE Cost:</b>	<b>Periodic Review Results:</b>

**Study Objective:** To establish protocols for study of the epidemiology of urogenital chlamydia infections.

**Technical Approach:** Epidemiologic

**Number of subjects enrolled to date:** 97

**Progress:** None were positive of those tested. Study was terminated.

HSHF-PAT

SUBJECT: Annual Publications Report - November 1993

DETAIL SUMMARY SHEET

<b>Date:</b>	29 Oct 93	<b>Protocol</b>	93-14	<b>Status</b>	Ongoing
<b>Title:</b>	Smoking Cessation in Active Duty Army Trainees: The Effects of Direct Health Care Provider Advice and Follow-up				
<b>Start Date:</b>			<b>Est. Compl. Date:</b>		
<b>Principal Investigator(s):</b>	John Littell, CPT, MC		<b>Facility:</b>	Eisenhower Army Medical Center	
<b>Department/Service:</b>	Family Practice		<b>Associate Investigators:</b>	Charles Stargel, CPT, MC	
<b>Key Words:</b>					
<b>Accumulative MEDCASE Cost:</b>			<b>Periodic Review Results:</b>		

**Study Objective:** Trainees will be identified and surveyed at the time of both in and outprocessing (variable time frame usually 2-4 months) to determine the effectiveness of direct Health Care Provider (HCP) advice/counseling. The intervention and followup visits are to be arranged in conjunction with the trainee's command and excused by sick slip to insure compliance. **Study design:** Prospective quasi-experimental study, to ascertain behavior modification secondary to direct HCP advice alone and subsequently more extensive HCP counseling in a second group, as compared to a similar group without either of these interventions (total groups - 3). Investigator believed that composition of trainees is comparable among the three TMC's.

**Technical Approach:**

**Number of subjects enrolled for reporting period:**

**Progress:** Smoking cessation classes have been held, but changes in processing of troops and personnel have limited enrollment. Followup data is being sought with supplemental personnel.

HSHF-PAT

SUBJECT: Annual Publications Report - November 1993

DETAIL SUMMARY SHEET

<b>Date:</b>	29 Oct 93	<b>Protocol</b>	93-23	<b>Status</b>	Completed
<b>Title:</b>	The Effect of Self-Care Booklet on the Self-Efficacy of Parents				
<b>Start Date:</b>				<b>Est. Compl. Date:</b>	
<b>Principal Investigator(s):</b>	Michelle D. Bannon, PA, DAC			<b>Facility:</b>	Eisenhower Army Medical Center
<b>Department/Service:</b>	Family Practice			<b>Associate Investigators:</b>	
<b>Key Words:</b>	Self-care booklet Self-efficacy				
<b>Accumulative MEDCASE Cost:</b>	Periodic Review Results:				

**Study Objective:** To assess the effect of a self-care booklet on the self-efficacy of parents enrolled in the Family Practice Clinic at Fort Gordon, Georgia. The hypothesis was that parents receiving a self-care booklet with instructions and a motivational statement regarding its use would demonstrate a greater rise in self-efficacy than those participants receiving a booklet only.

**Technical Approach:**

**Number of subjects enrolled for reporting period:** A total of 60 participants were enrolled in the study. 49 completed follow-up surveys, 22 from the B/I group and 27 from the B/O group.

**Progress:** No significant difference in the level of self-efficacy was noted between the groups on the initial survey. On the follow-up survey, an increase in self-efficacy was noted for both groups with a significant increase noted in the control group. This was confirmed by a paired T-test ( $p=.002$ ). Two variables, rank of the active duty sponsor and educational levels of respondent were found to be significant. Those respondents with an enlisted sponsor, or those respondents with a high school (or less) education were more likely to significantly increase their self-efficacy score after the intervention. We concluded that a self-care booklet alone can be an effective tool in increasing the self-efficacy of parents, particularly in those groups previously mentioned.

HSHF-PAT  
SUBJECT: Annual Publications Report - November 1993

DETAIL SUMMARY SHEET

<b>Date:</b>	29 Oct 93	<b>Protocol</b>	93-25	<b>Status</b>	Ongoing
<b>Title:</b>	HELLP Syndrome: The Incidence - A Prospective Study				
<b>Start Date:</b>			<b>Est. Compl. Date:</b>		
<b>Principal Investigator(s):</b>	Kenneth Trzepkowski, CPT, MC		<b>Facility:</b>	Eisenhower Army Medical Center	
<b>Department/Service:</b>	Family Practice/OB-GYN		<b>Associate Investigators:</b>	Wayne Blount, LTC, MC Keven Kelly, LTC, MC	
<b>Key Words:</b>					
<b>Accumulative MEDCASE Cost:</b>			<b>Periodic Review Results:</b>		

**Study Objective:** To determine the incidence of HELLP and determining clinical characteristics associated with the development of the syndrome.

**Technical Approach:** Measure serum marers prospectively on volunteer pregnant patients.

Number of subjects enrolled to date: 199

**Progress:** Approximately 75 patients have completed this study so far with the remaining in different stages of completion. There was a goal of 200 patients, but due to drop out of some of the patients (i.e., moving away from the area, etc.), this number will need to be increased to about 225.

HSHF-PAT

SUBJECT: Annual Publications Report - November 1993

**DETAIL SUMMARY SHEET**

<b>Date:</b>	29 Oct 93	<b>Protocol</b>	93-32	<b>Status</b>	Ongoing
<b>Title:</b>	Infant Feeding Practices in the Military Community: The Incidence and Duration of Breast Feeding in the Military Community and the Factors Affecting this Decision				
<b>Start Date:</b>			<b>Est. Compl. Date:</b>		
<b>Principal Investigator(s):</b>	B. Wayne Blount, MD, MAJ, MC		<b>Facility:</b>	Eisenhower Army Medical Center	
<b>Department/Service:</b>	Family Practice		<b>Associate Investigators:</b>	Cindy Lee, MC John Kugler, MD Dana Anderson, MD Evelyn L. Lewis, MD Kathy Holder, MD William Blanke, MD	
<b>Key Words:</b>			<b>Periodic Review Results:</b>		
<b>Accumulative MEDCASE Cost:</b>					

**Study Objectives:** To determine the incidence and duration of infant feeding methods of women in the military community. To determine the incidence and duration of breast feeding in active duty women as a subset of employed mothers. To identify the factors affecting women's infant feeding decisions, specifically those affecting active duty women.

**Technical Approach:** Questionnaire will be completed by post-partum patients. Telephone or mail contact of subjects at six months for followup data.

**Number of subjects enrolled to date:** 25 active duty and 50 dependent women.

**Progress:** Continuing to enroll subjects. Anticipate completion by end of calendar year 1993.

HSHF-PAT  
SUBJECT: Annual Publications Report - November 1993

**DETAIL SUMMARY SHEET**

<b>Date:</b>	29 Oct 93	<b>Protocol</b>	93-41	<b>Status</b>	Terminated
<b>Title:</b>	Comparison of Oral, Tympanic Skin Thermometry in an Emergency Department				
<b>Start Date:</b>		<b>Est. Compl. Date:</b>			
<b>Principal Investigator(s):</b>	Bruce N. Gibbon, MD, CPT, MC		<b>Facility:</b>	Eisenhower Army Medical Center	
<b>Department/Service:</b>	Emergency Dept/Family Practice		<b>Associate Investigators:</b>	Lisabeth J. Mortimore, SGT	
<b>Key Words:</b>		<b>Medical Monitor:</b>	Mark Remz, M.D., MAJ, MC		
<b>Accumulative MEDCASE Cost:</b>		<b>Periodic Review Results:</b>			

**Objectives:** To assess the correlation between the two thermometry methods and will evaluate if liquid crystal skin thermometry can accurately correlate with these two methods for spot temperature measurements.

**Technical Approach:**

**Number of subjects enrolled to date:**

**Progress:** The study has been completed and presentation was given on the Transitional Residents Research Day. The primary investigator has been transferred to Korea and the paper is in preparation.

HSHF-PAT  
 SUBJECT: Annual Publications Report - November 1993

DETAIL SUMMARY SHEET

<b>Date:</b> 29 Oct 93		<b>Protocol</b> 93-62		<b>Status</b> Ongoing	
<b>Title:</b> A Survey of Resident Perceptions of Effective Teaching Behaviors in Different Residencies					
<b>Start Date:</b>			<b>Est. Compl. Date:</b>		
<b>Principal Investigator(s):</b> J. Gregory Jolissaint, CPT, MC			<b>Facility:</b> Eisenhower Army Medical Center		
<b>Department/Service:</b> Family Practice			<b>Associate Investigators:</b> David P. Goldman, CPT, MC B. Wayne Blount, LTC, MC Robert Webb, LTC, MC		
<b>Key Words:</b>					
<b>Accumulative MEDCASE Cost:</b>			<b>Periodic Review Results:</b>		

**Objectives:** This study is designed to inform faculty members of different residency programs of teaching behaviors their house officers deemed most helpful to their learning process in residency (as well as those felt to be least helpful). By "arming" faculty members with this information during faculty orientation and/or faculty development sessions, there should be a resultant improvement in training for physicians at DDEAMC and ultimately higher quality patient care delivered by graduates of DDEAMC residencies.

**Technical Approach:**

Number of subjects enrolled to date:

Progress:

HSHF-PAT  
 SUBJECT: Annual Publications Report - November 1993

**DETAIL SUMMARY SHEET**

<b>Date:</b>	28 Oct 93	<b>Protocol</b>	89-46	<b>Status</b>	Completed
<b>Title:</b>	Effects of non-Ionic surfactants in sunburns using a rat model				
<b>Start Date:</b>			<b>Est. Compl. Date:</b>		
<b>Principal Investigator(s):</b>	Michael S. Riel, MAJ, MC		<b>Facility:</b>	Eisenhower Army Medical Center	
<b>Department/Service:</b>	Medicine/Clinical Investigation		<b>Associate Investigators:</b>	James C. McPherson, III, PhD MAJ, MC James C. McPherson, Jr., MD Paul W. Paustian, MC Royce R. Runner, ASCP	
<b>Key Words:</b>	sunburn Pluronic polyols				
<b>Accumulative MEDCASE Cost:</b>			<b>Periodic Review Results:</b>	Oct 93 Completed	

**Study Objective:** To evaluate possible protective effects of non-ionic surfactants in ultraviolet induced first degree skin burns using an albino rat model.

**Technical Approach:** Male, Aprague-Dawley rats weighing greater than 320 gm will be used. A 3x6cm area will be exposed to UV light at 3x the minimal erythermal dose. This study is based on earlier work which showed that the non-ionic surfactant F-127 injected shortly after a full thickness burn of the skin could reduce the amount of damage to the underlying tissue and speed healing. The mechanism of this protective effect is not yet known. This study is an attempt to isolate the steps in the process by examining first degree burns to see if these same protective effects would also work with skin which is merely injured.

**Progress:** Completed pilot project. Results presented at ACP Associates of Georgia, DDEAMC, on Resident Research Day, and received Admiral Eske Award at AMOPS for outstanding research.

HSHF-PAT

SUBJECT: Annual Publications Report - November 1993

DETAIL SUMMARY SHEET

<b>Date:</b> 29 Oct 93 <b>Protocol</b> 90-16 <b>Status</b> Ongoing	
<b>Title:</b> Study of Vespa fire ant venom in the diagnosis of fire ant reactivity	
<b>Start Date:</b>	<b>Est. Compl. Date:</b>
<b>Principal Investigator(s):</b> Angelina J. LePage, MAJ, MC	<b>Facility:</b> Eisenhower Army Medical Center
<b>Department/Service:</b> Medicine/Allergy	<b>Associate Investigators:</b> Chester Stafford, MD, MCG Richard T. Hatch, MC
<b>Key Words:</b>	
<b>Accumulative MEDCASE Cost:</b>	<b>Periodic Review Results:</b>

**Study Objective:** To compare skin test reactivity of Vespa fire ant venom to that of two commercially available IFA whole body extract preparations.

**Number of subjects enrolled to date:** 35 adults  
**Number enrolled for reporting period:**

**Progress:** The study in adults has been completed and results published. There were 35 adults enrolled. According to Dr. stafford, the study hopes to include children but at this time there are none enrolled and no progress to report.

HSHF-PAT-  
SUBJECT: Annual Publications Report - November 1993

**DETAIL SUMMARY SHEET**

<b>Date:</b>	27 Oct 93	<b>Protocol</b>	91-14	<b>Status</b>	Ongoing
<b>Title:</b>	Comparison of intravenous H-2 antagonists and their influence on gastric emptying on insulin dependent diabetics				
<b>Start Date:</b>			<b>Est. Compl. Date:</b>		
<b>Principal Investigator(s):</b>	Michael P. Goldfinger, CPT, MC		<b>Facility:</b>	Eisenhower Army Medical Center	
<b>Department/Service:</b>	Medicine		<b>Associate Investigators:</b>	Eugene H. Ryan, CPT, MC, Staff Internist, Fort Rucker, Alabama Stephen G. Oswald, LTC, MC	
<b>Key Words:</b>			<b>Periodic Review Results:</b>	Jan 93 Continue	
<b>Accumulative MEDCASE Cost:</b>					

**Study Objective:** To study the effect of a single standard IV dose of famotidine, cimetidine and ranitidine on GE in adult diabetics.

**Technical Approach:** Each patient will be studied in the fasting state on four different days spaced at least 72 hours apart. Prior to each gastric emptying study the subjects will receive an IV bolus injection of either one of cimetidine, ranitidine, famotidine, or placebo.

**Number of subjects enrolled for the reporting period:** 4

**Progress:** This study was amended to include females as subjects. The study and the consent were revised to include an HCG test for pregnancy within 24 hours preceding the test and to warn of the potential dangers to the fetus of any undetected pregnancy. The hope is to broaden the potential patient base sufficiently to complete the study.

HSHF-PAT  
 SUBJECT: Annual Publications Report - November 1993

DETAIL SUMMARY SHEET

<b>Date:</b>	29 Oct 93	<b>Protocol</b>	92-1	<b>Status</b>	Completed
<b>Title:</b>	Serologic survey of active duty dependent and retired military population for evidence of <i>helicobacter pylori</i> ( <i>Campylobacter pylori</i> ) infection at a US Army Medical Treatment Facility				
<b>Start Date:</b>		<b>Est. Compl. Date:</b>			
<b>Principal Investigator(s):</b>	David R. Haburchak, COL, MC		<b>Facility:</b>	Eisenhower Army Medical Center	
<b>Department/Service:</b>	Medicine		<b>Associate Investigators:</b>	David W. Craft, PhD, MAJ, MS Donald E. Sutherland, PhD, MAJ, MS Norma Best, MT	
<b>Key Words:</b>					
<b>Accumulative MEDCASE Cost:</b>			<b>Periodic Review Results:</b>	Jan 93 Continue	

**Study Objective:** What is the prevalence of *H. pylori* associated infection in a military population including gastroenterology patients? What is the efficacy of triple therapy in a nonselected population of seropositive patients?

**Technical Approach:** A simplified nonblinded treatment protocol will be instituted based on the knowledge of the role of *Helicobacter* in association with gastritis and peptic ulcer disease in the literature, its responsiveness to therapy and the ethics of withholding potentially curative therapy. This study will simulate clinical practical use of this modality of treatment/management for its practicality and ease.

Subjects enrolled to date: 22

**Progress:** 50% of 22 patients had evidence of *H. pylori* based on serology. All patients who received drug combination completed therapy with follow-up improvement in pain in most patients. Since the project was begun, the medical literature now supports use of triple antibiotics after endoscopy in patients who relapse after initial course of H2 blockers or have a complication of peptic ulcer. Non-ulcer dyspepsia is not been demonstrated to be caused by *H. pylori*. The frequency of *h. pylori* in the DDEAMC population is compatible with publicized results in larger studies.

**Action:** Study closed as new literature precludes benefit to patients.

HSHF-PAT  
SUBJECT: Annual Publications Report - November 1993

DETAIL SUMMARY SHEET

<b>Date:</b>	29 Oct 93	<b>Protocol</b>	92-10	<b>Status</b>	Ongoing
<b>Title:</b>	A comparison of the efficacy, safety, and tolerance of ceftibuten (SCH 39720) 300 mg given BID and augmentin 500 mg given TID in the treatment of community acquired pneumonia				
<b>Start Date:</b>			<b>Est. Compl. Date:</b>		
<b>Principal Investigator(s):</b>	Warren L. Whitlock, LTC, MC		<b>Facility:</b>	Eisenhower Army Medical Center	
<b>Department/Service:</b>	Medicine/Pulmonary		<b>Associate Investigators:</b>	Wayne T. Honeycutt, MAJ, MC Jesse J. Doers, MAJ, MC	
<b>Key Words:</b>					
<b>Accumulative MEDCASE Cost:</b>			<b>Periodic Review Results:</b>		

**Study Objective:** To compare the efficacy, safety, and tolerance of high-dose ceftibuten (SCH 39720) 300 mg BID with that of augmentin 500 mg TID in the treatment of pneumonia in adults.

**Technical Approach:** Treatment will follow outline in Schering-Plough protocol.

**Subjects enrolled to date:** 5

**Progress:** Over 30 patients have been screened with 12 patients enrolled. The protocol will continue in 1994. Major problems have been isolation of the causative organism on cultures. The laboratory has started doing double culture plates to increase the diagnostic yield.

HSHF-PAT  
 SUBJECT: Annual Publications Report - November 1993

**DETAIL SUMMARY SHEET**

<b>Date:</b>	29 Oct 93	<b>Protocol</b>	92-9	<b>Status</b>	Ongoing
<b>Title:</b>	A comparison of the efficacy, safety, and tolerance of ceftibuten (SCH 39720) 400 mg (I x 400 mg capsule) in the fed and fasted state and augmentin amoxicillin/clavulanate 1.5 gm (I x 500 mg tablet TIC) in the fed state in the treatment of acute exacerbations of chronic bronchitis				
<b>Start Date:</b>			<b>Est. Compl. Date:</b>		
<b>Principal Investigator(s):</b>	Warren L. Whitlock, LTC, MC		<b>Facility:</b>	Eisenhower Army Medical Center	
<b>Department/Service:</b>	Medicine/Pulmonary		<b>Associate Investigators:</b>	Wayne T. Honeycutt, MAJ, MC Jesse J. Doers, MAJ, MC	
<b>Key Words:</b>					
<b>Accumulative MEDCASE Cost:</b>			<b>Periodic Review Results:</b>		

**Study Objective:** To compare the efficacy, safety, and primarily, the GI tolerance of once-daily Cedax ceftibuten (SCH 39720) in both the fed and fasted state with that of Augmentin amoxicillin/clavulanate given TID in the fed state in the treatment of acute exacerbations of chronic bronchitis in adults.

**Technical Approach:** Treatment will follow outline in Schering-Plough protocol.

**Subjects enrolled to date:** 6

**Progress:** Over 70 patients have been screened and 24 patients have been enrolled. The protocol will end in 1993. There have been positive results in most patients without complications. We hope to finish enrollment before the end of the protocol.

HSHF-PAT

SUBJECT: Annual Publications Report - November 1993

DETAIL SUMMARY SHEET

<b>Date:</b>	29 Oct 93	<b>Protocol</b>	92-18	<b>Status</b>	Terminated
<b>Title:</b>	Prediction of endogenous erythropoietin levels from the hematocrit and serum creatinine				
<b>Start Date:</b>			<b>Est. Compl. Date:</b>		
<b>Principal Investigator(s):</b>	Bobby W. Jones, CPT, MC		<b>Facility:</b>	Eisenhower Army Medical Center	
<b>Department/Service:</b>	Medicine/Hematol-Oncol, Nephrology/Family Practice		<b>Associate Investigators:</b>	Patrick W. Cobb, MAJ, MC John W. Nolan, MAJ, MC Amy W. Sprague, MAJ, MC	
<b>Key Words:</b>					
<b>Accumulative MEDCASE Cost:</b>			<b>Periodic Review Results:</b>		

**Study Objective:** To determine if the clinician can use values obtained from routine laboratory studies solely and appropriately in medical decision making with reference to exogenous erythropoietin therapy.

**Technical Approach:**

**Subjects enrolled to date:**

**Progress:** Test kits to assay erythropoietin are not available. Project terminated.

HSHF-PAT

SUBJECT: Annual Publications Report - November 1993

DETAIL SUMMARY SHEET

<b>Date:</b> 29 Oct 93	<b>Protocol</b> 92-30	<b>Status</b> Ongoing
<b>Title:</b> Techniques of use of metered dose inhalers		
<b>Start Date:</b> Apr 92	<b>Est. Compl. Date:</b>	June 93
<b>Principal Investigator(s):</b> Richard B. Hilburn, CPT, MC	<b>Facility:</b> Eisenhower Army Medical Center	
<b>Department/Service:</b> Medicine/Pulmonary Disease	<b>Associate Investigators:</b> Warren L. Whitlock, MAJ, MC Jesse T. Doers, MAJ, MC Ray Scarlett, CRT	
<b>Key Words:</b> MDI, Metered dose inhalers		
<b>Accumulative MEDCASE Cost:</b>	<b>Periodic Review Results:</b>	

**Study Objective:** To evaluate the techniques of use of MDI by the EAMC patient population. To determine which of three teaching modalities is the most effective in improving technique. To detect any implication of impact of improved technique upon emergency room visits and hospitalizations for the study population.

Subjects enrolled to date: 43

**Progress:** 101 subjects have been enrolled to date. Phase I and II have been completed and Phase III is in progress. Phase I data was presented at the American Thoracic Society annual meeting in May 1993 and Phase II data will be presented at the American College of Chest Physicians' annual meeting in October 1993. A manuscript has been written and submitted to the journal Chest for publication of Phase I and II data.

HSHF-PAT  
SUBJECT: Annual Publications Report - November 1993

DETAIL SUMMARY SHEET

<b>Date:</b>	29 Oct 93	<b>Protocol</b>	92-47	<b>Status</b>	Ongoing
<b>Title:</b>	A double-blind, placebo controlled, parallel group, multicenter study of the use of weekly azithromycin as prophylaxis against the development of <i>Mycobacterium avium</i> complex disease in HIV infected people				
<b>Start Date:</b>			<b>Est. Compl. Date:</b>		
<b>Principal Investigator(s):</b>	Daniel B. Craig, COL, MC		<b>Facility:</b>	Eisenhower Army Medical Center	
<b>Department/Service:</b>	Medicine/Infectious Disease		<b>Associate Investigators:</b>	Craig E. Smith, MAJ, MC David R. Haburchak, COL, MC	
<b>Key Words:</b>					
<b>Accumulative MEDCASE Cost:</b>			<b>Periodic Review Results:</b>		

**Study Objective:** To evaluate the safety and efficacy of azithromycin administered once a week in the prevention of disseminated MAC in severely immunocompromised HIV infected patients with a CD4 count < 100/ul.

**Technical Approach:** Treatment will follow outline per Pfizer protocol.

**Subjects enrolled to date:** 9

**Progress:** Nine patients screened. One patient did not meet entry qualifications, one patient dropped from study before receiving drug, one patient died while on study not related to drugs. Six patients continue on study.

HSHF-PAT

SUBJECT: Annual Publications Report - November 1993

DETAIL SUMMARY SHEET

<b>Date:</b>	27 Oct 93	<b>Protocol</b>	92-60	<b>Status</b>	Ongoing
<b>Title:</b>	A double-blind randomized parallel study of the antiemetic effectiveness of IV Dolasetron mesylate VS IV Zofran in patients receiving cisplatin chemotherapy (MCPR0031)				
<b>Start Date:</b>		<b>Est. Compl. Date:</b>			
<b>Principal Investigator(s):</b>	Karen J. Bowen, MAJ, MC		<b>Facility:</b>	Eisenhower Army Medical Center	
<b>Department/Service:</b>	Medicine/Oncology		<b>Associate Investigators:</b>	Don W. Shaffer, MAJ, MC Robert Krywicki, MAJ, MC Stephen G. Oswald, LTC, MC Charles T. Thornsvar, COL, MC Lyle M. Glascock, PharmD	
<b>Key Words:</b>					
<b>Accumulative MEDCASE Cost:</b>			<b>Periodic Review Results:</b>		

**Study Objective:** To determine the relative effectiveness of a single 2.4 mg/kg intravenous (IV) dose of dolasetron mesylate versus a single 32 mg dose of IV Zofran for complete prevention of emesis due to ( $\geq 70$  mg/m<sup>2</sup>) of cisplatin chemotherapy. To evaluate the safety and tolerance of dolasetron mesylate versus ondansetron when given for this indication. To compare patient satisfaction with the two antiemetic agents.

**Technical Approach:** This is a double-blind, randomized, parallel study in which patients with a history of histologically confirmed malignant disease will receive either IV dolasetron mesylate (2.4 mg/kg) or IV ondansetron (32 mg/kg). The cisplatin dose will be  $\geq 70$  mg/m<sup>2</sup> and infused over no more than 3 hours as the first component of a chemotherapy regimen.

Number of subjects enrolled to date: 12

**Progress:** The study objective and technical approach was amended in Nov 92 to include a single dose of Zofran as the comparative drug. There have been 12 patients enrolled and completed the study. There has been one serious adverse event - a Type I hypersensitivity reaction manifested by severe bronchospasm. The patient was treated with IV Benadryl, 50 mg, after Albuterol nebulizer therapy. The reaction subsequently subsided.

HSHF-PAT  
 SUBJECT: Annual Publications Report - November 1993

**DETAIL SUMMARY SHEET**

<b>Date:</b>	27 Oct 93	<b>Protocol</b>	92-61	<b>Status</b>	Ongoing
<b>Title:</b>	A five arm double-blind randomized dose-response study of the antiemetic effectiveness of IV Dolasetron mesylate in patients receiving cisplatin chemotherapy (MCPRO032)				
<b>Start Date:</b>		<b>Est. Compl. Date:</b>			
<b>Principal Investigator(s):</b>	Karen J. Bowen, MAJ, MC		<b>Facility:</b>	Eisenhower Army Medical Center	
<b>Department/Service:</b>	Medicine/Oncology		<b>Associate Investigators:</b>	Stephen G. Oswald, LTC, MC Don Shaffer, MAJ, MC Robert Krywicki, MAJ, MC Charles T. Thornsvard, COL, MC Lyle M. Glascock, PharmD	
<b>Key Words:</b>					
<b>Accumulative MEDCASE Cost:</b>			<b>Periodic Review Results:</b>		

**Study Objective:** To establish efficacy by showing that there is a trend toward decreased emesis following cisplatin ( $\geq 70$  mg/m<sup>2</sup>) with increasing doses of dolasetron mysylate. To evaluate the dose-response relationship across 0.6, 1.2, 1.8, 2.4, and 3.0 mg/kg single intravenous (IV) doses of dolasetron mysylate in preventing emesis due to cisplatin ( $\geq 70$  mg/m<sup>2</sup>) chemotherapy. To evaluate the safety and tolerance of dolasetron mesylate when given for this indication. To characterize the population pharmacokinetic and pharmacodynamic models of dolasetron mysylate and/or its metabolite(s) and their interindividual variabilities in patients receiving cisplatin. To compare the degree of patient satisfaction among the antiemetic dose levels.

**Technical Approach:** This is a five arm, double-blind, randomized, dose response in which patients with a history of histologically confirmed malignant disease will receive a single dose of dolasetron mesylate. Patients of either sex and any race will be admitted to this study. They must be undergoing their first course of cisplatin-containing chemotherapy. The cisplatin dose will be  $\geq 70$  mg/m<sup>2</sup> and infused over no more than 3 hours as the first component of a chemotherapy regimen.

Number of subjects enrolled to date: 0

**Progress:** This study has not begun yet and is on hold while the other Dolasetron study (DDEAMC 91-61) is progressing. There may be some patients randomized this year and the pharmacokinetic samples would be deleted.

HSHF-PAT

SUBJECT: Annual Publications Report - November 1993

DETAIL SUMMARY SHEET

<b>Date:</b>	29 Oct 93	<b>Protocol</b>	92-67	<b>Status</b>	Terminate
<b>Title:</b>	Evaluation of the Use of <sup>99m</sup> Tc Technetium Pertechnetate with Potassium Perchlorate Wash-out and <sup>99m</sup> Tc Technetium MIBI in Parathyroid Imaging in Patients with Suspected Parathyroid Neoplasia or Hyperplasia				
<b>Start Date:</b>			<b>Est. Compl. Date:</b>		
<b>Principal Investigator(s):</b>	Rama G. Eachempati, MD, LTC, MC		<b>Facility:</b>	Eisenhower Army Medical Center	
<b>Department/Service:</b>	Medicine/Infectious Disease		<b>Associate Investigators:</b>		
<b>Key Words:</b>					
<b>Accumulative MEDCASE Cost:</b>			<b>Periodic Review Results:</b>		

Study Objective:

Technical Approach:

Progress: PI has left military service with no progress, terminate. No patients were enrolled.

HSHF-PAT  
SUBJECT: Annual Publications Report - November 1993

DETAIL SUMMARY SHEET

<b>Date:</b>	29 Oct 93	<b>Protocol</b>	92-73	<b>Status</b>	Terminate
<b>Title:</b>	Comparative Study of Liver Biopsies and Quantitative Hepatobiliary Scanning in Patients with Hepatitis C				
<b>Start Date:</b>			<b>Est. Compl. Date:</b>		
<b>Principal Investigator(s):</b>	Anwar K. Malik, MD, MAJ, MC		<b>Facility:</b>	Eisenhower Army Medical Center	
<b>Department/Service:</b>	Medicine		<b>Associate Investigators:</b>		
<b>Key Words:</b>					
<b>Accumulative MEDCASE Cost:</b>			<b>Periodic Review Results:</b>		

**Study Objective:** To determine if quantified hepatobiliary scan with 99Tc-IDA could be substituted for liver biopsy in patients with Hepatitis C.

**Technical Approach:**

**Number of subjects enrolled to date:** None

**Progress:** No progress to report.

HSHF-PAT

SUBJECT: Annual Publications Report - November 1993

DETAIL SUMMARY SHEET

<b>Date:</b>	29 Oct 93	<b>Protocol</b>	92-78	<b>Status</b>	Ongoing
<b>Title:</b>	A Multicenter, Open Label, Pilot Study of Azithromycin in the Outpatient Treatment of Lower Respiratory Tract Infection Due to Atypical Respiratory Pathogens				
<b>Start Date:</b>			<b>Est. Compl. Date:</b>		
<b>Principal Investigator(s):</b>	Warren L. Whitlock, MD, LTC, MC		<b>Facility:</b>	Eisenhower Army Medical Center	
<b>Department/Service:</b>	Medicine/Pulmonary		<b>Associate Investigators:</b>		
<b>Key Words:</b>					

HSHF-PAT  
 SUBJECT: Annual Publications Report - November 1993

**DETAIL SUMMARY SHEET**

<b>Date:</b>	29 Oct 93	<b>Protocol</b>	93-6	<b>Status</b>	Ongoing
<b>Title:</b>	Phase I, Trial of VP-16 + Immunex r-GM-CSF in Patients with Advanced Malignancies				
<b>Start Date:</b>			<b>Est. Compl. Date:</b>		
<b>Principal Investigator(s):</b>	Don W. Shaffer, MAJ, MC		<b>Facility:</b>	Eisenhower Army Medical Center	
<b>Department/Service:</b>	Medicine/Oncology		<b>Associate Investigators:</b>	Geoffrey R. Weiss, MD	
<b>Key Words:</b>					
<b>Accumulative MEDCASE Cost:</b>			<b>Periodic Review Results:</b>	Oct 93 Continue	

**Study Objective:** To estimate the maximally tolerated dosage, and frequency and types of toxicities of etoposide when combined with r-GM-CSF in patients with advanced malignancy; to determine which schedule of administration of r-GM-CSF (prior to or during etoposide delivered; to determine a superior in terms of the greater amount of etoposide delivered; to determine a recommended dosage and schedule for etoposide +/- r-GM-CSF to be used in Phase II trials; to document any responses which may be observed during treatment with the combined regimen; and to evaluate the effects of rHuGM-CSF on the blood levels of etoposide administered orally.

**Technical Approach:**

Number of subjects enrolled for reporting period: 7

**Progress:** Since implementation of the protocol, we have enrolled 7 patients. Level 2 is nearing completion (3 more patients). Toxicities have been acceptable and if the additional three patients do well then Dr. Weiss (San Antonio) will go to level 3. One patient died of febrile neutropenia and sepsis on Arm A here at Eisenhower. There have been no other significant toxicities.

HSHF-PAT

SUBJECT: Annual Publications Report - November 1993

**DETAIL SUMMARY SHEET**

<b>Date:</b>	29 Oct 93	<b>Protocol</b>	93-24	<b>Status</b>	Terminate
<b>Title:</b>	The Detection of Antibodies to <i>Helicobacter pylori</i> in Samples obtained with the Principal OraSure Oral Specimen Collection Device				
<b>Start Date:</b>			<b>Est. Compl. Date:</b>		
<b>Principal Investigator(s):</b>	Timothy E. Mecredy, MAJ, MC		<b>Facility:</b>	Eisenhower Army Medical Center	
<b>Department/Service:</b>	Medicine/Gastroenterology		<b>Associate Investigators:</b>	Francisco I. Cuartas, COL, MC Howard M. Rosen, COL, MC Michael R. Fisher, MAJ, MC	
<b>Key Words:</b>					
<b>Accumulative MEDCASE Cost:</b>			<b>Periodic Review Results:</b>		

**Study Objective:** To determine if the OraSure device collects oral specimens which are suitable for use with enzyme immunoassay kits for the detection of *Helicobacter pylori* IgGs. To determine if OraSure samples result in sensitivities and specificities comparable to those obtained with serum when assayed with *H. pylori*-specific EIA kits.

**Technical Approach:**

**Number of subjects enrolled for the reporting period:**

**Progress:** This study was not started because of technician shortages.

HSHF-PAT

SUBJECT: Annual Publications Report - November 1993

DETAIL SUMMARY SHEET

<b>Date:</b>	29 Oct 93	<b>Protocol</b>	93-26	<b>Status</b>	Ongoing
<b>Title:</b>	A Comparative Trial of 256U87 and Acyclovir for the Treatment of First-Episode Genital Herpes Infection				
<b>Start Date:</b>			<b>Est. Compl. Date:</b>		
<b>Principal Investigator(s):</b>	Mark G. Blaskis, MD, MAJ, MC		<b>Facility:</b>	Eisenhower Army Medical Center	
<b>Department/Service:</b>	Medicine/Dermatology		<b>Associate Investigators:</b>	Jerome C. Hill, MD, MAJ, MC William L. Heimer, MD, MAJ, MC	
<b>Key Words:</b>			<b>Medical Monitor:</b>	David R. Haburchak, MD, COL, MC	
<b>Accumulative MEDCASE Cost:</b>			<b>Periodic Review Results:</b>		

**Study Objective:** To determine the efficacy of a new antiviral agent administered twice a day instead of five times a day as acyclovir is administered.

**Technical Approach:** Therapy will follow schema outlined in Burroughs-Wellcome protocol.

**Number of subjects enrolled to date:** Two

**Progress:** One patient has completed the trial with no adverse effects. The second patient decided to discontinue the trial after the second day.

HSHF-PAT

SUBJECT: Annual Publications Report - November 1993

DETAIL SUMMARY SHEET

<b>Date:</b>	29 Oct 93	<b>Protocol</b>	93-30	<b>Status</b>	Ongoing
<b>Title:</b>	A Multicenter Investigator Blinded Study of the Efficacy and Safety of Azithromycin vs Amoxicillin/Clavulanate in the Treatment of Acute Bacterial Exacerbations of Chronic Obstructive Pulmonary Disease (Chronic Bronchitis)				
<b>Start Date:</b>			<b>Est. Compl. Date:</b>		
<b>Principal Investigator(s):</b>	Warren L. Whitlock, MD, LTC, MC		<b>Facility:</b>	Eisenhower Army Medical Center	
<b>Department/Service:</b>	Medicine/Pulmonary		<b>Associate Investigators:</b>	Jesse T. Doers, MD, MAJ, MC Wayne T. Honeycutt, MD, MAJ, MC	
<b>Key Words:</b>					
<b>Accumulative MEDCASE Cost:</b>			<b>Periodic Review Results:</b>		

**Study Objective:** To compare the safety and efficacy of orally administered azithromycin and amoxicillin/clavulanate in the treatment of acute exacerbations of COPD (Chronic Bronchitis) Caused by susceptible bacterial pathogens.

**Technical Approach:** Therapy will follow schema outlined in Pfizer protocol.

**Number of subjects enrolled to date:** Three

**Progress:** Three patients have been enrolled with a total goal of 10 patients from our site.

HSHF-PAT

SUBJECT: Annual Publications Report - November 1993

**DETAIL SUMMARY SHEET**

<b>Date:</b>	29 Oct 93	<b>Protocol</b>	93-31	<b>Status</b>	Ongoing
<b>Title:</b>	A Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of Three Doses of CP-0127 and Placebo in Patients with Presumed Sepsis and the Systemic Inflammatory Response Syndrome (SIRS)				
<b>Start Date:</b>		<b>Est. Compl. Date:</b>			
<b>Principal Investigator(s):</b>	Warren L. Whitlock, MD, LTC, MC		<b>Facility:</b>	Eisenhower Army Medical Center	
<b>Department/Service:</b>	Medicine/Pulmonary, Infectious Disease		<b>Associate Investigators:</b>	Wayne T. Honeycutt, MD, MAJ, MC Jesse T. Doers, MD, MAJ, MC Craig Smith, MD, MAJ, MC	
<b>Key Words:</b>					
<b>Accumulative MEDCASE Cost:</b>			<b>Periodic Review Results:</b>		

**Study Objective:** To investigate the efficacy and safety of a 72-hour infusion of three doses of CP-0127 or placebo in the treatment of patients with SIRS and presumed sepsis.

**Technical Approach:** Therapy will follow schema outlined in Cortech protocol.

**Number of subjects enrolled to date:** Four

**Progress:** Four patients have been enrolled with a plan for 10 patients. One patient died of causes not related to the protocol. Estimated mortality due to underlying disease is 45%. The blind will be broken when 50% of patients are enrolled from the multicenter sites nation-wide for initial review.

HSHF-PAT  
 SUBJECT: Annual Publications Report - November 1993

DETAIL SUMMARY SHEET

<b>Date:</b>	29 Oct 93	<b>Protocol</b>	93-34	<b>Status</b>	Completed
<b>Title:</b>	A Comparison of Arm and Calf Blood Pressure Values Obtained by the Dinamap Device				
<b>Start Date:</b>			<b>Est. Compl. Date:</b>		
<b>Principal Investigator(s):</b>	Peter J. Ahn, MD, CPT, MC		<b>Facility:</b>	Eisenhower Army Medical Center	
<b>Department/Service:</b>	Medicine		<b>Associate Investigators:</b>		
<b>Key Words:</b>					
<b>Accumulative MEDCASE Cost:</b>			<b>Periodic Review Results:</b>		

**Objective:** To use the Dinamap device to measure the blood pressures from the arm and calf and to provide the comparative results.

**Number of subjects enrolled during reporting period:**

**Progress:** Clinical trials completd and information presented at the Transitional Intern Presentation Day. Written paper in progress with planned submission for journal acceptance within the calender year. The investigator has PCS'ed to Walter Reed AMC to start an Anesthesiology Residency.

HSHF-PAT

SUBJECT: Annual Publications Report - November 1993

DETAIL SUMMARY SHEET

<b>Date:</b>	29 Oct 93	<b>Protocol</b>	93-51	<b>Status</b>	Ongoing
<b>Title:</b>	A study to Investigate the Efficacy and Safety of Oral Valacyclovir (1000 mg or 500 mg, twice daily) Compared with Placebo in the Treatment of Recurrent Genital Herpes in Immunocompetent Patients				
<b>Start Date:</b>			<b>Est. Compl. Date:</b>		
<b>Principal Investigator(s):</b>	Marshall A. Guill, MD, COL, MC		<b>Facility:</b>	Eisenhower Army Medical Center	
<b>Department/Service:</b>	Medicine/Dermatology		<b>Associate Investigators:</b>	Roger V. Bruce, LTC, MC Mark G. Blaskis, MAJ, MC Susan Montieth, MT (ASCP)	
<b>Key Words:</b>					
<b>Accumulative MEDCASE Cost:</b>			<b>Periodic Review Results:</b>		

**Study Objective:** This is a company sponsored study to evaluate the efficacy and safety of valacyclovir to placebo in treating recurrent genital herpes in immunocompetent patients. By using the parent compound to acyclovir with less frequent dosing and giving to patients at home so as to start treatment within hours of symptom occurrence, it is hoped that greater efficacy may be found than has been true of earlier studies with acyclovir. It has three arms consisting of the two dose levels and placebo.

**Technical Approach:** Approve as a company sponsored more than minimal risk human use study and forward to HSC for further disposition and for permission to accept the drugs and placebos from Burroughs-Wellcome.

**Number of subjects enrolled to date:** None

**Progress:** No patients yet enrolled

HSHF-PAT

SUBJECT: Annual Publications Report - November 1993

DETAIL SUMMARY SHEET

<b>Date:</b>	29 Oct 93	<b>Protocol</b>	93-64	<b>Status</b>	Ongoing
<b>Title:</b>	A Randomized, Double-Blind, Multicenter Trial Comparing 10 Days of Oral Therapy with CP-99,219 (100 mg or 300 mg Daily) or Ofloxacin (800 mg Daily) for the Treatment of Acute Exacerbation of Chronic Bronchitis				
<b>Start Date:</b>		<b>Est. Compl. Date:</b>			
<b>Principal Investigator(s):</b>	Warren L. Whitlock, LTC, MC		<b>Facility:</b>	Eisenhower Army Medical Center	
<b>Department/Service:</b>	Medicine/Pulmonary		<b>Associate Investigators:</b>	Wayne T. Honeycutt, MAJ, MC Jesse T. Doers, MAJ, MC	
<b>Key Words:</b>		<b>Medical Monitor:</b>	David R. Haburchak, COL, MC		
<b>Accumulative MEDCASE Cost:</b>		<b>Periodic Review Results:</b>			

**Study Objective:** To Investigate the efficacy and safety of two doses of CP-99,219 and Ofloxacin in the treatment of patients with acute exacerbations of chronic bronchitis.

**Technical Approach:**

**Number of subjects enrolled to date:**

**Progress:**

HSHF-PAT  
 SUBJECT: Annual Publications Report - November 1993

**DETAIL SUMMARY SHEET**

<b>Date:</b>	12 Oct 93	<b>Protocol</b>	92-72	<b>Status</b>	Completed
<b>Title:</b>	Experiences of Couples Participating in a Counseling Program to Abate Spouse Abuse: A Descriptive Clinical Report				
<b>Start Date:</b>			<b>Est. Compl. Date:</b>		
<b>Principal Investigator(s):</b>	Dorothy A. Anderson, MAJ, AN		<b>Facility:</b>	Eisenhower Army Medical Center	
<b>Department/Service:</b>	Nursing		<b>Associate Investigators:</b>		
<b>Key Words:</b>	Spouse Abuse Abatement				
<b>Accumulative MEDCASE Cost:</b>			<b>Periodic Review Results:</b>		

**Study Objective:** To provide an indepth description of couples' counseling process from the perspective of the couples in the program.

**Technical Approach:** Retrospective qualitative study.

**Progress:** This study has been completed. Defended on 9 Dec 92 for the completion of graduate course work.

HSHF-PAT

SUBJECT: Annual Publications Report - November 1993

DETAIL SUMMARY SHEET

<b>Date:</b>	29 Oct 93	<b>Protocol</b>	93-15	<b>Status</b>	Ongoing
<b>Title:</b>	Satisfaction with Patient Controlled Analgesia				
<b>Start Date:</b>			<b>Est. Compl. Date:</b>		
<b>Principal Investigator(s):</b>	Mary Hardy, MAJ, AN		<b>Facility:</b>	Eisenhower Army Medical Center	
<b>Department/Service:</b>	Nursing		<b>Associate Investigators:</b>	Barbara Miller, CPT, AN Michael E. Streeter, CPT, AN	
<b>Key Words:</b>	Analgesia patient controlled analgesia				
<b>Accumulative MEDCASE Cost:</b>			<b>Periodic Review Results:</b>		

**Study Objective:** To determine patient satisfaction with postoperative pain control using the patient controlled analgesia (PCA) infuser, to identify the frequency of PCA use, and to identify problems associated with PCA use.

**Technical Approach:**

Number of subjects enrolled for reporting period: 40

**Progress:** Data have been collected on 40 inpatients receiving patient controlled analgesia and progressing as anticipated. Cursory analysis of data only completed to this point. It is expected to reach 100 subjects by Dec 93, and will stop at that time if greater than 50 is reached.

HSHF-PAT

SUBJECT: Annual Publications Report - November 1993

**DETAIL SUMMARY SHEET**

<b>Date:</b>	25 Oct 93	<b>Protocol #:</b>	93-5	<b>Status:</b>	Closed
<b>Title:</b>	The Effect of Uncomplicated Labor and Delivery on Serum Levels of Creatine Kinase				
<b>Start Date:</b>			<b>Est. Compl. Date:</b>		
<b>Principal Investigator(s):</b>	Thomas E. Page, CPT, MC		<b>Facility:</b>	Eisenhower Army Medical Center	
<b>Department/Service:</b>	OB-GYN		<b>Associate Investigators:</b>	Joseph C. White, MAJ, MC	
<b>Key Words:</b>					
<b>Accumulative MEDCASE Cost:</b>			<b>Periodic Review Results:</b>		

**Study Objective:** To determine the effects of uncomplicated labor and delivery on serum values of CK and its isoenzymes.

**Technical Approach:**

**Number of subjects enrolled for reporting period:** 30

**Progress:** Study closed.

HSHF-PAT  
SUBJECT: Annual Publications Report - November 1993

**DETAIL SUMMARY SHEET**

<b>Date:</b>	25 Oct 93	<b>Protocol #:</b>	93-50	<b>Status:</b>	Ongoing
<b>Title:</b>	Application of Ophthalmoscopic Examination Fluorescein Angiography in Early Diagnosis of Candida Endophthalmitis in Rabbits				
<b>Start Date:</b>			<b>Est. Compl. Date:</b>		
<b>Principal Investigator(s):</b>	F. Ridgely Benton, Jr., LTC, MC		<b>Facility:</b>	Eisenhower Army Medical Center	
<b>Department/Service:</b>	Pathology		<b>Associate Investigators:</b>	John F. Fisher, MD, Staff Infectious Disease, Medical College of Georgia David Craft, MAJ, MS Steve Tobias, MAJ, VC	
<b>Key Words:</b>					
<b>Accumulative MEDCASE Cost:</b>			<b>Periodic Review Results:</b>		

**Study Objective:** To assess the diagnostic efficacy of fluorescein labelled anti-Candida antibody to recognize infection by this organism at a clinically earlier stage than is now possible. It will look for early retinal lesions by using the tagged antibodies. This rabbit model has been used before and should be well suited for this type of study.

**Technical Approach:**

**Number of animals used for reporting period:** none

**Progress:** Study has not been implemented.

HSHF-PAT  
 SUBJECT: Annual Publications Report - November 1993

**DETAIL SUMMARY SHEET**

<b>Date:</b>	29 Oct 93	<b>Protocol #:</b>	92-23	<b>Status:</b>	Completed
<b>Title:</b>	Determinants in the development of insight for substance dependence in rehabilitation facility inpatients				
<b>Start Date:</b>	Feb 92	<b>Est. Compl. Date:</b>	Jan 93		
<b>Principal Investigator(s):</b>	James Spinelli, MAJ, MC		<b>Facility:</b>	Eisenhower Army Medical Center	
<b>Department/Service:</b>	Psychiatry & Neurology		<b>Associate Investigators:</b>	Robert Ness, PhD Daniel Hendricks, PhD	
<b>Key Words:</b>	Insight, Substance abuse, Substance dependence				
<b>Accumulative MEDCASE Cost:</b>			<b>Periodic Review Results:</b>	Jan 93 Completed	

**Study Objective:** To discern specific aspects of an Inpatient Rehabilitation Facility which are most closely associated with the development of patient insight into acceptance of the disease of substance dependence or abuse.

**Technical Approach:** Using a questionnaire, anonymously survey a number of substance abuse patients gauging their insight before and after enrolling in the RTF. Then, comparing that data with their feelings about specific aspects of the RTF, measure statistical significance to see if certain aspects of RTF are more closely associated with insight formation than others.

**Subjects enrolled to date:** 92

**Progress:** All data collection has been completed as well as calculations and tabulations with the assistance of Mr. Henry Davis and Dr. Bob Hess at MCG. LTC Spinelli is in the process of preparing both written and oral reports for future publications.

HSHF-PAT  
 SUBJECT: Annual Publications Report - November 1993

**DETAIL SUMMARY SHEET**

<b>Date:</b>	29 Oct 93	<b>Protocol #:</b>	92-43	<b>Status:</b>	Ongoing
<b>Title:</b>	The first break psychosis study				
<b>Start Date:</b>	Sep 92	<b>Est. Compl. Date:</b>	May 95		
<b>Principal Investigator(s):</b>	Elaine Correnti, MAJ, MC		<b>Facility:</b>	Eisenhower Army Medical Center	
<b>Department/Service:</b>	Psychiatry & Neurology		<b>Associate Investigators:</b>	Richard Borison, MD Manuel Casanova, MD Laura Davidson, PhD Bruce Diamond, MD Sahebarao P. Mohadik, MD Sukdeb Mukherjee, MD Thomas Ralston, LTC, MC Russell Scheffer, CPT, MC Neal Trent, MAJ, MC	
<b>Key Words:</b>					
<b>Accumulative MEDCASE Cost:</b>			<b>Periodic Review Results:</b>		

**Study Objective:** To determine whether specific biological abnormalities previously found in chronic schizophrenic patients are present at the beginning of the illness and, if so, to examine their relations to clinical characteristics of the illness; and to examine whether selected clinical, historical, and biological measures are predictive of short-term clinical outcome in patients experiencing their first episode of psychosis.

**Technical Approach:** Patients will undergo comprehensive psychiatric, neuropsychological, and neurological examinations at baseline, and blood samples will be taken for determination of RBC activities of specific enzymes and measurement of tritiated imipramine binding in platelets. A skin biopsy will be performed to develop fibroblast cell lines in culture and examine whether fibroblasts from patients show the abnormalities of growth and morphology noted in studies of chronic schizophrenic patients.

**Subjects enrolled to date:** 15 as of 16 Sep 93

**Progress:** Two presentations at the American Psychiatric Association's Annual Meeting: (1) Neurological Signs at the Onset of Psychosis, (2) Fibroblast Studies in First Break Psychosis. Paper submitted to Biological Psychiatry: Plasma Membrane Phospholipid and Cholesterol Distribution of

HSHF-PAT  
SUBJECT: Annual Publications Report - November 1993

Skin Fibroblasts from Drug-Naive Patients at the Onset of Psychosis. Presentation at the Society of Biological Psychiatry Annual Meeting.

HSHF-PAT  
SUBJECT: Annual Publications Report - November 1993

**DETAIL SUMMARY SHEET**

<b>Date:</b> 29 Oct 93	<b>Protocol #:</b> 92-59	<b>Status:</b> Completed
<b>Title:</b> Monitoring of mood states in substance dependent subjects in inpatient rehabilitation facility		
<b>Start Date:</b>	<b>Est. Compl. Date:</b>	
<b>Principal Investigator(s):</b> Patrick W. Clapper, CPT, MC	<b>Facility:</b> Eisenhower Army Medical Center	
<b>Department/Service:</b> Psychiatry & Neurology	<b>Associate Investigators:</b> Daniel Hendricks, PhD	
<b>Key Words:</b>		
<b>Accumulative MEDCASE Cost:</b>	<b>Periodic Review Results:</b>	

**Study Objective:** To determine whether the variation of mood states for the rehab patient follows a predictable general trend and whether this study's findings replicate other studies generally (although other studies have not examined mood variation on a weekly basis). To determine what, if any, difference there is in the general trend of mood states in patients with ETOH dependence alone as compared to patients with mixed substance dependence.

**Technical Approach:** Administer assessment - POMS each week for six weeks of treatment.

**Number of subjects enrolled to date:**

**Progress:** Project completed. Cpt Clapper is writing up results presented at Grand Rounds of Psychiatry.

HSHF-PAT  
SUBJECT: Annual Publications Report - November 1993

**DETAIL SUMMARY SHEET**

<b>Date:</b>	29 Oct 93	<b>Protocol #:</b>	93-13	<b>Status:</b>	Ongoing
<b>Title:</b>	Dexamethasone Augmentation in the Treatment of Major Depression				
<b>Start Date:</b>			<b>Est. Compl. Date:</b>		
<b>Principal Investigator(s):</b>	Kerry Cleary, CPT, MC		<b>Facility:</b>	Eisenhower Army Medical Center	
<b>Department/Service:</b>	Psychiatry & Neurology		<b>Associate Investigators:</b>	Russell Scheffer, CPT, MC Michael Sokol, MAJ, MC Joseph Sutcliffe, CPT, MC	
<b>Key Words:</b>					
<b>Accumulative MEDCASE Cost:</b>			<b>Periodic Review Results:</b>		

**Study Objective:** This is a double-blind, placebo controlled study to test the hypothesis of decreased latency of response to traditional antidepressant medication with a one time dose of Dexamethasone as adjunct on initiation of pharmacotherapy Double Blind Placebo Control.

**Technical Approach:**

Number of subjects enrolled for reporting period: 4 patients recruited; one disenrolled from study secondary to probably reaction to Prozac.

**Progress:** Recruitment of patients has been slow. Other possible candidates have been screened but have failed to meet inclusion criteria or have met an exclusion criteria (usually initiation of antidepressant medication has already taken place). Since changing the protocol to include outpatients, the number of patients screened has increased and we hope to continue with this trend. With the exception of the modification to include outpatients, there has been no indication to modify the initial protocol. Given the technical approach of our study, none of the raw data has yet been analyzed in order to insure the double blind and maintain investigator objectivity.

HSHF-PAT

SUBJECT: Annual Publications Report - November 1993

DETAIL SUMMARY SHEET

<b>Date:</b>	29 Oct 93	<b>Protocol #:</b>	93-18	<b>Status:</b>	Completed
<b>Title:</b>	Determination of Effects of Birth Order (First born vs Second Born) on Death Anxiety in a Military Outpatient and Non-Psychiatric Population				
<b>Start Date:</b>		<b>Est. Compl. Date:</b>			
<b>Principal Investigator(s):</b>	Jeanette Oleskowicz, CPT, MC		<b>Facility:</b>	Eisenhower Army Medical Center	
<b>Department/Service:</b>	Psychiatry & Neurology		<b>Associate Investigators:</b>	Neil Trent, MAJ, MS	
<b>Key Words:</b>					
<b>Accumulative MEDCASE Cost:</b>			<b>Periodic Review Results:</b>		

Study Objective: As stated above.

Technical Approach: Self-completed questionnaires.

Number of subjects enrolled for reporting period:

Progress: Investigation completed. Questionnaires (birth order, state-trait and death anxiety) were randomly administered to 71 first born and 68 second born active duty soldiers of Charlie and Delta Companies at Fort Gordon. Full consent was obtained. A total of 33 questionnaires (17 first born and 16 second born) were not included in statistical analysis due in incomplete responses. Thus, 54 first born and 52 second born questionnaires were examined statistically to determine the effects of birth order on death anxiety. Results yielded no statistically significant findings that would indicate death anxiety was higher among first vs second borns. An incidental finding was that in this particular population, religious preference appeared to be an influencing factor. Those indicating they were of the Baptist denomination evidenced statistically significant higher death anxiety scores ( $p < 0.05$ ) than those of the Catholic denomination.

HSHF-PAT  
SUBJECT: Annual Publications Report - November 1993

**DETAIL SUMMARY SHEET**

<b>Date:</b>	29 Oct 93	<b>Protocol #:</b>	93-27	<b>Status:</b>	Completed
<b>Title:</b>	Evaluation of Smoking Rates After Cessation of Alcohol or Illicit Drug Use				
<b>Start Date:</b>			<b>Est. Compl. Date:</b>		
<b>Principal Investigator(s):</b>	Timothy R. Jennings, MD, CPT, MC		<b>Facility:</b>	Eisenhower Army Medical Center	
<b>Department/Service:</b>	Psychiatry/RTF		<b>Associate Investigators:</b>		
<b>Key Words:</b>					
<b>Accumulative MEDCASE Cost:</b>			<b>Periodic Review Results:</b>		

**Study Objective:** To document the change in smoking rate, if any, which occurs after the cessation of alcohol or illicit drug use.

**Technical Approach:** Self report questionnaire to be completed by inpatients on admission, 4th, and sixth week of treatment.

**Number of subjects enrolled to date:** 42

**Progress:** Data collection has been completed and statistical analysis of data is in progress.

HSHF-PAT  
SUBJECT: Annual Publications Report - November 1993

**DETAIL SUMMARY SHEET**

<b>Date:</b> 29 Oct 93	<b>Protocol #:</b> 93-37	<b>Status:</b> Ongoing
<b>Title:</b> The Relationship of Menstrual Phase to Presentation of Acute Psychiatric Treatment		
<b>Start Date:</b>	<b>Est. Compl. Date:</b>	
<b>Principal Investigator(s):</b> Miguel Oquendo, MD, MAJ, MC	<b>Facility:</b> Eisenhower Army Medical Center	
<b>Department/Service:</b> Psychiatry	<b>Associate Investigators:</b> John F. Mackey, MD, CPT, MC	
<b>Key Words:</b>		
<b>Accumulative MEDCASE Cost:</b>	<b>Periodic Review Results:</b>	

**Objective:** To evaluate the effect of menstrual cycle on the presentation of a patient for acute psychiatric evaluation.

**Technical Approach:** Subjects will be interviewed to include a review of systems, history of menstrual cycle. Epidemiologic data will then be evaluated to determine the characteristics of the patients considered.

Number of subjects enrolled for the reporting period: 60

**Progress:** In order to expand the study sample size, coordination with other MEDDACs in our area has been made with the purpose of enrolling these facilities in the data collection process. A total of 300 data collecting sheets were distributed among the Department of Psychiatry at Moncrief Army Hospital, Fort Jackson, Fort Benning; and Winn Army Hospital, Fort Stewart. A preliminary review of the data so far collected has been completed. All data is expected to be collected by January 1994. An abstract of this study has been submitted to the American Society of Psychosomatic Obstetrics and Gynecology for research awards and symposium as part of the Society 22nd Annual Meeting scheduled for 23-27 February 1994.

HSHF-PAT.  
SUBJECT: Annual Publications Report - November 1993

**DETAIL SUMMARY SHEET**

<b>Date:</b>	29 Oct 93	<b>Protocol #:</b>	93-47	<b>Status:</b>	Ongoing
<b>Title:</b>	A Double-Blind, Placebo Controlled Exploratory Study of Sertraline in Adolescent Outpatients with Nondelusional Major Depressive Disorder.				
<b>Start Date:</b>			<b>Est. Compl. Date:</b>		
<b>Principal Investigator(s):</b>	Walter J. Duffy, CPT, MC		<b>Facility:</b>	Eisenhower Army Medical Center	
<b>Department/Service:</b>	Psychiatry		<b>Associate Investigators:</b>	Lawrence M. Correnti, MAJ(P), MC	
<b>Key Words:</b>					
<b>Accumulative MEDCASE Cost:</b>			<b>Periodic Review Results:</b>		

**Objective:** To compare the efficacy of sertraline HC1 (SER) in major depressive disorder without psychotic features with placebo in a double blind fashion using a population of thirty 12 to 18 year old adolescent outpatients.

**Technical Approach:** Various structured interviews and instruments will be used to insure that DSM-III-R criteria are met. A washout period will precede randomization.

**Number of subjects enrolled for the reporting period:**

**Progress:** No patients have been enrolled in the study yet as physicians are in the process of training themselves and associates in the use of the intake assessment instrument.

HSHF-PAT

SUBJECT: Annual Publications Report - November 1993

DETAIL SUMMARY SHEET

<b>Date:</b> 29 Oct 93	<b>Protocol #:</b> 90-1	<b>Status:</b> Ongoing
<b>Title:</b> Technitium 99m antimony trisulfide colloid for investigation of lymphatic drainage		
<b>Start Date:</b>	<b>Est. Compl. Date:</b>	
<b>Principal Investigator(s):</b> Stephen G. Oswald, LTC, MC	<b>Facility:</b> Eisenhower Army Medical Center	
<b>Department/Service:</b> Radiology/Nuclear Medicine	<b>Associate Investigators:</b>	
<b>Key Words:</b>		
<b>Accumulative MEDCASE Cost:</b>	<b>Periodic Review Results:</b> Jan 93 Continue	

**Study Objective:** To provide a radiopharmaceutical whereby lymphatic drainage may be characterized.

**Technical Approach:** Intradermal injection of radiolabeled colloidal particles with serial gamma camera images to evaluate lymphatic drainage.

**Number of subjects enrolled to date:** 3

**Progress:** No additional patients enrolled. Radiopharmaceutical temporarily unavailable due to change in manufacturer. Protocol should remain open.

HSHF-PAT  
 SUBJECT: Annual Publications Report - November 1993

**DETAIL SUMMARY SHEET**

<b>Date:</b> 29 Oct 93		<b>Protocol #:</b> 90-36		<b>Status:</b> Ongoing	
<b>Title:</b> Treatment of internal contamination by plutonium and other transuranic elements with two investigational new drugs (Ca-DTPA and Zn-DTPA)					
<b>Start Date:</b>			<b>Est. Compl. Date:</b>		
<b>Principal Investigator(s):</b> Robert J. Kaminski, LTC, MC			<b>Facility:</b> Eisenhower Army Medical Center		
<b>Department/Service:</b> Radiology/Nuclear Medicine			<b>Associate Investigators:</b> Stephen G. Oswald, LTC, MC		
<b>Key Words:</b>					
<b>Accumulative MEDCASE Cost:</b>			<b>Periodic Review Results:</b>		

**Study Objective:** The principal objective of this protocol is to obtain approval from the IRC to use Ca-DTPA and Zn-DTPA for the treatment of patients at Eisenhower Army Medical Center who are internally contaminated with plutonium or other transuranic elements.

This is not an investigational study, approval allows us to store the drugs in this facility.

HSHP-PAT

SUBJECT:-- Annual Publications Report - November 1993

DETAIL SUMMARY SHEET

<b>Date:</b> 29 Oct 93	<b>Protocol #:</b> 91-13	<b>Status:</b> Ongoing
<b>Title:</b> Scintigraphy of tumors of neuroectodermal origin with 131-iodine-meta-iodobenzylguanibine sulfate (131-I-MIBG)		
<b>Start Date:</b>	<b>Est. Compl. Date:</b>	
<b>Principal Investigator(s):</b> Stephen G. Oswald, LTC, MC	<b>Facility:</b> Eisenhower Army Medical Center	
<b>Department/Service:</b> Radiology/Nuclear Medicine	<b>Associate Investigators:</b> Robert J. Kaminski, LTC, MC James H. Corley, LTC, MC	
<b>Key Words:</b>		
<b>Accumulative MEDCASE Cost:</b>	<b>Periodic Review Results:</b> Jan 93 Continue	

**Study Objective:** To provide a mechanism whereby this agent is available for use in diagnostic studies in patients undergoing evaluation of pheochromocytoma or staging of neuroblastoma.

**Technical Approach:** Intravenous injection of a radiopharmaceutical (MIBG) with subsequent *gamma camera imaging*.

Number of subjects enrolled: 3

**Progress:** One additional patient enrolled during past year. No adverse side effects or reactions noted. Study ongoing.

HSHF-PAT

SUBJECT: Annual Publications Report - November 1993

**DETAIL SUMMARY SHEET**

<b>Date:</b> 29 Oct 93		<b>Protocol #:</b> 91-39		<b>Status:</b> Ongoing	
<b>Title:</b> Adrenal imaging with 131-iodine-6-beta-iodomethyl-norcholesterol (NP-59)					
<b>Start Date:</b>			<b>Est. Compl. Date:</b>		
<b>Principal Investigator(s):</b> Stephen G. Oswald, LTC, MC			<b>Facility:</b> Eisenhower Army Medical Center		
<b>Department/Service:</b> Radiology/Nuclear Medicine			<b>Associate Investigators:</b> Robert J. Kaminski, LTC, MC Daryl S. Moyer, CPT, MS		
<b>Key Words:</b>					
<b>Accumulative MEDCASE Cost:</b>			<b>Periodic Review Results:</b>		

**Study Objective:** To provide a mechanism whereby NP-59 is available for correlative adrenal imaging for patients with biochemically established ACTH-independent Cushing's syndrome, primary aldosteronism, or androgen excess states as well as characterization of the functional status of euadrenal masses.

**Technical Approach:** Intravenous injection of a radiopharmaceutical (NP-59) with subsequent gamma camera imaging.

**Progress:** No patients enrolled. Study ongoing.

HSHF-PAT

SUBJECT: Annual Publications Report - November 1993

DETAIL SUMMARY SHEET

<b>Date:</b>	25 Oct 93	<b>Protocol #:</b>	85-5	<b>Status:</b>	Ongoing
<b>Title:</b>	Advanced Trauma Life Support Course				
<b>Start Date:</b>	Jan 85	<b>Est. Compl. Date:</b>			
<b>Principal Investigator(s):</b> Paul Lepage, MAJ(P), MC		<b>Facility:</b> Eisenhower Army Medical Center			
<b>Department/Service:</b> Surgery/Clinical Investigation		<b>Associate Investigators:</b>			
<b>Key Words:</b>					
<b>Accumulative MEDCASE Cost:</b>		<b>Periodic Review Results:</b> Sep 93 Continue			

**Study Objective:** To provide training for physicians who are not dealing with major trauma on a day-to-day basis, and who may have to evaluate the *seriously injured patient* during the period immediately after injury. Also, it is intended to provide the basic knowledge and skills necessary to identify those patients whose need is for rapid assessment, resuscitation, and stabilization.

**Technical Approach:**

a. **Design:** The advanced trauma life support course is a two day training session in which participants are given didactic instruction followed by practical skill stations and an animal lab. Testing is accomplished by a written exam and a practical exercise in which a simulated trauma victim is resuscitated.

b. **Manpower:** Requirements as follows: Course Director (1 MC)  
Course Administrator (MS)  
Instructors (6 MC)  
Logistical support (2 EM)  
Moulage patients (4 EM)

c. **Funding:** Administrative cost derived from Office of Medical Education.

**Progress:** Successful ATLS Course was given in 1992 with 32 physicians trained. A course is scheduled for early 1994.

HSHF-PAT  
 SUBJECT: Annual Publications Report - November 1993

**DETAIL SUMMARY SHEET**

<b>Date:</b>	25 Oct 93	<b>Protocol #:</b>	88-5	<b>Status:</b>	Completed
<b>Title:</b>	Investigation of cryotreatment on the epiphysis of growing rabbit bones				
<b>Start Date:</b>		<b>Est. Compl. Date:</b>			
<b>Principal Investigator(s):</b>	Roberto H. Barja, COL, MC		<b>Facility:</b>	Eisenhower Army Medical Center	
<b>Department/Service:</b>	Surgery/Orthopedics		<b>Associate Investigators:</b>		
<b>Key Words:</b>					
<b>Accumulative MEDCASE Cost:</b>			<b>Periodic Review Results:</b>	Oct 93 Completed	

**Study Objective:** 1) To evaluate cryotherapy times on the epiphysis of 6 week old rabbits (right femur); 2) to examine both grossly and microscopically, the effects of cryotherapy on bone growth epiphyseal closure.

**Technical Approach:** A cryoprobe after surgical cut-down is applied to epiphyses in the distal right femur of 6 week old rabbits. Four weeks post-cryotreatment the rabbits are euthanized, then a surgical cut-down is performed to remove the right and left femur. The pathologist then determines the gross effect on growth plates and any deformities present on the right vs the left femur. Microscopic specimens of the cryotreated epiphyses are examined to evaluate remaining potential for growth, microvascular structures, and uniformity of cryological effects.

**Progress:** Ten rabbits underwent percutaneous epiphysiodesis by the cryoprobe. The growth plate was successfully interrupted with promising results and data analysis is in progress.

HSHF-PAT

SUBJECT: Annual Publications Report - November 1993

**DETAIL SUMMARY SHEET**

<b>Date:</b> 29 Oct 93	<b>Protocol #:</b> 88-6	<b>Status:</b> Terminated
<b>Title:</b> Distal thigh pain and stress transfer in uncemented total hip arthroplasties. A scintigraphic analysis		
<b>Start Date:</b>	<b>Est. Compl. Date:</b>	
<b>Principal Investigator(s):</b> Scott R. Duffin, MAJ, MC	<b>Facility:</b> Eisenhower Army Medical Center	
<b>Department/Service:</b> Surgery/Orthopedics	<b>Associate Investigators:</b> Orthopedic Residents Joseph M Erpelding, MD, MAJ, MC	
<b>Key Words:</b>		
<b>Accumulative MEDCASE Cost:</b>	<b>Periodic Review Results:</b>	

**Study Objective:** To determine if anterior thigh pain in uncemented total hip arthroplasties is caused by distal stress transfer through the femur prosthesis.

**Technical Approach:** Routine bone scans will be done at various time intervals following cemented and uncemented total hip arthroplasties. The bone scan is an accepted method of evaluating hip prostheses, having demonstrated both prospectively and retrospectively excellent sensitivity and good specificity in detecting and defining abnormalities such as loosening, fracture, and infection.

Number of subjects enrolled to date: 77

Number of subjects enrolled for reporting period: 0

**Progress:** Phase I completed: comparison of cemented vs uncemented PCA hips.  
Phase II will compare above to uncemented cluster/E series hips.

HSHF-PAT  
SUBJECT: Annual Publications Report - November 1993

**DETAIL SUMMARY SHEET**

<b>Date:</b> 29 Oct 93.		<b>Protocol #:</b> 90-25	<b>Status:</b> Terminated
<b>Title:</b> A prospective randomized study of the prophylaxis of thromboembolism dihydroergotamine/heparin <i>versus</i> sodium warfarin in total joint patients			
<b>Start Date:</b> Jun 90		<b>Est. Compl. Date:</b>	
<b>Principal Investigator(s):</b> David A. Volgas, CPT, MC		<b>Facility:</b> Eisenhower Army Medical Center	
<b>Department/Service:</b> Surgery/Orthopedics		<b>Associate Investigators:</b> Melissa McMillan, MAJ, MC Robert Scharstein, MAJ, MC	
<b>Key Words:</b>			
<b>Accumulative MEDCASE Cost:</b>		<b>Periodic Review Results:</b>	

**Study Objective:** To compare two regimens commonly used for thromboembolism prophylaxis in the total joint patient.

**Number of subjects enrolled to date:** 25  
**Number of subjects enrolled for reporting period:** 0

**Progress:** Study terminated.

HSHF-PAT  
SUBJECT: Annual Publications Report - November 1993

**DETAIL SUMMARY SHEET**

<b>Date:</b> 25 Oct 93	<b>Protocol #:</b> 90-32	<b>Status:</b> Ongoing
<b>Title:</b> Training general surgery residents utilizing goat and pig models		
<b>Start Date:</b>	<b>Est. Compl. Date:</b>	
<b>Principal Investigator(s):</b> Paul A. LePage, MAJ, MC	<b>Facility:</b> Eisenhower Army Medical Center	
<b>Department/Service:</b> <i>Surgery/Clinical Investigation</i>	<b>Associate Investigators:</b>	
<b>Key Words:</b>		
<b>Accumulative MEDCASE Cost:</b>	<b>Periodic Review Results:</b> Sep 93 Continue	

**Study Objective:** To allow the practicing and refinement of surgical approaches and techniques on animal models prior to performing the same procedure in the human.

**Progress:** Two major Southeast regional courses were conducted to successfully train in new laparoscopic hernia and colorectal surgery to 38 students and weekly training to residents and staff. Also, nursing anesthesia students were trained on field Army anesthesia machines during these sessions. Operating room nurses were trained on laproscopic techniques and a multidisciplined laboratory training session for gynecologists and general surgeons in gastro/enterology laparoscopy.

HSHF-PAT  
 SUBJECT: Annual Publications Report - November 1993

**DETAIL SUMMARY SHEET**

<b>Date:</b>	29 Oct 93	<b>Protocol #:</b>	91-59	<b>Status:</b>	Ongoing
<b>Title:</b>	Use of the rat model for teaching and practicing microvascular surgical technique				
<b>Start Date:</b>		<b>Est. Compl. Date:</b>			
<b>Principal Investigator(s):</b>	Brian K. Barnard, MAJ, MC		<b>Facility:</b>	Eisenhower Army Medical Center	
<b>Department/Service:</b>	Surgery/Orthopedics		<b>Associate Investigators:</b>	Orthopedic Residents	
<b>Key Words:</b>					
<b>Accumulative MEDCASE Cost:</b>			<b>Periodic Review Results:</b>	Nov 93 continue	

**Study Objective:** To utilize the rat model for the practice and teaching of microvascular surgical techniques.

**Technical Approach:** Training procedures include end-to-end, end-to-side, and side-to-side anastomosis of the femoral artery and vein, as well as, interpositional vein grafting.

**Progress:** Six residents have undergone training.

HSHF-PAT

SUBJECT: Annual Publications Report - November 1993

**DETAIL SUMMARY SHEET**

<b>Date:</b> 29 Oct 93	<b>Protocol #:</b> 91-81	<b>Status:</b> Ongoing
<b>Title:</b> Evaluation of the current routine post op feeding regimens		
<b>Start Date:</b>	<b>Est. Compl. Date:</b> Dec 93	
<b>Principal Investigator(s):</b> M. Brian Harkins, CPT, MC	<b>Facility:</b> Eisenhower Army Medical Center	
<b>Department/Service:</b> Surgery	<b>Associate Investigators:</b> Robert G. Martindale, MAJ, MC	
<b>Key Words:</b>		
<b>Accumulative MEDCASE Cost:</b>	<b>Periodic Review Results:</b> Jan 93 Continue	

**Study Objective:** To determine if patients are able to tolerate a regular diet rather than clear liquids as their first P.O. intake following intraabdominal surgery.

**Technical Approach:** Randomized patients to alternate diets.

**Number of subjects enrolled to date:** approximately 125-150

**Progress:** Study ongoing, data collection continuing.

HSHF-PAT  
SUBJECT: Annual Publications Report - November 1993

**DETAIL SUMMARY SHEET**

<b>Date:</b> 29 Oct 93		<b>Protocol #:</b> 91-82		<b>Status:</b> Completed	
<b>Title:</b> The effect of non-ionic surfactants on GI mucosal integrity and bacterial translocation from the gut (mice)					
<b>Start Date:</b>			<b>Est. Compl. Date:</b>		
<b>Principal Investigator(s):</b> Robert G. Martindale, MAJ, MC			<b>Facility:</b> Eisenhower Army Medical Center		
<b>Department/Service:</b> Surgery			<b>Associate Investigators:</b> James McPherson III, PhD David Turgeon, PhD, MAJ, MS		
<b>Key Words:</b>					
<b>Accumulative MEDCASE Cost:</b>			<b>Periodic Review Results:</b> Oct 93 Completed		

**Study Objective:** To evaluate the potential protective effects of non-ionic surfactants on GI mucosa.

**Technical Approach:**

**Progress:** Dose responses have been completed, it appears surfactants have minimal effect, if any, on preventing translocation of bacteria. Had had problems establishing adequate dose of endotoxin to use.

HSHF-PAT

SUBJECT: Annual Publications Report - November 1993

**DETAIL SUMMARY SHEET**

<b>Date:</b>	29 Oct 93	<b>Protocol #:</b>	92-3	<b>Status:</b>	Terminate
<b>Title:</b>	Free dermal fat grafts in expanded tissue recipient pockets in the pig				
<b>Start Date:</b>		<b>Est. Compl. Date:</b>			
<b>Principal Investigator(s):</b>	Richard A. Beck, MAJ, MC		<b>Facility:</b>	Eisenhower Army Medical Center	
<b>Department/Service:</b>	Surgery/Otolaryngology-HNS		<b>Associate Investigators:</b>		
<b>Key Words:</b>					
<b>Accumulative MEDCASE Cost:</b>			<b>Periodic Review Results:</b>	Oct 93 Terminate	

**Study Objective:** To determine if free dermal fat grafts have improved survival and predictable rates of resorption after implantation in expanded tissue pockets in the pig model. Also, to determine the histologic characteristics of the capsule which forms around expanded/nonexpanded silicone prostheses, and the free dermal fat grafts at specified intervals following transplantation.

**Technical Approach:**

**Progress:** Investigator PCS'd, no progress, terminate.

HSHF-PAT  
SUBJECT: Annual Publications Report - November 1993

**DETAIL SUMMARY SHEET**

<b>Date:</b>	29 Oct 93	<b>Protocol #:</b>	92-4	<b>Status:</b>	Ongoing
<b>Title:</b>	The effect of pentoxifyline vs allopurinol on sigmoid mucosal ischemia during abdominal aortic surgery				
<b>Start Date:</b>			<b>Est. Compl. Date:</b>		
<b>Principal Investigator(s):</b>	William C. Calton, CPT, MC		<b>Facility:</b>	Eisenhower Army Medical Center	
<b>Department/Service:</b>	Surgery		<b>Associate Investigators:</b>	Robert G. Martindale, MAJ, MC Manuel F. Ramirez, LTC, MC	
<b>Key Words:</b>					
<b>Accumulative MEDCASE Cost:</b>			<b>Periodic Review Results:</b>	Jan 93 Continue	

**Study Objective:** This study will make considerable use of a new noninvasive technique to measure the adequacy of tissue oxygenation called tonometry.

**Technical Approach:** Tonometry relies upon the fact that CO<sub>2</sub> is freely permeable between the lumen, luminal fluid and superficial layer of the mucosa. By measuring CO<sub>2</sub> in the luminal fluid and simultaneously measuring arterial blood gases, mucosal pH can be calculated using the Henderson-Hasselbalch equation. The validity and safety of this technique has now been substantiated in several studies.

**Progress:** Project on hold due to lack of technical assistance and equipment limitations. Protocol will continue when research nurse is available.

HSHF-PAT

SUBJECT: Annual Publications Report - November 1993

**DETAIL SUMMARY SHEET**

<b>Date:</b> 29 Oct 93	<b>Protocol #:</b> 92-12	<b>Status:</b> Terminated
<b>Title:</b> Implications of Urinary Phosphate Level After Thyroid or Parathyroid Surgery		
<b>Start Date:</b>	<b>Est. Compl. Date:</b>	
<b>Principal Investigator(s):</b> William J. Kaiser, CPT, MC	<b>Facility:</b> Eisenhower Army Medical Center	
<b>Department/Service:</b> Surgery/General Surgery	<b>Associate Investigators:</b> Robert G. Martindale, MAJ, MC Michael P. Byrne, LTC, MC	
<b>Key Words:</b>		
<b>Accumulative MEDCASE Cost:</b>	<b>Periodic Review Results:</b>	

**Study Objective:** To prospectively follow serum Ca<sup>2+</sup> and urinary PO<sub>4</sub> in patients undergoing thyroid/parathyroid surgery; and to evaluate if it has any predictive effect.

**Technical Approach:**

**Subjects enrolled for the reporting period:** 16

**Progress:** Retrieval of data greater than two years old; paper to be presented to Army Surgical Symposium 1995.

HSHF-PAT-  
 SUBJECT: Annual Publications Report - November 1993

**DETAIL SUMMARY SHEET**

<b>Date:</b>	29 Oct 93	<b>Protocol #:</b>	92-13	<b>Status:</b>	Ongoing
<b>Title:</b>	The effect of IV pentoxifylline on endotoxin mediated small bowel mucosal ischemia using the pig model				
<b>Start Date:</b>			<b>Est. Compl. Date:</b>	Dec 93	
<b>Principal Investigator(s):</b>	William C. Calton, Jr., CPT, MC		<b>Facility:</b>	Eisenhower Army Medical Center	
<b>Department/Service:</b>	Surgery/General Surgery		<b>Associate Investigators:</b>	Robert G. Martindale, MAJ, MC Michael P. Byrne, LTC, MC David Turgeon, PhD, MAJ, MS	
<b>Key Words:</b>					
<b>Accumulative MEDCASE Cost:</b>			<b>Periodic Review Results:</b>		

**Study Objective:** To determine if pentoxifylline can attenuate the splanchnic vasoconstriction seen with endotoxin.

**Technical Approach:**

**Progress:** The effect of Pentoxifylline is to be worked out in the rat model. Once this work has been completed, work on the pig model will be resumed with the expected date of Jan/Feb 94.

HSHF-PAT  
SUBJECT: Annual Publications Report - November 1993

**DETAIL SUMMARY SHEET**

<b>Date:</b> 29 Oct 93	<b>Protocol #:</b> 92-21	<b>Status:</b> Terminate
<b>Title:</b> A comparison of rigidity of combat external fixators		
<b>Start Date:</b>	<b>Est. Compl. Date:</b>	
<b>Principal Investigator(s):</b> Scott R. Duffin, MAJ, MC	<b>Facility:</b> Eisenhower Army Medical Center	
<b>Department/Service:</b> Surgery/Orthopedics	<b>Associate Investigators:</b> Joseph Erpelding, LTC, MC	
<b>Key Words:</b>		
<b>Accumulative MEDCASE Cost:</b>	<b>Periodic Review Results:</b>	

**Study Objective:** To determine which field external fixator has the most rigid combination of bars and connections; and, which system overall provides the greatest rigidity when applied in its most biomechanically sound configuration.

**Technical Approach:** The rigidity would be evaluated in an axial load, AP bending load, lateral bending load and torsional load.

**Subjects enrolled to date:** None

**Progress:** Study terminated.

HSHF-PAT

SUBJECT: Annual Publications Report - November 1993

**DETAIL SUMMARY SHEET**

<b>Date:</b>	29 Oct 93	<b>Protocol #:</b>	92-26	<b>Status:</b>	Ongoing
<b>Title:</b>	The effects of somatostatin analog (octreotide acetate) on wound healing in the mouse model				
<b>Start Date:</b>		<b>Est. Compl. Date:</b>			
<b>Principal Investigator(s):</b>	Robert G. Martindale, MAJ, MC		<b>Facility:</b>	Eisenhower Army Medical Center	
<b>Department/Service:</b>	Surgery/General Surgery		<b>Associate Investigators:</b>	Donald E. Sutherland, PhD, MAJ, MS William Calton, Jr, CPT, MC Sam Miller, CPT, MC	
<b>Key Words:</b>					
<b>Accumulative MEDCASE Cost:</b>			<b>Periodic Review Results:</b>	Oct 93	

**Study Objective:** To determine if the somatostatin analog affects wound healing.

**Technical Approach:**

**Progress:** Techniques for PTFE implantation have been perfected. Study is near completion and researching additional information related to wound healing.

HSHF-PAT  
 SUBJECT: Annual Publications Report - November 1993

**DETAIL SUMMARY SHEET**

<b>Date:</b>	29 Oct 93	<b>Protocol #:</b>	92-27	<b>Status:</b>	Ongoing
<b>Title:</b>	Natural history of free gallstones within the peritoneum in a rabbit model and mouse model				
<b>Start Date:</b>		<b>Est. Compl. Date:</b>	Dec 93		
<b>Principal Investigator(s):</b>	Ray Workman, CPT, MC		<b>Facility:</b>	Eisenhower Army Medical Center	
<b>Department/Service:</b>	Surgery/General Surgery		<b>Associate Investigators:</b>	Michael Byrne, LTC, MC Robert G. Martindale, MAJ, MC Thomas R. Gadacz, M.D.	
<b>Key Words:</b>					
<b>Accumulative MEDCASE Cost:</b>			<b>Periodic Review Results:</b>	Oct 93	

**Study Objective:** To determine the physiologic response to free gallstones within the peritoneum in the rabbit and mouse models.

**Technical Approach:**

**Progress:** Initial surgery has been completed and waiting for specific times to gather data on acute inflammatory changes associated with spillage of gallstones using histologic, microbiologic, and immunologic procedures.

HSHF-PAT

SUBJECT: Annual Publications Report - November 1993

**DETAIL SUMMARY SHEET**

<b>Date:</b>	6 Oct 92	<b>Protocol #:</b>	92-52	<b>Status:</b>	Ongoing
<b>Title:</b>	Laparoscopic appendectomy vs standard appendectomy				
<b>Start Date:</b>		<b>Est. Compl. Date:</b>			
<b>Principal Investigator(s):</b>	Thomas Taylor, CPT, MC		<b>Facility:</b>	Eisenhower Army Medical Center	
<b>Department/Service:</b>	Surgery/General Surgery		<b>Associate Investigators:</b>	Victor L. Modesto, MAJ, MC Paul A. LePage, MAJ, MC	
<b>Key Words:</b>					
<b>Accumulative MEDCASE Cost:</b>			<b>Periodic Review Results:</b>	Aug 93 Continuue	

**Study Objective:** To compare hospital stay, amount of post-operative pain medications, amount of post-operative complications such as wound infection and abscess formation, and the percentage of false positives to that of open appendectomy. We also wish to become proficient in the art of laparoscopic appendectomy.

**Technical Approach:** Open appendectomy will be performed in the standard fashion utilizing a Rockey Davis incision. An extension of this incision may be utilized as deemed necessary by the senior surgeon performing the case. All open appendectomies will undergo irrigation of the pelvis in the reverse trendelenburg position.

**Subjects enrolled to date:** 17

**Progress:** We continue to gather subjects for our study. So far we have only 17. We need several more to better evaluate the difference. No problems encountered.

HSHF-PAT

SUBJECT: Annual Publications Report - November 1993

**DETAIL SUMMARY SHEET**

<b>Date:</b> 29 Oct 93		<b>Protocol #:</b> 93-1	<b>Status:</b> Terminated
<b>Title:</b> Early Detection of Hearing Loss Due to Ototoxic Agents by High Frequency Auditory Evaluation			
<b>Start Date:</b>		<b>Est. Compl. Date:</b>	
<b>Principal Investigator(s):</b> Vernon D. Larson, PhD, VA		<b>Facility:</b> Eisenhower Army Medical Center	
<b>Department/Service:</b> Audiology		<b>Associate Investigators:</b> Carl Loovis, LTC, MS Stephen A. Fausti, PhD	
<b>Key Words:</b>			
<b>Accumulative MEDCASE Cost:</b>		<b>Periodic Review Results:</b>	

**Study Objective:** To determine whether the proposed experimental method of monitoring hearing detects drug related hearing loss earlier than the current clinical procedure.

**Technical Approach:**

**Number of subjects enrolled for reporting period:**

**Progress:** None owing to personnel shortages

HSHF-PAT  
SUBJECT: Annual Publications Report - November 1993

**DETAIL SUMMARY SHEET**

<b>Date:</b> 29 Oct 93	<b>Protocol #:</b> 93-4	<b>Status:</b> Ongoing
<b>Title:</b> The Effect of Early Enteral Feeding on Patients Undergoing Abdominal Aortic Surgery		
<b>Start Date:</b>	<b>Est. Compl. Date:</b>	
<b>Principal Investigator(s):</b> William C. Calton, Jr., CPT, MC	<b>Facility:</b> Eisenhower Army Medical Center	
<b>Department/Service:</b> Surgery	<b>Associate Investigators:</b> Robert G. Martindale, MAJ, MC Donald E. Sutherland, MAJ, MS	
<b>Key Words:</b>		
<b>Accumulative MEDCASE Cost:</b>	<b>Periodic Review Results:</b>	

**Study Objective:** To evaluate the effect of early enteral feeding on outcome, nutritional parameters and wound healing in patients undergoing abdominal aortic surgery.

**Technical Approach:**

Number of subjects enrolled for reporting period: 10

**Progress:** Still accumulating data on vascular patients (aortic cases). Principal Investigator has departed but protocol will continue under supervision of C, Vascular Surgery.

HSHF-PAT  
SUBJECT: Annual Publications Report - November 1993

DETAIL SUMMARY SHEET

<b>Date:</b>	29 Oct 93	<b>Protocol #:</b>	93-16	<b>Status:</b>	Completed
<b>Title:</b>	Stomate Valve Redesign Efficacy Study				
<b>Start Date:</b>		<b>Est. Compl. Date:</b>			
<b>Principal Investigator(s):</b>	Robert G. Martindale, MAJ, MC		<b>Facility:</b>	Eisenhower Army Medical Center	
<b>Department/Service:</b>	Surgery		<b>Associate Investigators:</b>	William C. Calton, CPT, MC Patricia Challenger, RN	
<b>Key Words:</b>					
<b>Accumulative MEDCASE Cost:</b>			<b>Periodic Review Results:</b>		

**Study Objective:** To compare the insertion performance of the slit dome Stomate and the flapper valve Stomate in an adult population, to compare potential complications associated with the flapper valve Stomate and the slit dome Stomate and to compare potential complications associated with the Stomate right angle extension tubing and Y-port connector utilized with the Stomate, and to compare the removal performance of the slit dome Stomate and flapper valve Stomate.

**Technical Approach:**

Number of subjects enrolled for reporting period: 16

**Progress:** Study has been completed. Sixteen patients were enrolled and 13 completed study. Findings revealed that new valve design decreases leaks and "stomate" breakdown.

HSHF-PAT

SUBJECT: Annual Publications Report - November 1993

**DETAIL SUMMARY SHEET**

<b>Date:</b>	29 Oct 93	<b>Protocol #:</b>	93-17	<b>Status:</b>	Terminated
<b>Title:</b>	Gastrostomy Tube Balloon Comparison Study				
<b>Start Date:</b>			<b>Est. Compl. Date:</b>		
<b>Principal Investigator(s):</b>	Robert G. Martindale, MAJ, MC		<b>Facility:</b>	Eisenhower Army Medical Center	
<b>Department/Service:</b>	Surgery		<b>Associate Investigators:</b>	William C. Calton, CPT, MC Patricia Challenger, RN	
<b>Key Words:</b>					
<b>Accumulative MEDCASE Cost:</b>			<b>Periodic Review Results:</b>		

**Study Objective:** To determine gastrostomy tube balloon life up to two months, to identify the incidence of mechanical complications associated with tube failure, and to compare the efficacy of balloons that are cured by two different methods.

**Technical Approach:**

**Number of subjects enrolled for reporting period:**

**Progress:** This study was terminated as it was never started.

HSHF-PAT

SUBJECT: Annual Publications Report - November 1993

**DETAIL SUMMARY SHEET**

<b>Date:</b>	29 Oct 93	<b>Protocol #:</b>	93-35	<b>Status:</b>	Ongoing
<b>Title:</b>	Effects of Somatostatin Analog (Octreotide Acetate) on Wound Healing in Bowel and Gastric Anastomosis in the Rat Model				
<b>Start Date:</b>		<b>Est. Compl. Date:</b>			
<b>Principal Investigator(s):</b>	Samuel K. Miller, MD, CPT, MC		<b>Facility:</b>	Eisenhower Army Medical Center	
<b>Department/Service:</b>	Surgery		<b>Associate Investigators:</b>	Robert G. Martindale, MD, MAJ, MC William Calton Jr, MD, CPT, MC Donald Sutherland, MAJ, MS	
<b>Key Words:</b>					
<b>Accumulative MEDCASE Cost:</b>			<b>Periodic Review Results:</b>	Oct 93 Continue	

**Objective:** To determine the effects of somatostatin analog (Octreotide acetate) on bowel and gastric anastomosis.

**Technical Approach:**

**Progress:** Two sets of rats (35 in first; 40 in second) show trend but no significant progress as of yet.

HSHF-PAT  
SUBJECT: Annual Publications Report - November 1993

**DETAIL SUMMARY SHEET**

<b>Date:</b>	29 Oct 93	<b>Protocol #:</b>	93-36	<b>Status:</b>	Terminate
<b>Title:</b>	Efficacy of a New Blunt Tip Trocar				
<b>Start Date:</b>		<b>Est. Compl. Date:</b>			
<b>Principal Investigator(s):</b>	Paul A. LePage, MD, MAJ, MC		<b>Facility:</b>	Eisenhower Army Medical Center	
<b>Department/Service:</b>	Surgery		<b>Associate Investigators:</b>	Victor L. Modesto, MD, MAJ, MC Robert G. Martindale, MD, MAJ, MC Sidney R. Steinberg, MD, COL, MC	
<b>Key Words:</b>					
<b>Accumulative MEDCASE Cost:</b>			<b>Periodic Review Results:</b>		

**Objective:** To test the efficacy of a new trocar and cannula for open laparoscopy.

**Number of subjects enrolled for reporting period:** None.

**Progress:** Device approved by FDA and is now available on the market. Trocar no longer being evaluated. Terminate per investigator instructions.

HSHF-PAT  
 SUBJECT: --Annual Publications Report - November 1993

**DETAIL SUMMARY SHEET**

<b>Date:</b>	29 Oct 93	<b>Protocol #:</b>	93-38	<b>Status:</b>	Ongoing
<b>Title:</b>	Biomechanical Analysis: Multiple Lag Screw vs Plate Fixation of the Distal Fibula				
<b>Start Date:</b>			<b>Est. Compl. Date:</b>		
<b>Principal Investigator(s):</b>	Paul J. Cutting, MD, CPT, MC		<b>Facility:</b>	Eisenhower Army Medical Center	
<b>Department/Service:</b>	Surgery/Orthopedics		<b>Associate Investigators:</b>	Jeffrey M. Oettinger, MD, CPT, MC Francis K. Moll, MD, CPT, MC Joseph M. Erpelding, MD, LTC, MC	
<b>Key Words:</b>					
<b>Accumulative MEDCASE Cost:</b>			<b>Periodic Review Results:</b>		

**Objective:** To analyze rotational strengths of multiple lag screw vs plate fixation.

**Technical Approach:**

**Number of subjects enrolled for reporting period:**

**Progress:** Specimens have been harvested and experimental fractures fixated. Awaiting completion of jig for Instron to measure torsional resistance to failure. Literature review complete.

HSHF-PAT

SUBJECT: Annual Publications Report - November 1993

**DETAIL SUMMARY SHEET**

<b>Date:</b> 29 Oct 93	<b>Protocol #:</b> 93-40	<b>Status:</b> Terminated
<b>Title:</b> The Predictors of Long-Term Outcome in Elderly Patients with Colles' Fractures		
<b>Start Date:</b>	<b>Est. Compl. Date:</b>	
<b>Principal Investigator(s):</b> David A. Volgas, MD, CPT, MC	<b>Facility:</b> Eisenhower Army Medical Center	
<b>Department/Service:</b> Surgery/Orthopedics	<b>Associate Investigators:</b> Brian Barnard, MD, MAJ, MC Ron Christopher	
<b>Key Words:</b>		
<b>Accumulative MEDCASE Cost:</b>	<b>Periodic Review Results:</b>	

**Objective:** To determine if the same risk factors which are associated with a poor outcome in young patients are applicable to older patients who may place less demand upon their wrists.

**Technical Approach:**

**Number of subjects enrolled for reporting period:**

**Progress:** Study terminated.

HSHF-PAT

SUBJECT: Annual Publications Report - November 1993

**DETAIL SUMMARY SHEET**

<b>Date:</b> 29 Oct 93	<b>Protocol #:</b> 93-42	<b>Status:</b> Ongoing
<b>Title:</b> Mechanical Peritoneal Retraction Laparoscopic Surgery		
<b>Start Date:</b>	<b>Est. Compl. Date:</b>	
<b>Principal Investigator(s):</b> Paul A. LePage, MD, MAJ, MC	<b>Facility:</b> Eisenhower Army Medical Center	
<b>Department/Service:</b> Surgery	<b>Associate Investigators:</b> Sidney R. Steinberg, MD, COL, MC David E. Rivera, MD, LTC, MC Manuel F. Ramirez, MD, LTC, MC General Surgery Service	
<b>Key Words:</b>	Kevin C. Kelley, MD, LTC, MC OB-GYN Service  Medical Monitor: Richard C. Traugott, MD, COL, MC	
<b>Accumulative MEDCASE Cost:</b>	<b>Periodic Review Results:</b>	

**Objective:** To demonstrate whether the Laparolift System provides equivalent or better exposure than conventional pneumoperitoneum.

**Technical Approach:**

**Number of subjects enrolled for reporting period:** None

**Progress:** Progress is help waiting for MEDCASE approval for purchase of laprolift device

HSHF-PAT  
 SUBJECT: Annual Publications Report - November 1993

**DETAIL SUMMARY SHEET**

<b>Date:</b> 29 Oct 93		<b>Protocol #:</b> 93-61		<b>Status:</b> Ongoing	
<b>Title:</b> The Effect of Vitamin A on the Steroid Induced Defect in Wound Healing: A Time Course Study in Mice					
<b>Start Date:</b>			<b>Est. Compl. Date:</b>		
<b>Principal Investigator(s):</b> Patricia S. Greatorex, CPT, MC			<b>Facility:</b> Eisenhower Army Medical Center		
<b>Department/Service:</b> Surgery			<b>Associate Investigators:</b> Robert G. Martindale, M.D., Ph.D. Peter M. Barcia, COL, MC Donald Sutherland, MAJ, MS Steven Tobias, MAJ, DVM		
<b>Key Words:</b>					
<b>Accumulative MEDCASE Cost:</b>			<b>Periodic Review Results:</b>		

**Objective:** To evaluate the potential beneficial effect of Vitamin A in reversing the detrimental effect steroids have on wound healing, examine in chronological sequence the inhibitory effect of corticosteroids on wound healing with and without the addition of Vitamin A, and create a time response curve that will demonstrate when steroids have their peak inhibitory effect and what role Vitamin A has in this time sequence.

**Technical Approach:**

**Number of animals used for reporting period:** None

**Progress:** Protocol was approved at the end of the fiscal year: will be started soon

HSHF-PAT

SUBJECT: Annual Publications Report - November 1993

**DETAIL SUMMARY SHEET**

<b>Date:</b> 29 Oct 93	<b>Protocol #:</b> 93-63	<b>Status:</b> Ongoing
<b>Title:</b> The Adverse Effects of Octreotide on Wound Healing in Rats Study in Mice		
<b>Start Date:</b>	<b>Est. Compl. Date:</b>	
<b>Principal Investigator(s):</b> Brad E. Waddell, CPT(P), MC	<b>Facility:</b> Eisenhower Army Medical Center	
<b>Department/Service:</b> Surgery	<b>Associate Investigators:</b> Robert G. Martindale, M.D., Ph.D. Cheuk Y. Hong, CPT, MC Steven Tobias, MAJ, VC	
<b>Key Words:</b>		
<b>Accumulative MEDCASE Cost:</b>	<b>Periodic Review Results:</b>	

**Objective:** To determine the nature and extent of octreotide's adverse effects on wound healing.

**Technical Approach:**

**Number of animals used for reporting period:** none

**Progress:**

HSHF-PAT

SUBJECT: Annual Publications Report - November 1993

**DETAIL SUMMARY SHEET**

<b>Date:</b> 29 Oct 93	<b>Protocol #:</b> 93-65	<b>Status:</b> Ongoing
<b>Title:</b> The Use of 1% Lidocaine With/Without Epinephrine in Breast Biopsy		
<b>Start Date:</b>	<b>Est. Compl. Date:</b>	
<b>Principal Investigator(s):</b> Samuel Miller, CPT, MC	<b>Facility:</b> Eisenhower Army Medical Center	
<b>Department/Service:</b> Surgery	<b>Associate Investigators:</b> Darrem Chapman, CPT, MC Scott Needham, CPT, MC Paul A. Lepage, MAJ, VC	
<b>Key Words:</b>		
<b>Accumulative MEDCASE Cost:</b>	<b>Periodic Review Results:</b>	

**Objective:** To determine complication rates in breast biopsies as influenced by the use of local anesthetic.

**Technical Approach:**

**Number of subjects enrolled for reporting period:**

**Progress:** Protocol was approved just prior to this reporting date

HSHF-PAT

SUBJECT: Annual Publications Report - November 1993

DETAIL SUMMARY SHEET

<b>Date:</b> 29 Oct 93		<b>Protocol #:</b> 91-27		<b>Status:</b> Ongoing	
<b>Title:</b> SWOG 8809 - A phase III study of alpha-interferon consolidation following chemotherapy with Promace-MOPP (Day 1-8) in patients with low grade malignant lymphomas					
<b>Start Date:</b>			<b>Est. Compl. Date:</b>		
<b>Principal Investigator(s):</b> Robert F. Krywicki, MAJ, MC			<b>Facility:</b> Eisenhower Army Medical Center		
<b>Department/Service:</b> Medicine/Oncology			<b>Associate Investigators:</b> Jayanti K. Sen, COL, MC Don Shaffer, MAJ, MC Charles T. Thornsward, MC Karen Bowen, MAJ, MC Stephen Oswald, LTC, MC		
<b>Key Words:</b>					
<b>Accumulative MEDCASE Cost:</b>			<b>Periodic Review Results:</b> continue		

**Study Objective:** To compare the disease-free survival of patients with low grade malignant lymphoma who receive alpha interferon consolidation therapy after intensive induction with chemotherapy-radiation therapy, to those who receive induction therapy alone. To determine the complete response rate, response duration and survival of low grade lymphoma patients treated with ProMACE-MCPP (day 1-8). To compare the toxicities of induction and induction plus consolidation therapy in this patient population.

**Technical Approach:** Therapy will follow schema outlined in SWOG protocol.

**Number of subjects enrolled for reporting period:** 1

**Progress:** One patient on therapy. No problems encountered during this period.

HSHF-PAT

SUBJECT: Annual Publications Report - November 1993

**DETAIL SUMMARY SHEET**

<b>Date:</b> 29 Oct 93	<b>Protocol #:</b> 91-29	<b>Status:</b> Ongoing
<b>Title:</b> SWOG 8854 (ECOG 1189, NCCTG 898051) Prognostic value of cytometry measurements of breast cancer DNA from postmenopausal patients with involved nodes and receptor positive tumors: A comparison protocol to SWOG 8814		
<b>Start Date:</b>	<b>Est. Compl. Date:</b>	
<b>Principal Investigator(s):</b> Robert F. Krywicki, MAJ, MC	<b>Facility:</b> Eisenhower Army Medical Center	
<b>Department/Service:</b> Medicine/Oncology	<b>Associate Investigators:</b> Karen Bowen, MAJ, MC Robert D. Ranlett, LTC, MC Arthur Wozniak, LTC, MS Don Shaffer, MAJ, MC Charles T. Thornsvar, LTC, MC Stephen Oswald, LTC, MC	
<b>Key Words:</b>		
<b>Accumulative MEDCASE Cost:</b>	<b>Periodic Review Results:</b> Continue	

**Study Objective:** To determine if ploidy analysis of breast cancer by routine clinical flow cytometry (FCM) technique can predict response to therapy and survival of patients registered to SWOG 8814. To determine if ploidy analysis by image processing technique more accurately predicts patient response to therapy and survival than ploidy analysis by FCM.

**Technical Approach:** As outlined in SWOG protocol.

**Number of subjects enrolled for reporting period:** One patient enrolled.

**Progress:** None to date.

HSHF-PAT  
 SUBJECT: Annual Publications Report - November 1993

**DETAIL SUMMARY SHEET**

<b>Date:</b> 29 Oct 93		<b>Protocol #:</b> 91-30		<b>Status:</b> Ongoing	
<b>Title:</b> SWOG 8814 (ECOG-4188, NCCTG-883051) Phase III Comparison of adjuvant chemoendocrine therapy with CAF and concurrent or delayed tamoxifen to tamoxifen alone in postmenopausal patients with involved axillary nodes and positive receptors					
<b>Start Date:</b>			<b>Est. Compl. Date:</b>		
<b>Principal Investigator(s):</b> Robert F. Krywicki, MAJ, MC			<b>Facility:</b> Eisenhower Army Medical Center		
<b>Department/Service:</b> Medicine/Oncology, Pathology			<b>Associate Investigators:</b> Robert D. Ranlett, LTC, MC Arthur Wozniak, LTC, MS Don Shaffer, MAJ, MC Charles T. Thornsverd, COL, MC Stephen Oswald, LTC, MC		
<b>Key Words:</b>					
<b>Accumulative MEDCASE Cost:</b>			<b>Periodic Review Results:</b> Continue		

**Study Objective:** To compare disease-free survival and overall survival of postmenopausal primary breast cancer patients with involved axillary nodes and positive estrogen and/or progesterone receptors treated with standard adjuvant therapy with long-term tamoxifen, or with chemoendocrine therapy with CAF, followed by long-term tamoxifen, or with concurrent chemoendocrine therapy with tamoxifen and CAF. To compare the relative toxicity of the three therapies.

**Technical Approach:** Therapy will follow schema outlined in SWOG protocol.

**Number of subjects enrolled for reporting period:** Two patients enrolled.

**Progress:** None to date.

## DETAIL SUMMARY SHEET

<b>Date:</b> 29 Oct 93	<b>Protocol #:</b> 91-31	<b>Status:</b> Ongoing
<b>Title:</b> SWOG 8897 (EST-2188, CALGB-8897, INT0102) Phase III Comparison of adjuvant chemotherapy with or without endocrine therapy in high-risk, node negative breast cancer patients, and a natural history follow-up study in low-risk, node negative patients		
<b>Start Date:</b>	<b>Est. Compl. Date:</b>	
<b>Principal Investigator(s):</b> Robert F. Krywicki, MAJ, MC	<b>Facility:</b> Eisenhower Army Medical Center	
<b>Department/Service:</b> Medicine/Oncology, Pathology	<b>Associate Investigators:</b> Karen Bowen, MAJ, MC Robert D. Ranlett, LTC, MS Arthur Wozniak, LTC, MS Don Shaffer, MAJ, MC Charles T. Thornsvard, COL, MC Stephen Oswald, LTC, MC	
<b>Key Words:</b>		
<b>Accumulative MEDCASE Cost:</b>	<b>Periodic Review Results:</b> Continue	

**Study Objective:** To compare disease-free survival (DFS) and overall survival (S) of high risk primary breast cancer patients with negative axillary lymph nodes treated with standard adjuvant chemotherapy with CMF for six cycles or with chemotherapy using CAF for six cycles. To assess the value of the addition of tamoxifen for five years compared to no tamoxifen in these patients. To compare the relative toxicity of the therapies. To assess the prognostic significance of DNA flow cytometry in patients with small, occult invasive breast cancer treated by local therapy only. To evaluate the DFS and S of low risk invasive breast cancer determined by receptor status, tumor size and S phase treated by local therapy only.

**Technical Approach:** Therapy will follow schema outlined in SWOG protocol.

**Number of subjects enrolled for reporting period:** 6 patients enrolled.

**Progress:** One patient taken off study. No patient contact since June 1992. One patient has developed deep left thalamic lesion. Metastatic disease plan: Neuro stereotactic Biopsy. No other problems encountered with the other patients.

HSHF-PAT

SUBJECT: Annual Publications Report - November 1993

DETAIL SUMMARY SHEET

<b>Date:</b> 29 Oct 93	<b>Protocol #:</b> 91-34	<b>Status:</b> Ongoing
<b>Title:</b> SWOG 8931 (EST-3189, INT-0108) Phase III Comparison of Cyclophosphamide, Doxorubicin, and 5-Fluorouracil (CAF) and a 16-Week Multi-Drug Regimen as Adjuvant Therapy for Patients with Hormone Receptor Negative, Node Positive Breast Cancer		
<b>Start Date:</b>	<b>Est. Compl. Date:</b>	
<b>Principal Investigator(s):</b> Robert F. Krywicki, MAJ, MC	<b>Facility:</b> Eisenhower Army Medical Center	
<b>Department/Service:</b> Medicine/Oncology, Pathology	<b>Associate Investigators:</b> Karen Bowen, MAJ, MC Paulino O. Vasallo, COL, MC Don Shaffer, MAJ, MC Charles T. Thornsvar, COL, MC Stephen Oswald, LTC, MC	
<b>Key Words:</b>		
<b>Accumulative MEDCASE Cost:</b>	<b>Periodic Review Results:</b> Continue	

**Objective:** To compare disease-free and overall survival in node positive receptor negative breast cancer patients receiving adjuvant CAF or a 16-week multi-drug chemotherapy regimen. To compare toxicities of adjuvant CAF and a 16-week multi-drug regimen.

**Technical Approach:** Therapy will follow schema outlined in SWOG protocol.

**Number of subjects enrolled for reporting period:** Two patients enrolled.

**Progress:** Two patient on therapy. No problems encountered.

HSHF-PAT  
 SUBJECT: Annual Publications Report - November 1993

**DETAIL SUMMARY SHEET**

<b>Date:</b> 29 Oct 93		<b>Protocol #:</b> 91-35		<b>Status:</b> Ongoing	
<b>Title:</b> SWOG 8947 Central lymphoma serum repository protocol. (Companion study to SWOG 8516, 8736, 8809 or 8816)					
<b>Start Date:</b>			<b>Est. Compl. Date:</b>		
<b>Principal Investigator(s):</b> Robert F. Krywicki, MAJ, MC			<b>Facility:</b> Eisenhower Army Medical Center		
<b>Department/Service:</b> Medicine/Oncology, Pathology			<b>Associate Investigators:</b> Rodney G. Day, LTC, MS Stephen Oswald, MAJ, MC Don Shaffer, MAJ, MC Karen Bowen, MAJ, MC Charles T. Thornsvar, COL, MC		
<b>Key Words:</b>					
<b>Accumulative MEDCASE Cost:</b>			<b>Periodic Review Results:</b> Continue		

**Study Objective:** To establish a central lymphoma serum repository that will serve as a resource to provide specimens for current and future scientific studies. To utilize the SWOG database to perform clinicopathologic correlations with the results of those studies.

**Technical Approach:** Blood sample will be drawn and shipped to the Serum Repository Laboratory for testing.

**Number of subjects enrolled for reporting period:** 2

**Progress:** Two patients on therapy. No problems encountered.

HSHF-PAT  
 SUBJECT: Annual Publications Report - November 1993

**DETAIL SUMMARY SHEET**

<b>Date:</b> 29 Oct 93	<b>Protocol #:</b> 91-36	<b>Status:</b> Terminated
<b>Title:</b> SWOG 9037 Prediction of recurrence and survival in node negative breast cancer patients using a panel of prognostic factors		
<b>Start Date:</b>	<b>Est. Compl. Date:</b>	
<b>Principal Investigator(s):</b> Robert F. Krywicki, MAJ, MC	<b>Facility:</b> Eisenhower Army Medical Center	
<b>Department/Service:</b> Medicine/Oncology, Pathology	<b>Associate Investigators:</b> Karen Bowen, MAJ, MC Robert D. Ranlett, LTC, MC Arthur Wozniak, LTC, MS Don Shaffer, MAJ, MC Charles T. Thornsvard, COL, MC	
<b>Key Words:</b>		
<b>Accumulative MEDCASE Cost:</b>	<b>Periodic Review Results:</b> Continue	

**Study Objective:** To measure histologic and nuclear grade, estrogen and progesterone receptors, HER-2 oncogene, cathepsin D, EGF receptor, PS2, hsp27, 70 and 90, in paraffin-embedded histopathological specimens from lymph node-negative breast cancer patients. To correlate the above factors with biological and clinical features including recurrence and survival in patients entered on SWOG 8897.

**Technical Approach:** Paraffin-embedded histopathological specimens will be submitted to a San Antonio laboratory for measurements.

**Number of subjects enrolled for reporting period:** 0

**Progress:** Study closed.

HSHF-PAT  
 SUBJECT: Annual Publications Report - November 1993

**DETAIL SUMMARY SHEET**

<b>Date:</b>	20 Oct 93	<b>Protocol #:</b>	91-41	<b>Status:</b>	Ongoing
<b>Title:</b>	SWOG 8736 Treatment of localized non-Hodgkin's lymphoma: Comparison of chemotherapy (CHOP) to chemotherapy plus radiation therapy				
<b>Start Date:</b>		<b>Est. Compl. Date:</b>			
<b>Principal Investigator(s):</b>	Robert F. Krywicki, MAJ, MC		<b>Facility:</b>	Eisenhower Army Medical Center	
<b>Department/Service:</b>	Medicine/Oncology, Pathology		<b>Associate Investigators:</b>		
<b>Key Words:</b>			Jayanti K. Sen, COL, MC Don Shaffer, MAJ, MC Charles T. Thronsvard, COL, MC Karen Bowen, MAJ, MC Stephen Oswald, LTC, MC		
<b>Accumulative MEDCASE Cost:</b>			<b>Periodic Review Results:</b>	Continue	

**Study Objective:** The primary study objective is to evaluate, in a cooperative group setting, the difference in survival, time to treatment failure and toxicity of two curative approaches to the treatment of patients with localized, intermediate or high grade, non-Hodgkin's lymphoma. The first treatment approach is chemotherapy using Cyclophosphamide, Doxorubicin, Vincristine and Prednisone (CHOP) for eight cycles. The second uses CHOP for three cycles followed by involved field radiation therapy.

**Technical Approach:** Therapy will follow schema outlined in SWOG protocol.

**Number of subjects enrolled for the reporting period:** 1

**Progress:** One patient on therapy.

HSHF-PAT

SUBJECT: Annual Publications Report - November 1993

DETAIL SUMMARY SHEET

<b>Date:</b> 29 Oct 93	<b>Protocol #:</b> 91-42	<b>Status:</b> Completed
<b>Title:</b> SWOG 9040 Intergroup rectal adjuvant protocol, A Phase III study		
<b>Start Date:</b>	<b>Est. Compl. Date:</b>	
<b>Principal Investigator(s):</b> Robert F. Krywicki, MAJ, MC	<b>Facility:</b> Eisenhower Army Medical Center	
<b>Department/Service:</b> Medicine/Oncology, Pathology	<b>Associate Investigators:</b> Paulino O. Vasallo, COL, MC Don Shaffer, MAJ, MC Charles T. Thornsvar, COL, MC Karen Bowen, MAJ, MC Stephen Oswald, LTC, MC	
<b>Key Words:</b>		
<b>Accumulative MEDCASE Cost:</b>	<b>Periodic Review Results:</b> Feb 93 Continue	

**Study Objective:** To determine the relative efficacy of 5-FU, 5-FU and leucovorin, 5-FU and levamisole, and 5-FU, leucovorin and levamisole when combined with pelvic radiation therapy in the treatment of Stages B-2 and C (TNM Stage II and III) rectal cancer. End points used will include local recurrence rates, probability of distant metastases, disease free survival rates, and overall survival. 5-FU with radiation therapy will comprise the control arm of the study. This will be a 4-armed study with the same radiation therapy program in all arms, but with varying drug regimens.

**Technical Approach:** Therapy will follow schema outlined in SWOG protocol.

**Number of subjects enrolled for the reporting period:** 0

**Progress:** Study closed.

HSHF-PAT  
 SUBJECT: Annual Publications Report - November 1993

**DETAIL SUMMARY SHEET**

<b>Date:</b>	20 Oct 93	<b>Protocol #:</b>	91-50	<b>Status:</b>	Ongoing
<b>Title:</b>	SWOG 8851 Phase III comparison of combination chemotherapy (CAF) and chemohormonal therapy (CAF + Zoladex or CAF + Zoladex + Tamoxifen) in premenopausal women with axillary node-positive, receptor-positive breast cancer -- intergroup				
<b>Start Date:</b>		<b>Est. Compl. Date:</b>			
<b>Principal Investigator(s):</b>	Robert F. Krywicki, MAJ, MC		<b>Facility:</b>	Eisenhower Army Medical Center	
<b>Department/Service:</b>	Medicine/Oncology, Pathology		<b>Associate Investigators:</b>	Robert D. Ranlett, LTC, MC Don Shaffer, MAJ, MC Charles T. Thornsvar, COL, MC Stephen Oswald, LTC, MC Karen Bowen, MAJ, MC	
<b>Key Words:</b>			<b>Periodic Review Results:</b>	Continue	
<b>Accumulative MEDCASE Cost:</b>					

**Study Objective:** To compare the recurrence rates, disease-free intervals (DFI), and hormone-receptor-positive survival for premenopausal women with axillary lymph node-positive breast cancer given adjuvant therapy with chemotherapy (CAF) alone or chemotherapy (CAF) followed by Zoladex (Z) or chemotherapy (CAF) followed by Zoladex plus Tamoxifen (X + T). We will compare CAF with CAF + Z and CAF + Z with CAF + Z + T. To compare the relative toxicities of these 3 regimens. To assess the effect of CAF, CAF + Z, and CAF + Z + T on hormone levels (LH, FSH, and estradiol) in premenopausal women treated with these adjuvant therapies.

**Technical Approach:** Therapy will follow schema outlined in SWOG protocol.

**Number of subjects enrolled for reporting period:** 1

**Progress:** Patient completed regiment. Taken off study. Patient is active duty and has since relocated to another area.

HSHF-PAT  
 SUBJECT: Annual Publications Report - November 1993

**DETAIL SUMMARY SHEET**

<b>Date:</b> 29 Oct 93	<b>Protocol #:</b> 91-53	<b>Status:</b> Ongoing
<b>Title:</b> SWOG 8952 Treatment of advanced Hodgkin's disease - A randomized Phase III study comparing ABVD vs MOPP/ABV hybrid		
<b>Start Date:</b>	<b>Est. Compl. Date:</b>	
<b>Principal Investigator(s):</b> Robert F. Krywicki, MAJ, MC	<b>Facility:</b> Eisenhower Army Medical Center	
<b>Department/Service:</b> Medicine/Oncology, Pathology	<b>Associate Investigators:</b> Jayanti K. Sen, COL, MC Karen Bowen, MAJ, MC Stephen Oswald, LTC, MC Don Shaffer, MAJ, MC Charles T. Thornsverd, COL, MC	
<b>Key Words:</b>		
<b>Accumulative MEDCASE Cost:</b>	<b>Periodic Review Results:</b> Continue	

**Study Objective:** To compare ABVD to the MOPP/ABV hybrid as therapy for patients with advanced Hodgkin's disease in terms of complete response rates, disease-free survival, failure-free survival and both immediate and long-term toxicities. To compare the rate of drug delivery of the anti-neoplastic agents, especially the comparative dose rate of ABV in the two treatment groups. To examine the prognostic importance of time to response, performance status, age, presence of bulky disease, C-reactive protein, erythrocyte sedimentation rate, and prior radiotherapy on survival.

**Technical Approach:** Therapy will follow schema outlined in SWOG protocol.

**Number of subjects enrolled for reporting period:** One

**Progress:** No problems encountered.

HSHF-PAT  
 SUBJECT: Annual Publications Report - November 1993

**DETAIL SUMMARY SHEET**

<b>Date:</b> 29 Oct 93.		<b>Protocol #:</b> 91-55		<b>Status:</b> Ongoing	
<b>Title:</b> SWOG 9013 A prospective randomized comparison of combined modality therapy for squamous carcinoma of the esophagus: Chemotherapy plus surgery alone for patients with local regional disease. Phase III intergroup					
<b>Start Date:</b>			<b>Est. Compl. Date:</b>		
<b>Principal Investigator(s):</b> Robert F. Krywicki, MAJ, MC			<b>Facility:</b> Eisenhower Army Medical Center		
<b>Department/Service:</b> Medicine/Oncology			<b>Associate Investigators:</b> Paulino O. Vasallo, COL, MC Don Shaffer, MAJ, MC Charles T. Thornsvar, COL, MC Karen Bowen, MAJ, MC Stephen Oswald, LTC, MC		
<b>Key Words:</b>					
<b>Accumulative MEDCASE Cost:</b>			<b>Periodic Review Results:</b> Mar 93 Continue		

**Study Objective:** To compare, using a prospective controlled randomized study design, the outcomes of therapy of surgery alone, versus pre- and post-operative chemotherapy and surgery for patients with local regional esophageal cancer. Outcome is defined as survival and relapse pattern. To assess the toxicities of a multimodality approach to esophageal carcinoma involving systemic chemotherapy and surgery. The toxicities of surgical resection, as initial therapy or following chemotherapy will be assessed as operative morbidity and mortality. To compare the local and distinct control rates with the two approaches and to define the pattern of failure. To compare the impact on overall and disease free survival of multimodality therapy with surgery alone.

**Technical Approach:** Therapy will follow schema outlined in SWOG protocol.

**Number of subjects enrolled for reporting period:** 1

**Progress:** One patient on therapy died February 1992

HSHF-PAT

SUBJECT: Annual Publications Report - November 1993

**DETAIL SUMMARY SHEET**

<b>Date:</b> 20 Oct 93	<b>Protocol #:</b> 91-67	<b>Status:</b> Closed
<b>Title:</b> SWOG 9012 Evaluation of low dose alpha-interferon in patients with advanced renal cell carcinoma		
<b>Start Date:</b>	<b>Est. Compl. Date:</b>	
<b>Principal Investigator(s):</b> Robert F. Krywicki, MAJ, MC	<b>Facility:</b> Eisenhower Army Medical Center	
<b>Department/Service:</b> Medicine/Oncology, Pathology	<b>Associate Investigators:</b> Jayanti K. Sen, COL, MC Don Shaffer, MAJ, MC Charles T. Thornsward, COL, MC Stephen Oswald, LTC, MC Karen Bowen, MAJ, MC	
<b>Key Words:</b>		
<b>Accumulative MEDCASE Cost:</b>	<b>Periodic Review Results:</b>	

**Study Objective:** The objectives of this Phase II study of low dose alpha-interferon in patients with advanced renal cell carcinoma, Stage II-IV, are to: 1) evaluate the likelihood of response in order to assess whether low dose alpha-interferon should be advanced to further studies and, 2) evaluate the qualitative and quantitative toxicities.

**Technical Approach:** Therapy will follow schema outlined in SWOG protocol.

**Number of subjects enrolled:** 0

**Progress:** Study Closed

HSHF-PAT  
SUBJECT: Annual Publications Report - November 1993

**DETAIL SUMMARY SHEET**

<b>Date:</b>	20 Oct 93	<b>Protocol #:</b>	91-68	<b>Status:</b>	Ongoing
--------------	-----------	--------------------	-------	----------------	---------

HSHF-PAT

SUBJECT: Annual Publications Report - November 1993

development of P-glycoprotein expression. To evaluate the relationship between the magnitude of cytoreduction and survival. To evaluate the significance of pretreatment serum lactic dehydrogenase (LDH) as a marker for aggressive myeloma.

Technical Approach: Therapy will follow schema outlined in SWOG protocol.

Number of subjects enrolled: 0

Progress: None.

HSHF-PAT  
 SUBJECT: Annual Publications Report - November 1993

**DETAIL SUMMARY SHEET**

<b>Date:</b>	14 Oct 93	<b>Protocol #:</b>	91-69	<b>Status:</b>	Ongoing
<b>Title:</b>	SWOG 9111 (EST-1690) Post-operative adjuvant interferon alpha-2 in resected high risk primary and regionally metastatic melanoma, intergroup				
<b>Start Date:</b>		<b>Est. Compl. Date:</b>			
<b>Principal Investigator(s):</b>	Robert F. Krywicki, MAJ, MC		<b>Facility:</b>	Eisenhower Army Medical Center	
<b>Department/Service:</b>	Medicine/Oncology, Pathology		<b>Associate Investigators:</b>	Jayanti K. Sen, COL, MC Don Shaffer, MAJ, MC Charles T. Thornsvard, MAJ, MC Stephen Oswald, LTC, MC Karen Bowen, MAJ, MC	
<b>Key Words:</b>					
<b>Accumulative MEDCASE Cost:</b>			<b>Periodic Review Results:</b>	Feb 93 Continue	

**Study Objective:** To establish the efficacy of 1 year at maximally tolerable dosages (IV and SC) interferon alpha-2 as an adjuvant to increase the disease free interval and overall survival in patients at high risk for recurrence after definitive surgery for deep primary lesions or after regional lymph node recurrence. To evaluate the efficacy and tolerance of long-term interferon alpha-2 at 3 MU/d (Sc TIW) as an adjuvant to increase the disease-free survival and overall survival of patients at high risk for recurrence after definitive surgery for deep primary lesions or after regional lymph node recurrence with melanoma, in comparison to 1 year of treatment of maximally tolerable dosages.

**Technical Approach:** Therapy will follow schema outlined in SWOG protocol.

**Number of subjects enrolled to date:** 0

**Progress:** None.

HSHF-PAT

SUBJECT: Annual Publications Report - November 1993

DETAIL SUMMARY SHEET

<b>Date:</b> 14 Oct 93	<b>Protocol #:</b> 91-70	<b>Status:</b> Ongoing
<b>Title:</b> SWOG 9125 A Phase II trial of CVAD/Verapamil/Quinine for treatment of non-Hodgkin's lymphoma		
<b>Start Date:</b>	<b>Est. Compl. Date:</b>	
<b>Principal Investigator(s):</b> Robert F. Krywicki, MAJ, MC	<b>Facility:</b> Eisenhower Army Medical Center	
<b>Department/Service:</b> Medicine/Oncology, Pathology	<b>Associate Investigators:</b> Jayanti K. Sen, COL, MC Don Shaffer, MAJ, MC Charles T. Thornsward, COL, MC Karen Bowen, MAJ, MC Stephen Oswald, LTC, MC	
<b>Key Words:</b>		
<b>Accumulative MEDCASE Cost:</b>	<b>Periodic Review Results:</b> Feb 93 Continue	

**Study Objective:** To evaluate the effectiveness of the CVAD chemotherapy regimen (cyclophosphamide, vincristine, doxorubicin and dexamethasone) when administered in combination with chemosensitizers (verapamil and quinine) which are intended to block the emergence of multidrug resistance in previously untreated patients with intermediate and high grade non-Hodgkin's lymphomas. The effectiveness of CVAD plus verapamil and quinine will be based on the estimate of the complete response rate and the time to treatment failure. To assess the toxicities and side effects associated with the CVAD regimen when combined with verapamil and quinine. A secondary objective is to further investigate the utility of the proliferative rate (determined by Ki-67 monoclonal antibody), the importance of cell-cell recognition molecules (using a panel of monoclonal antibodies specific for several cell recognition antigens), the role of host response (using markers of tumor infiltrating T-cells in B-cell lymphomas) and the value of detectable levels of P-glycoprotein as prognostic indicators of outcome (see companions study SWOG 8819). A secondary objective is to further utilize the central serum repository enabling clinicopathologic correlations with the results of studies on the material collected (see companion study SWOG 8947).

**Technical Approach:** Therapy will follow schema outlined in SWOG protocol.

**Number of subjects enrolled:** 0

**Progress:** None.

HSHF-PAT  
 SUBJECT: Annual Publications Report - November 1993

**DETAIL SUMMARY SHEET**

<b>Date:</b>	14 Oct 93	<b>Protocol #:</b>	92-6	<b>Status:</b>	Ongoing
<b>Title:</b>	SWOG 9008 Trial of adjuvant chemoradiation after gastric resection for adenocarcinoma, Phase III				
<b>Start Date:</b>		<b>Est. Compl. Date:</b>			
<b>Principal Investigator(s):</b>	Robert F. Krywicki, MAJ, MC		<b>Facility:</b>	Eisenhower Army Medical Center	
<b>Department/Service:</b>	Medicine/Oncology, Pathology		<b>Associate Investigators:</b>	Paulino O. Vasallo, LTC, MC Don Shaffer, MAJ, MC Charles T. Thornsvar, MAJ, MC Karen Bowen, MAJ, MC Stephen Oswald, LTC, MC	
<b>Key Words:</b>					
<b>Accumulative MEDCASE Cost:</b>			<b>Periodic Review Results:</b>	Feb 93 Continue	

**Study Objective:** 1) A comparison of overall and disease free survival between patients being treated with surgical resection only and those being treated with surgery plus adjuvant therapy. 2) A comparison of incidence and patterns of disease failure between surgery and surgery plus adjuvant therapy treated patients. 3) An assessment of patient tolerance of upper abdominal chemoradiation after gastric resection.

**Technical Approach:** Therapy will follow schema outlined in SWOG protocol.

**Subjects enrolled to date:** 0

**Progress:** None.

HSHF-PAT  
 SUBJECT: Annual Publications Report - November 1993

**DETAIL SUMMARY SHEET**

<b>Date:</b>	14 Oct 93	<b>Protocol #:</b>	92-7	<b>Status:</b>	Ongoing
<b>Title:</b>	SWOG 9108 (CALGB-9011, NCIC-CTGCL.1) A Phase III comparison of fludarabine phosphate vs chlorambucil vs (fludarabine) phosphate plus chlorambucil in previously untreated B-cell chronic lymphocytic leukemia				
<b>Start Date:</b>		<b>Est. Compl. Date:</b>			
<b>Principal Investigator(s):</b>	Robert F Krywicki, MAJ, MC		<b>Facility:</b>	Eisenhower Army Medical Center	
<b>Department/Service:</b>	Medicine/Oncology, Pathology		<b>Associate Investigators:</b>	Jayanti K. Sen, COL, MC Don Shaffer, MAJ, MC Charles T. Thornsvard, COL, MC Karen Bowen, MAJ, MC Stephen Oswald, LTC, MC	
<b>Key Words:</b>					
<b>Accumulative MEDCASE Cost:</b>			<b>Periodic Review Results:</b>	Feb 93 Continue	

**Study Objective:** 1) To compare in previously untreated CLL patients the response rates and progression free survival with the following three therapeutic regimens: i) fludarabine phosphate, ii) chlorambucil and iii) fludarabine phosphate + chlorambucil. 2) To determine whether the quality of life (need for transfusions, incidence of infections, and performance status) is superior using any of the three regimens. 3) To determine whether these two drugs (fludarabine phosphate and chlorambucil) are non-cross-resistant by a crossover design for patients failing to respond to the single agent to which they are initially randomized.

**Technical Approach:** Therapy will follow schema outlined in SWOG protocol.

**Subjects enrolled to date:** 1

**Progress:** No problems encountered.

HSHF-PAT  
SUBJECT: Annual Publications Report - November 1993

**DETAIL SUMMARY SHEET**

<b>Date:</b>	14 Oct 93	<b>Protocol #:</b>	92-37	<b>Status:</b>	Ongoing
<b>Title:</b>	SWOG 9007 Cytogenic studies in leukemia patients, ancillary				
<b>Start Date:</b>			<b>Est. Compl. Date:</b>		
<b>Principal Investigator(s):</b>	Robert F. Krywicki, MAJ, MC		<b>Facility:</b>	Eisenhower Army Medical Center	
<b>Department/Service:</b>	Medicine/Oncology, Pathology		<b>Associate Investigators:</b>	Don Shaffer, MAJ, MC Jayanti K. Sen, COL, MC Charles T. Thornsvar, MAJ, MC Karen Bowen, MAJ, MC Stephen Oswald, LTC, MC	
<b>Key Words:</b>			<b>Periodic Review Results:</b>	Feb 93 Continue	
<b>Accumulative MEDCASE Cost:</b>					

**Study Objective:** To estimate the frequencies and prognostic significance of cytogenetic abnormalities in marrow or blood cells of leukemia patients prior to treatment on Southwest Oncology Group protocols and at various times in the course of their treatment. To estimate correlations between the presence of cytogenetic features and of clinical, pathophysiological, cellular, or molecular characteristics in these patients. To provide quality control for all Southwest Oncology Group cytogenetic data.

**Technical Approach:** Therapy will follow schema outlined in SWOG protocol

**Subjects enrolled to date:** Two

**Progress:** No problems encountered.

HSHF-PAT  
 SUBJECT: Annual Publications Report - November 1993

**DETAIL SUMMARY SHEET**

<b>Date:</b>	14 Oct 93	<b>Protocol #:</b>	92-38	<b>Status:</b>	Ongoing
<b>Title:</b>	SWOG 9031 A Double-blind placebo controlled trial of daunomycin and cytosine arabinoside with or without rhG-CSF in elderly patients with acute myeloid leukemia, Phase III				
<b>Start Date:</b>		<b>Est. Compl. Date:</b>			
<b>Principal Investigator(s):</b>	Robert F. Krywicki, MAJ, MC		<b>Facility:</b>	Eisenhower Army Medical Center	
<b>Department/Service:</b>	Medicine/Oncology, Pathology		<b>Associate Investigators:</b>	Don Shaffer, MAJ, MC Jayanti K. Sen, COL, MC Charles T. Thornsvar, COL, MC Karen Bowen, MAJ, MC Stephen Oswald, LTC, MC	
<b>Key Words:</b>					
<b>Accumulative MEDCASE Cost:</b>			<b>Periodic Review Results:</b>	Feb 93 Continue	

**Study Objective:** To compare the complete response rates and durations of survival in patients aged 65 or older with acute myeloid leukemia (AML) when treated with standard doses of cytosine arabinoside (Ara-C) and daunorubicin (DNR), with or without recombinant human granulocyte-colony stimulating factor (rhG-CSF). To assess the frequency and severity of toxicities of the two treatment regimens. To compare the duration of neutropenia and thrombocytopenia; the total number of febrile days; the number of days of antibiotic therapy; the number and type of infection episodes; and the number of hospital days in patients treated with or without recombinant human granulocyte-colony stimulating factor (rhG-CSF). To correlate biological parameters including cell surface immunophenotype, ploidy and cytogenetics with clinical response.

**Technical Approach:** Therapy will follow schema outlined in SWOG protocol

**Subjects enrolled to date:** 0

**Progress:** None.

HSHF-PAT  
 SUBJECT: Annual Publications Report - November 1993

**DETAIL SUMMARY SHEET**

<b>Date:</b>	14 Oct 93	<b>Protocol #:</b>	92-39	<b>Status:</b>	Ongoing
<b>Title:</b>	SWOG 9139 Adjuvant therapy of primary osteogenic sarcoma, Phase II				
<b>Start Date:</b>			<b>Est. Compl. Date:</b>		
<b>Principal Investigator(s):</b>	Robert F. Krywicki, MAJ, MC		<b>Facility:</b>	Eisenhower Army Medical Center	
<b>Department/Service:</b>	Medicine/Oncology, Pathology		<b>Associate Investigators:</b>	Don Shaffer, MAJ, MC Jayanti K. Sen, COL, MC Charles T. Thornsvar, COL, MC Karen Bowen, MAJ, MC Stephen Oswald, LTC, MC	
<b>Key Words:</b>					
<b>Accumulative MEDCASE Cost:</b>			<b>Periodic Review Results:</b>	Feb 93 Continue	

**Study Objective:** To estimate the time to treatment failure and survival rate of the three drug combination adriamycin, cisplatin, and ifosfamide as adjunctive treatment of osteosarcoma of the extremity. To evaluate histopathologic tumor necrosis following preoperative adriamycin, cisplatin, and ifosfamide. To assess the feasibility of determining histopathologic tumor necrosis in a cooperative e group setting. To assess the influence of clinical prognostic variables on disease outcome. To assess the toxicity of this regimen.

**Technical Approach:** Therapy will follow schema outlined in SWOG protocol.

**Subjects enrolled to date:** 0

**Progress:** None.

HSHF-PAT  
 SUBJECT: Annual Publications Report - November 1993

**DETAIL SUMMARY SHEET**

<b>Date:</b>	14 Oct 93	<b>Protocol #:</b>	92-40	<b>Status:</b>	Terminated
<b>Title:</b>	SWOG 9151 Evaluation of topotecan in hepatoma				
<b>Start Date:</b>		<b>Est. Compl. Date:</b>			
<b>Principal Investigator(s):</b>	Robert F. Krywicki, MAJ, MC		<b>Facility:</b>	Eisenhower Army Medical Center	
<b>Department/Service:</b>	Medicine/Oncology, Pathology		<b>Associate Investigators:</b>	Don Shaffer, MAJ, MC Jayanti K. Sen, COL, MC Charles T. Thornsvar, COL, MC Karen Bowen, MAJ, MC Stephen Oswald, LTC, MC	
<b>Key Words:</b>					
<b>Accumulative MEDCASE Cost:</b>			<b>Periodic Review Results:</b>		

**Study Objective:** To evaluate the response rate of topotecan. To evaluate the qualitative and quantitative toxicities of topotecan administered in a Phase II study.

**Technical Approach:** Therapy will follow schema outlined in SWOG protocol.

**Subjects enrolled to date:** 0

**Progress:** Study closed - has met it's accrual.

HSHF-PAT  
 SUBJECT: Annual Publications Report - November 1993

**DETAIL SUMMARY SHEET**

<b>Date:</b>	11 Feb 93	<b>Protocol #:</b>	92-48	<b>Status:</b>	Completed
<b>Title:</b>	SWOG 9054 Ancillary bone mineral density study in premenopausal women on EST 5188 (Intergroup 0101)				
<b>Start Date:</b>		<b>Est. Compl. Date:</b>			
<b>Principal Investigator(s):</b>	Charles T. Thornsvar, COL, MC		<b>Facility:</b>	Eisenhower Army Medical Center	
<b>Department/Service:</b>	Medicine/Oncology, Pathology		<b>Associate Investigators:</b>	Don Shaffer, MAJ, MC Jayanti K. Sen, COL, MC Karen Bowen, MAJ, MC Stephen Oswald, LTC, MC Charles T. Thornsvar, COL, MC	
<b>Key Words:</b>					
<b>Accumulative MEDCASE Cost:</b>			<b>Periodic Review Results:</b>	Feb 93 Closed	

**Study Objective:** To determine whether tamoxifen (10 mg BID) protects against loss of bone mineral density in the lumbar spine and in the femur in premenopausal women with breast cancer following their being made postmenopausal by cytotoxic and ovarian function-suppressing hormonal therapy. To determine the effects Zoladex therapy has on bone mineral density in the lumbar spine and femur in premenopausal women with breast cancer following treatment with 6 cycles of cytotoxic chemotherapy. To determine the rates, pattern of rates and pattern of bone loss in the lumbar spine and femur occurring in premenopausal women treated with a standard course of 6 cycles of cytotoxic chemotherapy. To investigate the serum marker of bone mineral metabolism, serum osteocalcin, in a population of women undergoing significant changes in their bone density.

**Technical Approach:** Therapy will follow schema outlined in SWOG protocol.

**Subjects enrolled to date:** 0

**Progress:** Study closed, has met it's accural.

**DETAIL SUMMARY SHEET**

<b>Date:</b>	14 Oct 93	<b>Protocol #:</b>	92-49	<b>Status:</b>	Ongoing
<b>Title:</b>	SWOG 9019 A Phase III, Randomized prospective comparison between chemotherapy plus radiotherapy and the same chemotherapy plus radiotherapy together with surgery for selected Stage IIIA (positive mediastinal nodes) and selected Stage IIIB (no malignant effusion) non-small cell lung cancer				
<b>Start Date:</b>		<b>Est. Compl. Date:</b>			
<b>Principal Investigator(s):</b>	Robert F. Krywicki, MAJ, MC		<b>Facility:</b>	Eisenhower Army Medical Center	
<b>Department/Service:</b>	Medicine/Oncology, Pathology		<b>Associate Investigators:</b>	Don Shaffer, MAJ, MC Karen Bowen, MAJ, MC Robert D. Ranlett, LTC, MC Charles T. Thornsvard, COL, MC Stephen Oswald, LTC, MC	
<b>Key Words:</b>					
<b>Accumulative MEDCASE Cost:</b>			<b>Periodic Review Results:</b>	Feb 93 Continue	

**Study Objective:** To assess whether concurrent chemotherapy and radiotherapy followed by surgical resection results in a significant improvement in progression-free, overall, and long-term survival compared to the same chemotherapy plus standard radiotherapy alone for patients with stage IIIa (Ne-positive) and selected IIIB non-small cell lung cancer. To evaluate the patterns of local and distant failure for patients enrolled in each arm of the study, in order to assess the impact of the therapy on local control and distant metastases.

**Technical Approach:** Therapy will follow schema outlined in SWOG protocol.

**Subjects enrolled to date:** Two

**Progress:** One of the patients enrolled has completed therapy and no problems encountered. No problems experienced from the other patient enrolled.

HSHF-PAT-  
 SUBJECT: Annual Publications Report - November 1993

**DETAIL SUMMARY SHEET**

<b>Date:</b>	14 Oct 93	<b>Protocol #:</b>	92-50	<b>Status:</b>	Ongoing
<b>Title:</b>	SWOG 9035 Randomized trial of adjuvant immunotherapy with an allogenic melanoma vaccine for patients with intermediate thickness node negative malignant melanoma (T 3NOMO)				
<b>Start Date:</b>		<b>Est. Compl. Date:</b>			
<b>Principal Investigator(s):</b>	Robert F. Krywicki, MC		<b>Facility:</b>	Eisenhower Army Medical Center	
<b>Department/Service:</b>	Medicine/Oncology, Pathology		<b>Associate Investigators:</b>	Don Shaffer, MAJ, MC, Paulino D. Vasallo, COL, MC Charles T. Thornsvar, COL MC Karen Bowen, MAJ, MC Stephen Oswald, LTC, MC	
<b>Key Words:</b>					
<b>Accumulative MEDCASE Cost:</b>			<b>Periodic Review Results:</b>	Feb 93 Continue	

**Study Objective:** To compare disease-free survival and overall survival between patients with T3NOMO malignant melanoma who receive adjuvant immunotherapy with an allogeneic melanoma vaccine versus no adjuvant treatment. To evaluate the toxicity of adjuvant immunotherapy with an allogeneic melanoma vaccine in patients with T3NOMO malignant melanoma.

**Technical Approach:** Therapy will follow schema outlined in SWOG protocol.

**Subjects enrolled to date:** 0

**Progress:** None.

HSHF-PAT  
 SUBJECT: Annual Publications Report - November 1993

**DETAIL SUMMARY SHEET**

<b>Date:</b>	14 Oct 93	<b>Protocol #:</b>	92-51	<b>Status:</b>	Terminated
<b>Title:</b>	SWOG 9116 Evaluation of piroxantrone in disseminated malignant melanoma, Phase II				
<b>Start Date:</b>		<b>Est. Compl. Date:</b>			
<b>Principal Investigator(s):</b>	Robert F. Krywicki, MAJ, MC		<b>Facility:</b>	Eisenhower Army Medical Center	
<b>Department/Service:</b>	Medicine/Oncology, Pathology		<b>Associate Investigators:</b>	Don W. Shaffer, MAJ, MC Paulino D. Vasallo, COL, MC Charles T. Thornsvar, COL, MC Stephen Oswald, LTC, MC Karen Bowen, MAJ, MC	
<b>Key Words:</b>					
<b>Accumulative MEDCASE Cost:</b>			<b>Periodic Review Results:</b>	Feb 93 Continue	

**Study Objective:** To evaluate the response rate of disseminated malignant melanoma treated with piroxantrone. To assess the qualitative and quantitative toxicities of piroxantrone administered in a Phase II study.

**Technical Approach:** Therapy will follow schema outlined in SWOG protocol.

**Subjects enrolled to date:** 0

**Progress:** Study closed - has met its accural.

HSHF-PAT-  
 SUBJECT: Annual Publications Report - November 1993

**DETAIL SUMMARY SHEET**

<b>Date:</b> 20 Oct 93		<b>Protocol #:</b> 92-62		<b>Status:</b> Terminated	
<b>Title:</b> SWOG 9062 - Evaluation of 96 hour infusion 5-FU + cisplatin + alpha interferon in patients with recurrent/metastatic squamous cell carcinoma of head and neck, Phase II					
<b>Start Date:</b>			<b>Est. Compl. Date:</b>		
<b>Principal Investigator(s):</b> Robert F. Krywicki, MAJ, MC			<b>Facility:</b> Eisenhower Army Medical Center		
<b>Department/Service:</b>  Medicine/Oncology, Pathology			<b>Associate Investigators:</b> Charles T. Thornsvar, COL, MC Don Shaffer, MAJ, MC Karen Bowen, MAJ, MC Jayanti K. Sen, COL, MC Stephen Oswald, LTC, MC		
<b>Key Words:</b>					
<b>Accumulative MEDCASE Cost:</b>			<b>Periodic Review Results:</b>		

**Study Objective:** To evaluate the complete response rate in order to assess whether this regimen should be advanced to further studies. To evaluate the qualitative and quantitative toxicities associated with this regimen. To assess the feasibility of this regimen.

**Technical Approach:** Therapy will follow schema outlined in SWOG protocol.

**Number of subjects enrolled during reporting period:** 0

**Progress:** Study closed.

HSHF-PAT

SUBJECT: Annual Publications Report - November 1993

DETAIL SUMMARY SHEET

<b>Date:</b> 20 Oct 93	<b>Protocol #:</b> 92-63	<b>Status:</b> Terminate
<b>Title:</b> SWOG 9134 - A Phase II, trial of taxol and granulocyte-colony stimulating factor (G-CSF) in patients with advanced soft-tissue sarcoma		
<b>Start Date:</b>	<b>Est. Compl. Date:</b>	
<b>Principal Investigator(s):</b> Robert F. Krywicki, MAJ, MC	<b>Facility:</b> Eisenhower Army Medical Center	
<b>Department/Service:</b>  Medicine/Oncology, Pathology	<b>Associate Investigators:</b>  Don Shaffer, MAJ, MC Karen Bowen, MAJ, MC Charles T. Thornsvar, MC  Robert Krywicki, MAJ, MC Jayanti K. Sen, COL, MC	
<b>Key Words:</b>		
<b>Accumulative MEDCASE Cost:</b>	<b>Periodic Review Results:</b>	

**Study Objective:** To evaluate the clinical rate of taxol administered with G-CSF in advanced soft tissue sarcomas. To define the qualitative and quantitative toxicities of taxol administered with G-CSF in a Phase II study.

**Technical Approach:** Therapy will follow schema outlined in SWOG protocol.

**Number of subjects enrolled during reporting period:** 0

**Progress:** Study closed.

HSHF-PAT

SUBJECT: Annual Publications Report - November 1993

DETAIL SUMMARY SHEET

<b>Date:</b>	20 Oct 93	<b>Protocol #:</b>	92-64	<b>Status:</b>	Terminated
<b>Title:</b>	SWOG 9135 - A Phase II trial of taxol and granulocyte-colony stimulating factor (G-CSF) in patients with pancreatic adenocarcinoma				
<b>Start Date:</b>		<b>Est. Compl. Date:</b>			
<b>Principal Investigator(s):</b>	Robert F. Krywicki, MAJ,MC		<b>Facility:</b>	Eisenhower Army Medical Center	
<b>Department/Service:</b>	Medicine/Oncology, Pathology		<b>Associate Investigators:</b>	Don Shaffer, MAJ, MC Karen Bowen, MAJ, MC Jayanti K. Sen, COL, MC Charles T. Thornsvar, COL, MC Stephen Oswald, LTC, MC	
<b>Key Words:</b>					
<b>Accumulative MEDCASE Cost:</b>			<b>Periodic Review Results:</b>	Feb 93 Hold	

**Study Objective:** To evaluate the clinical response rate of taxol administered with G-CSF in pancreatic adenocarcinoma. To define the qualitative and quantitative toxicities of taxol administered with G-CSF in this patient population.

**Technical Approach:** Therapy will follow schema outlined in SWOG protocol

**Number of subjects enrolled to date:** 0

**Progress:** Study closed.

HSHF-PAT

SUBJECT: Annual Publications Report - November 1993

**DETAIL SUMMARY SHEET**

<b>Date:</b>	20 Oct 93	<b>Protocol #:</b>	92-65	<b>Status:</b>	Terminated
<b>Title:</b>	SWOG 9147 - Evaluation of tamoxifen in desmoid tumors, Phase II				
<b>Start Date:</b>		<b>Est. Compl. Date:</b>			
<b>Principal Investigator(s):</b>	Robert F. Krywicki, MAJ, MC		<b>Facility:</b>	Eisenhower Army Medical Center	
<b>Department/Service:</b>	Medicine/Oncology, Pathology		<b>Associate Investigators:</b>	Don Shaffer, MAJ, MC Karen Bowen, MAJ, MC Jayanti K. Sen, COL, MC Stephen Oswald, LTC, MC Charles T. Thornsvar, COL, MC	
<b>Key Words:</b>					
<b>Accumulative MEDCASE Cost:</b>			<b>Periodic Review Results:</b>		

**Study Objective:** To assess the response rate of fibromatosis to treatment with tamoxifen. To assess the clonality in "informative" female patients (i.e., females heterozygous for the genetic locus) utilizing a molecular probe for an X-linked enzyme.

**Technical Approach:** Therapy will follow schema outlined in SWOG protocol.

**Number of subjects enrolled to date:** 0

**Progress:** Study closed.

HSHF-PAT  
 SUBJECT: Annual Publications Report - November 1993

**DETAIL SUMMARY SHEET**

<b>Date:</b>	8 Oct 93	<b>Protocol #:</b>	92-68	<b>Status:</b>	Ongoing
<b>Title:</b>	SWOG 8955 - Treatment of Stage D, Hormone Refractory Carcinoma of the Prostate with 5-Fluorouracil and Roferon-A, Phase II				
<b>Start Date:</b>		<b>Est. Compl. Date:</b>			
<b>Principal Investigator(s):</b>	Robert F. Krywicki, MAJ, MC		<b>Facility:</b>	Eisenhower Army Medical Center	
<b>Department/Service:</b>	Medicine/Oncology		<b>Associate Investigators:</b>	Jayanti K. Sen, MD, COL, MC Karen Bowen, MAJ, MC Don Shaffer, MAJ, MC Stephen Oswald, LTC, MC Charles T. Thornsvard, COL, MC	
<b>Key Words:</b>			<b>Periodic Review Results:</b>	Feb 93 Continue	
<b>Accumulative MEDCASE Cost:</b>					

**Study Objective:** To evaluate the likelihood of response of hormone refractory, metastatic carcinoma of the prostate treated with F-FU and Roferon-A in order to assess whether this regimen should be advanced to further studies. To assess the qualitative and quantitative toxicities of this regimen administered in a phase II study.

**Technical Approach:** Therapy will follow schema outlined in SWOG protocol

**Number of subjects enrolled to date:** None

**Progress:** None to date.

HSHF-PAT  
 SUBJECT: Annual Publications Report - November 1993

**DETAIL SUMMARY SHEET**

<b>Date:</b>	8 Oct 93	<b>Protocol #:</b>	92-69	<b>Status:</b>	Ongoing
<b>Title:</b>	SWOG 9059 - Phase III Comparison of Standard Radiotherapy <i>versus</i> Radiotherapy Plus Simultaneous Cisplatin, <i>versus</i> Split-Course Radiotherapy Plus Simultaneous Cisplatin and 5-Fluorouracil, in Patients with Unresectable Squamous Cell Carcinoma of the Head and Neck				
<b>Start Date:</b>			<b>Est. Compl. Date:</b>		
<b>Principal Investigator(s):</b>	Robert F. Krywicki, MC		<b>Facility:</b>	Eisenhower Army Medical Center	
<b>Department/Service:</b>	Medicine/Oncology		<b>Associate Investigators:</b>	Jayanti K. Sen, MD, COL, MC Don Shaffer, MAJ, MC Karen Bowen, MAJ, MC Stephen Oswald, LTC, MC Charles T. Thornsvar, COL, MC	
<b>Key Words:</b>			<b>Periodic Review Results:</b>	Feb 93 Continue	
<b>Accumulative MEDCASE Cost:</b>					

**Study Objective:** To compare the effectiveness of standard radiation therapy alone to radiation therapy and simultaneous chemotherapy with cisplatin to split-course radiation therapy with cisplatin and 5-fluorouracil infusion in patients with unresectable Stage III and IV squamous cell carcinoma of the head and neck. Endpoints will include complete response rate, time to treatment failure, and overall survival. To compare the relative toxicities of these three treatment arms in this patient population. To compare patterns of relapse or treatment failure among these regimens. To further assess the role, timing, and success of surgery in patients achieving a response to non-operative therapy.

**Technical Approach:** Therapy will follow schema outlined in SWOG protocol.

**Number of subjects enrolled to date:** None

**Progress:** None.

HSHP-PAT  
 SUBJECT: Annual Publications Report - November 1993

**DETAIL SUMMARY SHEET**

<b>Date:</b>	8 Oct 93	<b>Protocol #:</b>	92-70	<b>Status:</b>	Ongoing
<b>Title:</b>	SWOG 9129, Phase III Randomized Study of All-Trans Retinoic Acid <i>versus</i> Cytosine Arabinoside and Daunorubicin as Induction Therapy for Patients with Previously Untreated Acute Promyelocytic Leukemia				
<b>Start Date:</b>		<b>Est. Compl. Date:</b>			
<b>Principal Investigator(s):</b>	Robert F. Krywicki, MAJ, MC		<b>Facility:</b>	Eisenhower Army Medical Center	
<b>Department/Service:</b>	Medicine/Oncology		<b>Associate Investigators:</b>	Jayanti K. Sen, MD, COL, MC Don Shaffer, MAJ, MC Karen Bowen, MAJ, MC Stephen Oswald, LTC, MC Charles T. Thornsvar, COL, MC	
<b>Key Words:</b>					
<b>Accumulative MEDCASE Cost:</b>			<b>Periodic Review Results:</b>	Feb 93 Continue	

**Study Objective:** To compare the complete remission rate and disease-free survival of TRA to that achieved with conventional induction chemotherapy including Cytosine Arabinoside plus Daunorubicin in Patients with previously untreated APL. To compare the toxicities of TRA to those of Cytosine Arabinoside plus Daunorubicin as induction therapy in APL. To determine the value of maintenance therapy with TRA.

**Technical Approach:** Therapy will follow schema outlined in SWOG protocol.

**Number of subjects enrolled to date:** One

**Progress:** One patient enrolled. Patient died due to advanced disease.

HSHF-PAT  
 SUBJECT: Annual Publications Report - November 1993

**DETAIL SUMMARY SHEET**

<b>Date:</b>	8 Oct 93	<b>Protocol #:</b>	92-71	<b>Status:</b>	Ongoing
<b>Title:</b>	SWOG 9150 - Evaluation of Topotecan in Gastric Cancer, Phase II				
<b>Start Date:</b>		<b>Est. Compl. Date:</b>			
<b>Principal Investigator(s):</b>	Robert F. Krywicki, MAJ, MC		<b>Facility:</b>	Eisenhower Army Medical Center	
<b>Department/Service:</b>	Medicine/Oncology		<b>Associate Investigators:</b>	Jayanti K. Sen, MD, COL, MC Don Shaffer, MAJ, MC Karen Bowen, MAJ, MC Stephen Oswald, LTC, MC Charles T. Thoransvard, COL, MC	
<b>Key Words:</b>			<b>Periodic Review Results:</b>	Feb 93 Hold	
<b>Accumulative MEDCASE Cost:</b>					

**Study Objective:** To evaluate the response rate of gastric carcinoma treated with topotecan. To evaluate the qualitative and quantitative toxicities of topotecan administered in a Phase II study.

**Technical Approach:** Therapy will follow schema outlined in SWOG protocol

**Number of subjects enrolled to date:** None.

**Progress:** None

HSHF-PAT  
 SUBJECT: Annual Publications Report - November 1993

**DETAIL SUMMARY SHEET**

<b>Date:</b> 29 Oct 93		<b>Protocol #:</b> 93-7		<b>Status:</b> Ongoing	
<b>Title:</b> SWOG 9104 - Evaluation of Doxorubicin/Vinblastine Combined with Inhibitors (Trifluoperazine/Verapamil) of P-Glycoprotein in Patients with Advanced Renal Cell Carcinoma, Phase II					
<b>Start Date:</b>			<b>Est. Compl. Date:</b>		
<b>Principal Investigator(s):</b> Robert F. Krywicki, MAJ, MC			<b>Facility:</b> Eisenhower Army Medical Center		
<b>Department/Service:</b> Medicine/Oncology			<b>Associate Investigators:</b> Don W. Shaffer, MAJ, MC Charles T. Thornsvar, COL, MC Jayanti K. Sen, COL, MC Karen Bowen, MAJ, MC Stephen Oswald, LTC, MC		
<b>Key Words:</b>					
<b>Accumulative MEDCASE Cost:</b>			<b>Periodic Review Results:</b> Feb 93 Continue		

**Study Objective:**

**Technical Approach:** Therapy will follow schema outlined in SWOG protocol

**Number of subjects enrolled for reporting period:** None

**Progress:**None to date.

HSHF-PAT

SUBJECT: Annual Publications Report - November 1993

**DETAIL SUMMARY SHEET**

<b>Date:</b> 29 Oct 93	<b>Protocol #:</b> 93-8	<b>Status:</b> Ongoing
<b>Title:</b> SWOG 9133 - Randomized Trial of Subtotal Nodal Irradiation versus Doxorubicin Plus Vinblastine and Subtotal Nodal Irradiation for Stage I-IIA Hodgkin's Disease, Phase III		
<b>Start Date:</b>	<b>Est. Compl. Date:</b>	
<b>Principal Investigator(s):</b> Robert F. Krywicki, MAJ, MC	<b>Facility:</b> Eisenhower Army Medical Center	
<b>Department/Service:</b> Medicine/Oncology	<b>Associate Investigators:</b> Don W. Shaffer, MAJ, MC Charles T. Thornsvar, COL, MC Jayanti K. Sen, COL, MC Stephen Oswald, LTC, MC Karen Bowen, MAJ, MC	
<b>Key Words:</b>		
<b>Accumulative MEDCASE Cost:</b>	<b>Periodic Review Results:</b> Feb 93 Continue	

**Study Objective:** To compare the ability of two treatment regimens (radiation therapy alone or radiation plus chemotherapy), one of which will be chosen to treat the cancer. This study will also determine whether these treatments have any effect on the patients disease free survival, and whether the effects of treatment are different for different people based on age, gender, type of disease and number of disease sites.

**Technical Approach:** Therapy will follow schema outlined in SWOG protocol.

**Number of subjects enrolled for reporting period:** None

**Progress:** None at this time.

HSHF-PAT

SUBJECT: Annual Publications Report - November 1993

**DETAIL SUMMARY SHEET**

<b>Date:</b> 29 Oct 93	<b>Protocol #:</b> 93-9	<b>Status:</b> Ongoing
<b>Title:</b> SWOG 9148 - A Phase II Study of Cisplatin Preceded by a 12-Hour Continuous Infusion of Concurrent Hydroxyurea and Cytosine Arabinoside (ARA-C) for Patients with Untreated Extensive Stage Small Cell and Non-Small Cell Lung Carcinoma		
<b>Start Date:</b>	<b>Est. Compl. Date:</b>	
<b>Principal Investigator(s):</b> Robert F. Krywicki, MAJ, MC	<b>Facility:</b> Eisenhower Army Medical Center	
<b>Department/Service:</b> Medicine/Oncology	<b>Associate Investigators:</b> Karen Bowen, MAJ, MC Don W. Shaffer, MAJ, MC Charles T. Thornsvar, COL, MC Jayanti Sen, COL, MC Stephen Oswald, LTC, MC	
<b>Key Words:</b>		
<b>Accumulative MEDCASE Cost:</b>	<b>Periodic Review Results:</b> Feb 93 Continue	

**Study Objective:** To determine if the chemotherapy agents cisplatin, cytosine arabinoside (ARA-C) and Hydroxyurea when used together may be more effective in lung cancer patients than when used alone.

**Technical Approach:** Therapy will follow schema outlined in SWOG protocol

**Number of subjects enrolled for reporting period:** None

**Progress:** None at this time.

HSHF-PAT  
SUBJECT: Annual Publications Report - November 1993

**DETAIL SUMMARY SHEET**

<b>Date:</b> 29 Oct 93	<b>Protocol #:</b> 93-10	<b>Status:</b> Ongoing
<b>Title:</b> SWOG 9215 - Quality of Life on Breast Cancer Adjuvant Trial		
<b>Start Date:</b>	<b>Est. Compl. Date:</b>	
<b>Principal Investigator(s):</b> Robert F. Krywicki, MAJ, MC	<b>Facility:</b> Eisenhower Army Medical Center	
<b>Department/Service:</b> Medicine/Oncology	<b>Associate Investigators:</b> Don W. Shaffer, MAJ, MC Charles T. Thornsvar, COL, MC Karen Bowen, MAJ, MC Stephen Oswald, LTC, MC	
<b>Key Words:</b>		
<b>Accumulative MEDCASE Cost:</b>	<b>Periodic Review Results:</b> Feb 93 Continue	

Study Objective:

Technical Approach:

Number of subjects enrolled for reporting period:

Progress:

**DETAIL SUMMARY SHEET**

<b>Date:</b> 29 Oct 93	<b>Protocol #:</b> 93-19	<b>Status:</b> Ongoing
<b>Title:</b> SWOG 9003 - Fludarabine for Waldenstrom's Macroglobulinemia (WM): A Phase II Pilot Study for Untreated and Previously Treated Patients		
<b>Start Date:</b>	<b>Est. Compl. Date:</b>	
<b>Principal Investigator(s):</b> Robert F. Krywicki, MAJ, MC	<b>Facility:</b> Eisenhower Army Medical Center	
<b>Department/Service:</b> Medicine/Oncology	<b>Associate Investigators:</b> Don W. Shaffer, MAJ, MC Charles T. Thornsvard, COL, MC Jayanti K. Sen, COL, MC Karen Bowen, MAJ, MC Stephen Oswald, LTC, MC	
<b>Key Words:</b>		
<b>Accumulative MEDCASE Cost:</b>	<b>Periodic Review Results:</b> Feb 93 Continue	

**Study Objective:** The objective of this study is to find out how well patients respond and how well patients respond and how long their response lasts when treated with Fludarabine. Fludarabine is now being evaluated to determine its benefits and effectiveness on Waldenstrom's Macroglobulinemia. We want to learn more about this disease and how long it can be observed without chemotherapy.

**Technical Approach:** Therapy will follow schema outlined in SWOG protocol.

**Number of subjects enrolled for reporting period:** None

**Progress:** None at this time.

**DETAIL SUMMARY SHEET**

<b>Date:</b> 29 Oct 93	<b>Protocol #:</b> 93-20	<b>Status:</b> Ongoing
<b>Title:</b> SWOG 9015 - A Randomized Trial of Pre- and PostOperative Chemotherapy Compared to Surgery Alone for Patients with Operable Non-Small Cell Carcinoma of the Lung, Phase III		
<b>Start Date:</b>	<b>Est. Compl. Date:</b>	
<b>Principal Investigator(s):</b> Robert F .Krywicki, MAJ, MC	<b>Facility:</b> Eisenhower Medical Center	
<b>Department/Service:</b> Medicine/Oncology	<b>Associate Investigators:</b> Don W. Shaffer, MAJ, MC Charles T. Thornsvard, COL, MC Jayanti K. Sen, COL, MC Stephen Oswald, LTC, MC Karen Bowen, MAJ, MC	
<b>Key Words:</b>		
<b>Accumulative MEDCASE Cost:</b>	<b>Periodic Review Results:</b> Feb 93 Continue	

**Study Objective:** To compare how well patients respond and how long the response lasts when treated with a combination of VP-16 and carboplatin before and after surgery or surgery alone, and to estimate the side effects of these drugs and how often they occur.

**Technical Approach:** Therapy will follow schema outlined in SWOG protocol

**Number of subjects enrolled for reporting period:** None.

**Progress:** None at this time.

**DETAIL SUMMARY SHEET**

<b>Date:</b> 29 Oct 93	<b>Protocol #:</b> 93-21	<b>Status:</b> Ongoing
<b>Title:</b> SWOG 9201 - Phase III, Trial to Preserve the Larynx: Induction Chemotherapy and Radiation Therapy versus Radiation Therapy		
<b>Start Date:</b>	<b>Est. Compl. Date:</b>	
<b>Principal Investigator(s):</b> Robert F. Krywicki, MAJ, MC	<b>Facility:</b> Eisenhower Army Medical Center	
<b>Department/Service:</b> Medicine/Oncology	<b>Associate Investigators:</b> Don W. Shaffer, MAJ, MC Charles T. Thornsvard, COL, MC Jayanti K. Sen, COL, MC Karen Bowen, MAJ, MC Stephen Oswald, LTC, MC	
<b>Key Words:</b>		
<b>Accumulative MEDCASE Cost:</b>	<b>Periodic Review Results:</b> Feb 93 Continue	

**Study Objective:** To preserve the larynx by using non-surgical treatments. Three treatments will be compared: (1) chemotherapy followed by radiation, or (2) chemotherapy given at the same time, or (3) radiation alone.

**Technical approach:** Therapy will follow schema outlined in SWOG protocol.

**Number of subjects enrolled for reporting period:** None

**Progress:** None at this time.

**DETAIL SUMMARY SHEET**

<b>Date:</b> 29 Oct 93	<b>Protocol #:</b> 93-22	<b>Status:</b> Ongoing
<b>Title:</b> SWOG 9205 - Central Prostate Cancer Serum Repository Protocol		
<b>Start Date:</b>	<b>Est. Compl. Date:</b>	
<b>Principal Investigator(s):</b> Robert F. Krywicki, MAJ, MC	<b>Facility:</b> Eisenhower Army Medical Center	
<b>Department/Service:</b> Medicine/Oncology	<b>Associate Investigators:</b> Don W. Shaffer, MAJ, MC Charles T. Thornsvard, COL, MC Karen Bowen, MAJ, MC Stephen Oswald, LTC, MC	
<b>Key Words:</b>		
<b>Accumulative MEDCASE Cost:</b>	<b>Periodic Review Results:</b> Feb 93 Continue	

**Study Objective:** To serve as a repository for serum of patients with prostate cancer entered onto Southwest Oncology Group approved studies. The purpose of this activity is to provide the opportunity for study of new or existing markers or other tests in a prospective or retrospective fashion in order to test their usefulness as diagnostic or management tools in prostate cancer at all stages.

**Technical Approach:** As outlined in SWOG protocol.

**Number of subjects enrolled for reporting period:** None

**Progress:** None at this time.

**DETAIL SUMMARY SHEET**

<b>Date:</b> 29 Oct 93	<b>Protocol #:</b> 93-28	<b>Status:</b> Ongoing
<b>Title:</b> SWOG-9158 - Evaluation of Trans Retinoic Acid and Alpha Interferon in Patients with Squamous Cell Carcinoma of the Lung (Stage IV)		
<b>Start Date:</b>	<b>Est. Compl. Date:</b>	
<b>Principal Investigator(s):</b> Robert F. Krywicki, MAJ, MC	<b>Facility:</b> Eisenhower Army Medical Center	
<b>Department/Service:</b> Medicine/Oncology	<b>Associate Investigators:</b> Don W. Shaffer, MD, MAJ, MC Charles T. Thornsvard, COL, MC Jayanti K. Sen, MD, MAJ, MC Karen Bowen, MAJ, MC Stephen Oswald, LTC, MC	
<b>Key Words:</b>		
<b>Accumulative MEDCASE Cost:</b>	<b>Periodic Review Results:</b>	

**Study Objective:** To assess the response rate to trans-Retinoic Acid and Alpha Interferon used in a daily schedule for patients with advanced, well differentiated squamous cell carcinoma of the lung. To further define the qualitative and quantitative toxicities of this regimen administered to this patient population in a Phase II study.

**Technical Approach:** Therapy will follow schema outlined in SWOG protocol.

**Number of subjects enrolled to date:** None

**Progress:** None to date.

**DETAIL SUMMARY SHEET**

<b>Date:</b> 29 Oct 93	<b>Protocol #:</b> 93-29	<b>Status:</b> Ongoing
<b>Title:</b> SWOG 9216 - A Randomized Phase III Study of CODE Plus Thoracic Irradiation versus Alternating CAV and EP for Extensive Stage Small Cell Lung Cancer		
<b>Start Date:</b>	<b>Est. Compl. Date:</b>	
<b>Principal Investigator(s):</b> Robert F. Krywicki, MAJ, MC	<b>Facility:</b> Eisenhower Army Medical Center	
<b>Department/Service:</b> Medicine/Oncology	<b>Associate Investigators:</b> Don W. Shaffer, MD, MAJ, MC Charles T. Thornsward, COL, MC Jayanti K. Sen, MD, COL, MC Karen Bowen, MAJ, MC Stephen Oswald, LTC, MC	
<b>Key Words:</b>		
<b>Accumulative MEDCASE Cost:</b>	<b>Periodic Review Results:</b>	

**Study Objective:** To determine whether the CODE regimen plus thoracic irradiation is superior to standard alternating CAV and EP in the treatment of extensive stage small cell lung cancer in terms of: overall survival, time to disease progression, response rate, response duration, and quality of life.

**Technical Approach:** Therapy will follow schema outlined in SWOG protocol.

**Number of subjects enrolled to date:** None

**Progress:** None at this time.

**DETAIL SUMMARY SHEET**

<b>Date:</b> 29 Oct 93	<b>Protocol #:</b> 93-43	<b>Status:</b> Ongoing
<b>Title:</b> SWOG 9126 - A Controlled Trial of Cyclosporine as a Chemotherapy-Resistance Modifier in High Risk Acute Myeloid Leukemia, Phase III		
<b>Start Date:</b>	<b>Est. Compl. Date:</b>	
<b>Principal Investigator(s):</b> Robert F. Krywicki, MAJ, MC	<b>Facility:</b> Eisenhower Army Medical Center	
<b>Department/Service:</b> Medicine/Oncology	<b>Associate Investigators:</b> Don W. Shaffer, M.D., MAJ, MC Charles T. Thornsvard, MAJ, MC Stephen G. Oswald, M.D., LTC, MC Jayanti K. Sen, M.D., COL, MC Karen Bowen, MAJ, MC	
<b>Key Words:</b>		
<b>Accumulative MEDCASE Cost:</b>	<b>Periodic Review Results:</b>	

**Study Objective:** To compare the complete remission rate and duration of survival in patients with high-risk acute myeloid leukemia (AML), when treated with either chemotherapy (ara-C/Daunomycin) alone, or chemotherapy plus the resistance modifier cyclosporine-A (CyA): To estimate the frequency of p-glycoprotein expression and the correlation with prognosis in patients with relapsed AML, primary refractory AML, and secondary AML; to compare the frequency and severity of toxicity of the two treatment regimens; and to investigate the relationship between response to treatment and the blood levels of cyclosporine-A and daunorubicin achieved.

**Technical Approach:** Therapy will follow schema outlined in SWOG protocol.

**Number of subjects enrolled to date:** None

**Progress:** None to date.

**DETAIL SUMMARY SHEET**

<b>Date:</b> 29 Oct 93	<b>Protocol #:</b> 93-44	<b>Status:</b> Ongoing
<b>Title:</b> SWOG 9237 - Evaluation of Topotecan in Refractory and Relapsing Multiple Myeloma, Phase II		
<b>Start Date:</b>	<b>Est. Compl. Date:</b>	
<b>Principal Investigator(s):</b> Robert F. Krywicki, MAJ, MC	<b>Facility:</b> Eisenhower Army Medical Center	
<b>Department/Service:</b> Medicine/Oncology	<b>Associate Investigators:</b> Don W. Shaffer, M.D., MAJ, MC Charles T. Thornsvar, COL, MC Stephen G. Oswald, M.D., LTC, MC Jayanti K. Sen, M.D., COL, MC Karen Bowen, MAJ, MC	
<b>Key Words:</b>		
<b>Accumulative MEDCASE Cost:</b>	<b>Periodic Review Results:</b>	

**Study Objective:** To evaluate the response rate for refractory myeloma treated with topotecan; the qualitative and quantitative toxicities of topotecan administered in a Phase II study; and measure topoisomerase levels in multiple myeloma cells.

**Technical Approach:** Therapy will follow schema outlined in SWOG protocol.

**Number of subjects enrolled to date:** None

**Progress:** None to date.

**DETAIL SUMMARY SHEET**

<b>Date:</b> 29 Oct 93		<b>Protocol #:</b> 93-45		<b>Status:</b> Ongoing	
<b>Title:</b> SWOG 9240 - A Phase II Trial of CVAD for Treatment of Non-Hodgkin's Lymphoma					
<b>Start Date:</b>			<b>Est. Compl. Date:</b>		
<b>Principal Investigator(s):</b> Robert F. Krywicki, MAJ, MC			<b>Facility:</b> Eisenhower Army Medical Center		
<b>Department/Service:</b> Medicine/Oncology			<b>Associate Investigators:</b> Don W. Shaffer, M.D., MAJ, MC Charles T. Thornsvard, COL, MC, MC Stephen G. Oswald, M.D., LTC, MC Karen Bowen, MAJ, MC Jayanti K. Sen, M.D., COL, MC		
<b>Key Words:</b>					
<b>Accumulative MEDCASE Cost:</b>			<b>Periodic Review Results:</b>		

**Study Objective:** To evaluate the effectiveness of the CVAD chemotherapy regimen (cyclophosphamide, vincristine, doxorubicin and dexamethasone) in previously untreated patients with intermediate and high grade non-Hodgkin's lymphomas. The effectiveness of CVAD will be based on the estimate of the complete response rate and the time to treatment failure.

**Technical Approach:** Therapy will follow schema outlined in SWOG protocol.

**Number of subjects enrolled to date:** None

**Progress:** None to date.

**DETAIL SUMMARY SHEET**

<b>Date:</b> 29 Oct 93	<b>Protocol #:</b> 93-46	<b>Status:</b> Ongoing
<b>Title:</b> SWOG 9246 - A Phase II Evaluation of Taxol in Patients with Relapsed Non-Hodgkin's Lymphoma or Relapsed Hodgkin's Disease		
<b>Start Date:</b>	<b>Est. Compl. Date:</b>	
<b>Principal Investigator(s):</b> Robert F. Krywicki, MAJ, MC	<b>Facility:</b> Eisenhower Army Medical Center	
<b>Department/Service:</b> Medicine/Oncology	<b>Associate Investigators:</b> Don W. Shaffer, M.D., MAJ, MC Charles T. Thornsward, COL, MC Stephen G. Oswald, M.D., LTC, MC Jayanti K. Sen, M.D., COL, MC Karen Bowen, MAJ, MC	
<b>Key Words:</b>		
<b>Accumulative MEDCASE Cost:</b>	<b>Periodic Review Results:</b>	

**Study Objective:** To assess the response rate of relapsed low grade non-Hodgkin's lymphoma, relapsed intermediate or high grade non-Hodgkin's lymphoma and relapsed Hodgkin's disease treated with taxol and to assess the qualitative and quantitative toxicities of taxol administered in a Phase II study.

**Technical Approach:** Therapy will follow schema outlined in SWOG protocol.

**Number of subjects enrolled to date:** None

**Progress:** None to date.

**DETAIL SUMMARY SHEET**

<b>Date:</b> 29 Oct 93	<b>Protocol #:</b> 93-53	<b>Status:</b> Ongoing
<b>Title:</b> SWOG-9221 - Phase III Double-Blind Randomized Trial of 13-Cis Retinoic Acid (13-cRA) to Prevent Second Primary Tumors (SPTs) in Stage I Non-Small Cell Lung Cancer		
<b>Start Date:</b>	<b>Est. Compl. Date:</b>	
<b>Principal Investigator(s):</b> Robert F. Krywicki, MAJ, MC	<b>Facility:</b> Eisenhower Army Medical Center	
<b>Department/Service:</b> Medicine/Oncology	<b>Associate Investigators:</b> Don W. Shaffer, M.D., MAJ, MC Charles T. Thornsvard, COL, MC Stephen G. Oswald, M.D., LTC, MC Jayanti K. Sen, M.D., COL, MC Karen Bowen, MAJ, MC	
<b>Key Words:</b>		
<b>Accumulative MEDCASE Cost:</b>	<b>Periodic Review Results:</b>	

**Study Objective:** To compare daily oral administration of 13-Cis Retinoic Acid against placebo in preventing new primary lung tumors from patients having had surgical treatment of a Stage I non-small cell lung tumor.

**Technical Approach:** As outlined in SWOG protocol.

**Number of subjects enrolled to date:** None

**Progress:** None to date.

**DETAIL SUMMARY SHEET**

<b>Date:</b> 29 Oct 93		<b>Protocol #:</b> 93-54		<b>Status:</b> Ongoing	
<b>Title:</b> SWOG 9157 - Trial of All Trans-Retinoic Acid in Hepatoma, Phase II					
<b>Start Date:</b>			<b>Est. Compl. Date:</b>		
<b>Principal Investigator(s):</b> Robert F. Krywicki, MAJ, MC			<b>Facility:</b> Eisenhower Army Medical Center		
<b>Department/Service:</b> Medicine/Oncology			<b>Associate Investigators:</b> Don W. Shaffer, M.D., MAJ, MC Charles T. Thornsward, COL, MC Stephen G. Oswald, M.D., LTC, MC Jayanti K. Sen, M.D., COL, MC Karen Bowen, MAJ, MC		
<b>Key Words:</b>					
<b>Accumulative MEDCASE Cost:</b>			<b>Periodic Review Results:</b>		

**Study Objective:** To compare thrice daily oral administration of all trans-retinoic acid or placebo on three week cycles for hepatoma, a malignancy for which no good treatment exists. Evidence of efficacy will lead to a wider clinical study.

**Technical Approach:** As outlined in SWOG protocol.

**Number of subjects enrolled to date:** None

**Progress:** None to date.

**DETAIL SUMMARY SHEET**

<b>Date:</b> 29 Oct 93.		<b>Protocol #:</b> 93-55		<b>Status:</b> Ongoing	
<b>Title:</b> SWOG 9210 - A Phase III Randomized Trial of Combination Therapy for Multiple Myeloma Comparison of (1) VAD-P to VAD-P/Quinine for Induction; (2) Randomization of Prednisone Dose Intensity for Remission Maintenance					
<b>Start Date:</b>			<b>Est. Compl. Date:</b>		
<b>Principal Investigator(s):</b> Robert F. Krywicki, MAJ, MC			<b>Facility:</b> Eisenhower Army Medical Center		
<b>Department/Service:</b> Medicine/Oncology			<b>Associate Investigators:</b> Don W. Shaffer, M.D., MAJ, MC Charles T. Thornsvard, COL, MC Stephen G. Oswald, M.D., LTC, MC Jayanti K. Sen, M.D., COL, MC Karen Bowen, MAJ, MC		
<b>Key Words:</b>					
<b>Accumulative MEDCASE Cost:</b>			<b>Periodic Review Results:</b>		

**Study Objective:** To compare the effectiveness of the VAD-P chemotherapy regimen when administered alone or in combination with the chemosensitizer quinine. It will evaluate the chemosensitizing potential of quinine to reverse drug resistance.

**Technical Approach:** As outlined in SWOG protocol.

**Number of subjects enrolled to date:** None

**Progress:** None to date.

**DETAIL SUMMARY SHEET**

<b>Date:</b> 29 Oct 93	<b>Protocol #:</b> 93-56	<b>Status:</b> Ongoing
<b>Title:</b> SWOG 9248 - A Phase II Trial of Paclitaxel (Taxol) in Patients with Metastatic Refractory Carcinoma of the Breast		
<b>Start Date:</b>	<b>Est. Compl. Date:</b>	
<b>Principal Investigator(s):</b> Robert F. Krywicki, MAJ, MC	<b>Facility:</b> Eisenhower Army Medical Center	
<b>Department/Service:</b> Medicine/Oncology	<b>Associate Investigators:</b> Don W. Shaffer, M.D., MAJ, MC Charles T. Thornsward, COL, MC Stephen G. Oswald, M.D., LTC, MC Jayanti K. Sen, M.D., COL, MC Karen Bowen, MAJ, MC, MD	
<b>Key Words:</b>		
<b>Accumulative MEDCASE Cost:</b>	<b>Periodic Review Results:</b>	

**Study Objective:** To evaluate the subjective improvement in patients with symptomatic refractory carcinoma of the female breast treated with paclitaxel. Information obtained from patients in studies like this one can, in the future, help a doctor and a patient make treatment decisions.

**Technical Approach:** As outlined in SWOG protocol.

**Number of subjects enrolled to date:** None

**Progress:** None to date.

**DETAIL SUMMARY SHEET**

<b>Date:</b> 29 Oct 93	<b>Protocol #:</b> 93-56	<b>Status:</b> Ongoing
<b>Title:</b> SWOG 9248 - A Phase II Trial of Paclitaxel (Taxol) in Patients with Metastatic Refractory Carcinoma of the Breast		
<b>Start Date:</b>	<b>Est. Compl. Date:</b>	
<b>Principal Investigator(s):</b> Robert F. Krywicki, MAJ, MC	<b>Facility:</b> Eisenhower Army Medical Center	
<b>Department/Service:</b> Medicine/Oncology	<b>Associate Investigators:</b> Charles T. Thornsward, M.D., COL, MC Karen Bowen, M.D., MAJ, MC Stephen G. Oswald, M.D., LTC, MC Jayanti K. Sen, M.D., COL, MC Don Shaffer, MAJ, MC, MD	
<b>Key Words:</b>		
<b>Accumulative MEDCASE Cost:</b>	<b>Periodic Review Results:</b>	

**Study Objective:** To evaluate the subjective improvement in patients with symptomatic refractory carcinoma of the female breast treated with paclitaxel. Information obtained from patients in studies like this one can, in the future, help a doctor and a patient make treatment decisions.

**Technical Approach:** As outlined in SWOG protocol.

**Number of subjects enrolled to date:** Two

**Progress:** No problems encountered.

**DETAIL SUMMARY SHEET**

<b>Date:</b> 6 Oct 92	<b>Protocol #:</b> 78-14	<b>Status:</b> Ongoing
<b>Title:</b> Intraocular Lens Study		
<b>Start Date:</b> Oct 81	<b>Est. Compl. Date:</b>	
<b>Principal Investigator(s):</b> Emil A. Stein, CPT, MC	<b>Facility:</b> USA MEDDAC, Ft Campbell, KY	
<b>Department/Service:</b> Surgery/Ophthalmology	<b>Associate Investigators:</b>	
<b>Key Words:</b>		
<b>Accumulative MEDCASE Cost:</b>	<b>Periodic Review Results:</b>	

**Study Objective:** To provide to cataract patients the latest development in ophthalmic surgery concerning the correction of surgical aphakia.

**Technical Approach:** Extracapsular cataract extraction followed by the implantation of an intraocular lens implant.

**Subjects enrolled to date:** 333  
**Subjects enrolled for the reporting period:** 96

**Progress:** Continued excellent surgical and visual results without significant complications.

**DETAIL SUMMARY SHEET**

<b>Date:</b>	6 Oct 92	<b>Protocol #:</b>	78-14A	<b>Status:</b>	Closed
<b>Title:</b> Pediatric Intraocular Lens Study					
<b>Start Date:</b>			<b>Est. Compl. Date:</b>		
<b>Principal Investigator(s):</b> Emil A. Stein, MAJ, MC			<b>Facility:</b> USA MEDDAC, Ft Campbell, KY		
<b>Department/Service:</b> Surgery/Ophthalmology			<b>Associate Investigators:</b>		
<b>Key Words:</b>					
<b>Accumulative MEDCASE Cost:</b>			<b>Periodic Review Results:</b>		

**Study Objective:** To provide pediatric patients with the latest development in ophthalmic surgery for the treatment of surgical aphakia.

**Technical Approach** Extracapsular cataract extraction followed by implantation of an intraocular lens implant.

**Subjects enrolled to date:** 2  
**Subjects enrolled for reporting period:** 1

**Progress:** PI has left the service. Study closed

**DETAIL SUMMARY SHEET**

<b>Date:</b> 29 Oct 93	<b>Protocol #:</b> 92-33	<b>Status:</b> Terminated
<b>Title:</b> Prolotherapy in the treatment of chronic low back pain - A double-blind study		
<b>Start Date:</b>	<b>Est. Compl. Date:</b>	
<b>Principal Investigator(s):</b> Michael D. Jacobson, MAJ, MC Mark A. Bonneville, MAJ, MC	<b>Facility:</b> USA MEDDAC, Ft Campbell, KY	
<b>Department/Service:</b> Family Practice	<b>Associate Investigators:</b> Walter E. Carnahan, CPT, MC	
<b>Key Words:</b>		
<b>Accumulative MEDCASE Cost:</b>	<b>Periodic Review Results:</b>	

**Objective:** To demonstrate the effectiveness of using a proliferant solution for the treatment of chronic, mechanical low back pain.

**Technical approach:**

**Progress:** The principal and associate investigators have left the Army and no other information is available.

**DETAIL SUMMARY SHEET**

<b>Date:</b> 6 Oct 92	<b>Protocol #:</b> 92-55	<b>Status:</b> Ongoing
<b>Title:</b> The effects of parental deployment on childhood behavior		
<b>Start Date:</b>	<b>Est. Compl. Date:</b>	
<b>Principal Investigator(s):</b> Marvin C. Arnold, MAJ, MS	<b>Facility:</b> USA MEDDAC, Ft Campbell, KY	
<b>Department/Service:</b> Psychiatry	<b>Associate Investigators:</b> Stephen N. Xenakis, COL, MC	
<b>Key Words:</b>		
<b>Accumulative MEDCASE Cost:</b>	<b>Periodic Review Results:</b>	

**Study Objective:** To determine those elements that impact on family functioning during deployment of the soldier, particularly on the children. To determine what neuro-psychological, social, and behavioral dysfunction occurred in children of deployed parents before, during and after Operation Desert Storm.

**Technical Approach:** (1) **Experimental design:** The study utilizes a stratified multi-cell (five cells) design. The population consists of parents of children in the following categories: single parents, dual career couples, intact/traditional families, parents of disturbed children (seen at Child Psychiatry, Community Mental Health Activity and Social Work Services during deployment), parents of nondisturbed children (seen at regular Family Practice visits). Stratified probability sampling will be employed to select the research sample. Sample size estimation is 200 subjects per cell. Sample size determination was made by selecting a population size (n) that is sufficient for the standard error of estimate not to exceed 0.05.

(2) **Manpower:** Consists of the Principal Investigator, a 91G Behavioral Science Specialist, and five research assistants employed at Blanchfield Army Hospital.

(3) **Funding:** Obtained from the Department of Military Psychiatry, Walter Reed Army Institute of Research, Washington, DC. Funding required for FY 92 only.

(4) **Number of subjects enrolled to date:** 1,836

(5) **Number of subjects enrolled for reporting period:** 336

(6) **Nature and extent of significant adverse reactions:** No adverse reactions to date. All subjects required to read and sign the Volunteer Agreement Affidavit.

**Progress:** Data collection is continuing at Blanchfield Army Hospital until 30 Sep 92. As of this date some conclusions have been made regarding the research. No studies have been terminated or completed. There have been no presentations at scientific meetings nor submission of articles for publication related to this research. Two to three publications are in progress.

**DETAIL SUMMARY SHEET**

<b>Date:</b>	<b>Protocol #:</b> 93-33	<b>Status:</b> Ongoing
<b>Title:</b> Vocal Cord Function and Voice Quality Evaluation of Active Duty U.S. Army Drill Instructors		
<b>Start Date:</b>	<b>Est. Compl. Date:</b>	
<b>Principal Investigator(s):</b> Jeffrey Paffrath, CPT, MC	<b>Facility:</b> USA MEDDAC, Ft Jackson, SC	
<b>Department/Service:</b>	<b>Associate Investigators:</b>	
<b>Key Words:</b>		
<b>Accumulative MEDCASE Cost:</b>	<b>Periodic Review Results:</b>	

**Objective:**To document the laryngeal pathology and record the acoustic effects of acute voice abuse in active duty US Army drill instructors during periods of intense training.

**Technical Approach:** Subjects will be chosen for videostroboscopy and acoustic analysis preceding and during the early phases of small unit training.

**Number of subjects enrolled for the reporting period:**

**Progress:** This protocol requested funding form the Medical Research and Development Command, Ft. Detrick, MD. CI has been informed that the study will be considered for early Feb 94 funding.

**DETAIL SUMMARY SHEET**

<b>Date:</b> 8 Jul 93	<b>Protocol #:</b> 93-52	<b>Status:</b> Ongoing
<b>Title:</b> Pregnancy Exercise Patterns and Post-partum Fitness		
<b>Start Date:</b>	<b>Est. Compl. Date:</b>	
<b>Principal Investigator(s):</b> Lori B. Newman, AN	<b>Facility:</b> USA MEDDAC, Ft Campbell, KY	
<b>Department/Service:</b>	<b>Associate Investigators:</b> Terence J. Caldwell, LTC, AN Bari C, Knobel, MAJ, AN Judith L. Chantelois, MAJ, MC Frank W. Montgomery, III, Asst Prof	
<b>Key Words:</b>		
<b>Accumulative MEDCASE Cost:</b>	<b>Periodic Review Results:</b>	

**Objective:** To describe pregnancy outcome measures in active duty women with various levels of self-directed or organized prenatal exercise.

**Technical Approach:** Compare the physical fitness test scores of active duty soldiers before and after experiencing pregnancy and childbirth.

**Number of subjects enrolled for the reporting period:**

**Progress:** Protocol not yet started. Waiting for funding from hospital's '94 budget.

**DETAIL SUMMARY SHEET**

<b>Date:</b>	<b>Protocol #:</b> 93-60	<b>Status:</b> Ongoing
<b>Title:</b> Clinical Comparability of Two Once-Daily Forms of Diltiazem: Effect of Substitution on Blood-Pressure Control		
<b>Start Date:</b>	<b>Est. Compl. Date:</b>	
<b>Principal Investigator(s):</b> Myron Piziak, LTC, MS	<b>Facility:</b> USA MEDDAC, Ft Rucker, AL	
<b>Department/Service:</b> Pharmacy Service	<b>Associate Investigators:</b> John D. Grabenstein, MAJ, MS Roger P. Potyk, LTC(P) MAJ, MS	
<b>Key Words:</b>		
<b>Accumulative MEDCASE Cost:</b>	<b>Periodic Review Results:</b>	

**Objective:** To assess the comparability of clinical effects of Cardizem CD and Dilacor XR in the treatment of hypertension. directed or organized prenatal exercise.

**Technical Approach:** The Food and Drug Administration has already found evidence of the safety and efficacy of these two dosage forms for this indication. Investigators will examine available medical records and maintain confidentiality.

**Number of subjects enrolled for the reporting period:**

**Progress:** Implementation has just begun.

AUTHOR INDEX

Adrian	32, 39, 42, 45, 54-56
Ahn	90
Akiyama	35
Anderson	4, 46, 68, 93
Austin	14, 33
Baker	11
Barja	12, 13, 111
Barnard	115, 133
Beck	8, 11, 118
Benton	11, 96
Bernhardt	5
Best	12, 22, 27, 74
Billman	32-36, 39, 52-54
Blaskis	87, 91
Blount	2, 8, 67, 68, 70
Blume	5
Borison	16, 98
Breault	47
Brennan	1, 2, 6, 8, 15, 16, 32-36, 39, 43, 44, 52, 53
Brewer	1-4, 10, 11, 19
Brooks	5
Bruce	60, 61, 69, 91, 98
Buxton	27
Byrne	120, 121, 124
Calton	12, 16, 119, 121, 123, 127-130
Carroll	8, 63
Challenger	128, 129
Chuang	6, 7, 15, 16, 22, 24, 28
Clapper	100
Cleary	101
Cobb	77
Corley	108
Correnti	11, 16, 98, 105
Craft	12, 27, 74, 96
Craig	29, 79, 89
Cutting	30, 46, 132
Czuszak	48
DeStefano	62
Diamond	98
Doers	16, 75, 76, 78, 88, 89, 92
Duffin	112, 122
Duffy	105
Eachempati	82
Ellis	31
Erpelding	5, 12, 14, 112, 122, 132
Fisher	86, 96
Flaherty	12
Foster	1
Gardner	2-4, 10, 40-42, 54-56
Garigan	64
Garland	5
Gaston	40, 41, 54-56
Gibbon	69
Goldfinger	73
Goldman	2, 64, 70
Goodhue	10, 11
Green	11
Guill	4, 91
Haburchak	15, 74, 79, 87, 92
Hanes	2-4, 10

Hanson	32-36, 39, 43, 44, 52-54
Hardy	94
Harkins	12, 116
Hendricks	97, 100
Hilburn	4, 16, 78
Honeycutt	75, 76, 88, 89, 92
Horner	1-4, 6, 7, 15, 19, 27, 30, 32, 46
Huffnagle	61
Hynes	5
Jackson	104, 197
Jacob	5
Jankowski	36
Jennings	103
Johnson	4
Jones	5, 6, 8, 34, 77
Kaiser	120
Kaminski	107-109
Karren	37
Keaton	3, 9
Kelley	134
Krywicki	80, 81, 138-151, 153-160, 162-191
Kudryk	53
Kulild	1, 2, 15, 30, 37, 38
Lake	2-4, 10
Lanier	30
Leibert	8, 9
LePage	12, 72, 110, 114, 125, 131, 134, 137
Lewis	10, 31, 68
Liewehr	2, 15, 38
Luzader	50
Lyle	10, 80, 81
Malik	83
McDonald	40
McMillan	113
McPherson	1, 6-8, 15, 16, 20, 22, 24-26, 28, 34-36, 46, 71, 117
McQuade	1-3, 15
Mecredy	86
Miller	15, 94, 123, 130, 137
Modesto	5, 12, 125, 131
Morris	55
Ness	97
Newman	198
Nguyen	15, 16, 27
Nolan	77
O'Neal	1, 2
O'Neill	2
Oleskowicz	102
Oquendo	104
Oswald	73, 80, 81, 106-109, 138-143, 145-151, 153-165, 167-191
Paffrath	197
Page	95
Parker	56
Parr	2-4, 10
Paustian	6, 7, 15, 16, 20, 22, 24, 26, 71
Peacock	2
Perry	4
Phelps	8, 9, 62
Piziak	199
Plowman	1-3, 15, 16, 20
Primack	2, 15, 30, 37, 46, 50, 51
Prior	18, 44, 73, 85, 114, 137, 148, 151, 157
Ralston	98

Ramirez . . . . .	12, 119, 134
Ranlett . . . . .	3, 10, 139-141, 144, 147, 162
Riel . . . . .	71
Robinson . . . . .	4
Romero . . . . .	3
Rouse . . . . .	2
Runner . . . . .	6, 7, 15, 16, 20, 22, 25, 26, 28, 36, 71
Ryan . . . . .	5, 73
Satava . . . . .	5
Scharstein . . . . .	113
Scheffer . . . . .	11, 16, 98, 101
Scheidt . . . . .	1-3, 15
Schenk . . . . .	11
Schmitt . . . . .	42
Schneck . . . . .	2
Scott . . . . .	112, 122, 137
Sen . . . . .	3, 9, 10, 138, 145, 148, 150, 151, 153, 154, 156-161, 165-175, 177-179, 181-191
Shaffer . . . . .	80, 81, 85, 138-150, 153-191
Shahan . . . . .	15, 16
Shikle . . . . .	10
Simpson . . . . .	1, 3
Sisk . . . . .	2-4, 10
Smith . . . . .	79, 89
Spinelli . . . . .	97
Sprague . . . . .	77
Stafford . . . . .	4, 72
Steflik . . . . .	3, 4, 10
Strong . . . . .	2, 3, 31
Sutherland . . . . .	1, 2, 15, 18, 27, 29, 33, 38, 53, 74, 123, 127, 130, 135
Tabor . . . . .	2, 7, 15, 31, 39
Taylor . . . . .	5, 13, 14, 125
Tenholder . . . . .	4
Thomas . . . . .	8, 11, 25, 33, 39, 51, 53, 64, 95, 98, 124, 125
Thompson . . . . .	1-3, 16
Tillman . . . . .	41
Tolson . . . . .	49
Trent . . . . .	98, 102
Trzepakowski . . . . .	67
Turgeon . . . . .	38, 117, 121
Vasallo . . . . .	142, 146, 149, 155, 163, 164
Vaughn . . . . .	4
Volgas . . . . .	113, 133
Waddell . . . . .	12, 136
Walsh . . . . .	64
Weller . . . . .	1
White . . . . .	5, 10, 95
Whitlock . . . . .	4, 9, 16, 31, 75, 76, 78, 84, 88, 89, 92
Williford . . . . .	11
Woollard . . . . .	46
Workman . . . . .	12, 124
Wozniak . . . . .	10, 11, 139-141, 144
Wright . . . . .	8, 9, 60

SUBJECT INDEX

Acute Myeloid Leukemia . . . . .	158, 183
Acute Psychiatric Treatment . . . . .	104
Adenocarcinoma . . . . .	155, 167
Antiemetic . . . . .	80, 81
Blood flow . . . . .	20-23
Blood Pressure . . . . .	4, 90
Bone . . . . .	3, 5, 10, 27, 30, 32, 39, 43, 52, 111, 112, 151, 161
Bronchitis . . . . .	76, 88, 92
Bronchospasm . . . . .	80
Burn treatment . . . . .	20
Ceftibuten . . . . .	75, 76
Cements . . . . .	47, 50, 56
Cessation of Alcohol . . . . .	103
Chlamydia . . . . .	64, 84
Chlorhexidine . . . . .	15, 16
Cisplatin . . . . .	80, 81, 159, 165, 170, 175
Colles' Fractures . . . . .	133
Dental implant . . . . .	2-4, 10
Dentin . . . . .	1-3, 36, 38
Depressive Disorder . . . . .	105
Dolasetron . . . . .	80, 81
Edema . . . . .	20, 21, 26
Effect of Vitamin A . . . . .	135
Elderly Patients . . . . .	133, 158
Electron Microscopy . . . . .	46
Endodontic sealers . . . . .	37
Endophthalmitis . . . . .	96
Fibroblasts . . . . .	1, 2, 11, 16, 25, 33, 36, 47, 48, 53, 98, 99
Gallium . . . . .	38
Gastric mucosa . . . . .	28
Genital Herpes . . . . .	87, 91
Gingival . . . . .	1, 2, 16, 25, 33, 36, 48, 53
Gingival Fibroblast . . . . .	25, 36
Gutta-percha . . . . .	37
Heat stroke . . . . .	24
Helicobacter Pylori . . . . .	74, 86
HELLP syndrome . . . . .	67
Hepatoma . . . . .	160, 188
Implant Angle . . . . .	55
Infant Feeding . . . . .	68
Isotonic . . . . .	28
Labor . . . . .	95
Lag Screw . . . . .	132
Laparoscopic Surgery . . . . .	134
Laser . . . . .	1, 22, 54
Lidocaine . . . . .	137
Metastatic . . . . .	169
Mice . . . . .	12, 26, 117, 135, 136
Multiple Myeloma . . . . .	151, 184, 189
Myeloma comparison . . . . .	189
Nicotine . . . . .	2, 33
Non-Hodgkin's Lymphoma . . . . .	145, 154, 185, 186
Non-Small cell Lung Cancer . . . . .	162, 187
Octreotide . . . . .	12, 123, 130, 136
Oncofetal tumor . . . . .	18
Operation Desert Storm . . . . .	12, 195
Periodontal ligament . . . . .	25
Pig . . . . .	9, 114, 118, 121
Plate Fixation . . . . .	132
Pluronic polyols . . . . .	6, 8, 20, 21, 24, 26, 28, 35, 49, 71
Pneumonia . . . . .	60, 75

Pressure . . . . .	4, 90, 199
Procera . . . . .	54
Psychosis . . . . .	11, 98, 99
Pulmonary Disease . . . . .	78, 88
Rabbits . . . . .	96, 111
Rat . . . . .	6, 15, 20-22, 24, 27, 28, 35, 49, 71, 115, 121, 130
Rehabilitation . . . . .	4, 97, 100
Restorations . . . . .	54
Scanning Electron . . . . .	4, 46
Screening . . . . .	44, 62, 63
Sealing . . . . .	50
Sepsis . . . . .	12, 85, 89
Skin Thermometry . . . . .	69
Squamous Cell carcinoma . . . . .	165, 170, 181
Substance dependence . . . . .	97, 100
Sunburn . . . . .	71
Surfactant . . . . .	20, 71
Tissue culture . . . . .	25, 38
Titanium implant . . . . .	1, 2, 32
Trauma . . . . .	14, 21, 110
Trocar . . . . .	131
Urinary sediment . . . . .	64
Wound healing . . . . .	12, 13, 20, 21, 35, 49, 123, 127, 130, 135, 136
Wound Healing in Rats . . . . .	12, 136

ANNUAL PROGRESS REPORT DISTRIBUTION LIST

Quantity of Copies	Agency
1	Commander US Army Medical Research Command Fort Detrick, ATTN: SGRD-HR Frederick, MD 21707
2	Defense Documentation Center ATTN: DDC-TCA, Cameron Station Alexandria, VA 22314
2	Clinical Investigation Regulatory Office ATTN: HSMC GCI CDR AMEDDC&S Fort Sam Houston, TX 78234-6125
1	Each US Army Medical Center